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ABSTRACT  
Streptococcus pneumoniae is the leading cause of infectious childhood conditions 
such as Otitis Media (OM) and Pneumonia. Amoxicillin is the recommended first-line 
treatment for these indications. But because of growing resistance to penicillin 
based and other antibiotics prevention via effective immunisation is a more desirable 
approach.  PCV7 was introduced in the UK in 2006. Studies conducted in the USA 
and Europe have shown that the use of this vaccine successfully reduces the 
incidence of OM and pneumonia. Yet its impact on community antibiotic use in the 
UK has not to date been adequately described. 
 
This thesis presents the findings of two retrospective cohort studies that analysed 
the diagnosed incidence of OM and pneumonia and the associated antibiotic 
prescribing, using the IMS DA and THIN GP databases. The extensive data 
manipulation conducted shows that the overall number of (all cause) pneumonia 
episodes in children recorded by GPs declined by 14% between 2006 and 2010.  
Associated antibiotic prescribing fell by 10%. In addition, the research presented 
here identified a fall of more than a third in primary care recorded OM diagnoses 
and antibiotic prescribing for the treatment of OM in children between 2006 and 
2010.   
 
These data represent new evidence that the introduction of the original conjugated 
PCV7 contributed to a decline in antibiotic prescribing by GPs. However, additional 
prescribing behaviour change drivers were involved and consumption by patients 
may have fallen faster than the available data sets suggest.  
 
The PCV7 has now been replaced by the PCV13. Against this background a range 
of additional policy questions are discussed. They include issues relating to bacterial 
serotype replacement trends and virulence shifts, and the implications of effective 
infant and child protection for the health of older adults at high risk of contracting 
pneumococcal infections. 
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OVERVIEW OF THESIS CHAPTERS 
CHAPTER ONE: INTRODUCTION 
This presents a broad overview of information and issues relevant to this thesis and 
the content of each subsequent chapter. 
 
CHAPTER TWO: RESEARCH TOOLS AND METHODOLOGY 
This chapter provides details of the research tools and methodology used 
throughout this thesis. 
 
CHAPTER THREE: SYSTEMATIC & LITERATURE REVIEW 
This chapter reviews the current literature in order to assess what is already known 
to date about the efficacy and adverse events linked with PCV7 use in children. It 
primarily assesses the efficacy of PCV7 in preventing pneumococcal infection 
diseases, including factors like serotype specific antibody concentrations and 
geometric mean concentrations (GMCs). It secondarily investigates the local and 
systemic adverse drug events associated with the administration of the PCV7 to 
children. 
 
CHAPTER FOUR: VALIDATION STUDY FOR THE IMMUNISATION RECORDS IN 
IMS DATA FOR CHILDREN AGED UP TO 2 YEARS  
This compares the percentage of children receiving PCV7 in the IMS DA with 
national data (COVER) and seeks to validate PC7 records in a sample of randomly 
selected children aged 0-2 years in IMS DA through a GP questionnaire based 
survey. It is of note in this context that in the UK immunisations are usually given in 
GP surgeries. However, various other healthcare professionals such as practice 
nurses, health visitors and school nurses can also administer vaccines to children.  
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Not all of these professionals have direct access to the patients’ electronic record. 
This can lead to under-recording of immunisation rates in GP's computerised 
records. To the best of our knowledge there has been no study carried out to 
validate the immunisation records in GP practice for the IMS. The research findings 
reported in this chapter therefore add new knowledge. 
 
CHAPTER FIVE:  IMPACT OF PCV7 ON THE INCIDENCE OF OM AND 
ANTIBIOTIC PRESCRIBING FOR OM IN CHILDREN AGED BETWEEN 0-18 
YEARS OLD IN UK GENERAL PRACTICE  
Data on the annual incidence of OM and antibiotic prescribing patterns in children 
before and after the introduction of PCV7 between 2002 and 2010 into the UK 
primary care are presented, stratified by age and gender. Interrupted time series 
analyses is used to evaluate the impact of PCV7 on OM before and after its 
introduction, which allows for factors such as seasonal variations to be taken into 
account. 
It is noted that OM is the most frequent GP diagnosis in sick children. Studies from 
the United States (US) and continental Europe have shown that the incidence of OM 
and antibiotic prescribing has reduced since the introduction of PCV7 in children. 
Other work has reported a similar decline in UK OM diagnosis and antibiotic 
prescribing for OM treatment that may be related to the introduction of national 
guidance in 1997 to restrict the use of antibiotic for OM treatment. However, this 
research throws new light onto trends in OM management in General Practice since 
the introduction of PCV7 into UK in 2006.  
 
 
 19 
 
CHAPTER SIX: IMPACT OF PCV7 ON THE INCIDENCE OF PNEUMONIA AND 
ANTIBIOTIC PRESCRIBING FOR PNEUMONIA IN CHILDREN  AGED BETWEEN 
0-15 YEARS IN UK GENERAL PRACTICE 
The analysis offered in this chapter describes annual pneumonia incidence rates 
related to antibiotic prescribing patterns in children recorded between 2002 and 
2010 in UK primary care, stratified by age and gender. It is noted that in the US all 
cause pneumonia admissions in children under 2 years of age fell by 39% within 2 
years of the introduction of a mass immunisation using PCV7. Likewise in England 
hospital admission data showed reductions in serotyped pneumonia cases of 
around 20% in children aged 0-15 years within 2 years of PCV7's introduction. 
However, the impact of PCV7 on the diagnosis and level of antibiotic treatment for 
all cause pneumonia in primary care in the UK has until now been unclear.  
 
 CHAPTER SEVEN: OVERALL DISCUSSION 
Thus chapter summarises and discusses critically the overall findings and public 
health policy and practice implications of the findings of this thesis against the 
background of the wider body of relevant research available. Future research topics 
are also identified. 
 
  
                                                       CHAPTER ONE 
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CHAPTER ONE: INTRODUCTION  
1. BACKGROUND 
This study examines the impact of seven-valent pneumococcal conjugate vaccine 
(PCV7) on childhood pneumococcal diseases in the UK.  Its main focus is on this 
vaccine’s role in preventing Otitis Media (a non-invasive pneumococcal disease) 
and pneumonia (an invasive pneumococcal disease) and its consequent impacts on 
associated antibiotic prescribing.  As an introduction to the area, pneumococcal 
disease is outlined in this Chapter. This is followed by a closer look at classifications 
of Otitis Media and pneumonia, the associated burden of disease, relevant risk 
factors, pathology and complications, diagnosis and clinical management. There is 
then an overview of the PCV7 itself, and the rising number of cases of antibiotic 
resistance that led to its introduction is noted. Data on the vaccine’s safety and 
efficacy is reviewed, and the schedule of administration in this country described.  
This study focuses on the PCV7 and its impact following its introduction in 2006. But 
readers should be aware that in 2010, in part due to increasing cases of serotype 
replacement disease, a vaccine with a broader coverage of 13 serotypes (PCV13) 
replaced the initial vaccine. 
 
1.1 PNEUMOCOCCAL DISEASES 
In 1881 a U.S Army physician called George Sternberg first isolated the 
pneumococcus bacterium. From 1920, the organism was termed Diplococcus 
pneumoniae, due to the appearance of the organism in the form of two joined cells 
of Gram positive anaerobic bacteria. In 1974, however the organism was renamed 
Streptococcus pneumoniae (S. pneumoniae) as it grows in chains in liquid media 
(Gillespie and Hawkey, 2006).  
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S. pneumoniae causes pneumococcal infections including pneumonia, septicaemia, 
meningitis, otitis and sinusitis. Pneumococcal infection spreads from one person to 
another by droplet inhalation from the respiratory tract (Ledingham and Warrell, 
2000) (Table 1.1).   
Table 1.1: The Pathway of Pneumococcal Infection 
 (Taken from Ledingham and Warrell, 2000) 
 
 
Individuals with immature or weakened immune systems are at higher risk of 
developing a pneumococcal infection. This typically includes infants and children 
under two years of age, many adults over 65 years of age and other younger 
individuals with an underlying health condition such as HIV or types 1 and 2 
diabetes (Fireman et al., 2003).  
 
S. pneumoniae is ubiquitous. Some 55% of healthy children have at any one time S. 
pneumonia colonies in their nasopharynx (Pettigrew et al., 2006; Pettigrew et al., 
2008).  It can spread from the nose and throat to the upper and lower respiratory 
tract to cause Otitis Media (OM) and/or pneumonia.  
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The bacterium also has the ability to spread from localised infection sites in the 
middle ear and lungs to cause life threatening invasive meningitis infections. It has 
been reported that there are over a thousand cases of pneumococcal meningitis in 
the United States (US) and one million cases worldwide annually, with a 30-80% 
mortality rate (Marra & Brigham, 2001).  
 
The global disease burden caused by pneumococcal infections is difficult to 
estimate, but considerable. However, several reports published by the World Health 
Organization (WHO) suggest that pneumococcal disease rates are highest in 
children under 5 years of age. With immune system maturation the prevalence of 
these diseases declines in adequately fed older children and healthy young adults. 
The WHO estimates that up to one million deaths per annum worldwide are caused 
by pneumococcal disease amongst children aged under 5 years. It is the leading 
cause of mortality and morbidity in young children, with some 140,000 reported 
deaths annually in India alone (Table 1.2).   
 Table 1.2: Estimated pneumococcal deaths and cases  
                                             (Taken from WHO, 2013)   
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Moreover, six countries (India, Nigeria, Ethiopia, the Democratic Republic of Congo, 
Afghanistan and China) account for more than half of all pneumococcal deaths 
worldwide (Table 1.3) (Chaloner-Larson, Anderson & Egan, 1997; WHO, 1999; 
WHO, 2007, WHO, 2013).  
                
Table 1.3: Number of child pneumococcal deaths 
 (Taken from WHO, 2013)                                            
 
Pneumococcal diseases are either invasive or non-invasive. These two discrete 
types of infection are described below. 
 
1.1.1 INVASIVE PNEUMOCOCCAL DISEASES  
Invasive pneumococcal disease (IPD) includes pneumonia (lung infection), 
meningitis (inflammation of the meninges, the protective membranes covering the 
brain and spinal cord) and septicaemia (infection of the blood) (Table 1.4) 
(Department of Health (DOH), 2006).   
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There are more than 1 million deaths due to pneumococcal pneumonia and 
meningitis combined in young children every year worldwide (WHO, 1999). The 
Health Protection Agency (HPA – now part of Public Health England) has estimated 
that 5,000-6,000 cases of IPD occur every year in England and Wales, of which 
approximately 530 are amongst children aged under 2 years (HPA, 2010). 
 
Table 1.4: Symptoms and complications related to pneumococcal infection 
   (DOH, 2006) 
Disease caused 
by 
pneumococcal 
infection  
Symptoms  Serious complications  
Pneumonia  Cough, breathing 
 difficulties, chest 
 pains, fever, 
 headache, confusion  
Can lead to septicaemia (bacteria in the blood 
stream) where the infection can spread to the 
lining of the heart (pericarditis) or brain 
(meningitis)  
Septicaemia 
(blood poisoning)  
Fever, confusion, low 
blood pressure 
(shock) 
 
Can cause death  
Meningitis 
(inflammation 
around the brain)  
Confusion, fever, 
 headache  
Can cause death. Five out of ten cases of 
meningitis result in permanent damage including 
deafness, intellectual impairment, speech and 
language problems, paralysis, cerebral palsy, 
epilepsy and blindness. 
Bronchitis  Coughing, mucus 
 secretion  
 
Peritonitis 
(inflammation of 
the abdomen)  
Abdominal pain,  
fever  
Can cause death  
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1.1.2 NON-INVASIVE PNEUMOCOCCAL DISEASES 
Non-invasive pneumococcal disease is less serious but much more common than 
IPD. It occurs outside the major organs or the blood stream and includes Otitis 
Media (a middle ear infection most often found in children), sinusitis (infection of the 
sinuses) and bronchitis (infection of the airways without the systemic infection and 
degree of inflammation in the alveoli characteristic of pneumonia). 
 
More than 60,000 diagnosed cases of pneumococcal Otitis Media occur in England 
and Wales every year (Lawrenson et al., 1998; National Institute for Health and 
Clinical Excellence (NICE), 2007, HPA, 2010). In the US (with five times the UK 
population) there are believed to be seven million cases of Otitis Media caused by 
S. pneumoniae every year (Marra & Brigham, 2001). 
 
1.2 OTITIS MEDIA 
Overview 
As already noted, OM is a condition that involves inflammation of the middle ear, 
behind the tympanic membrane. This is usually caused by bacterial infection such 
as S. pneumoniae, Moraxella catarrhalis and non-typeable Haemophilus influenza, 
or viral upper respiratory tract infections caused by organisms such as Respiratory 
Syncytial virus, Rhinovirus, Adenovirus, Parainfluenza and Coronavirus. On 
occasions OM is associated with both bacterial and viral pathogens. The infection(s) 
involved typically first causes a sore throat, cold, or other respiratory problems and 
then spreads to the middle ear (Doherty, 2008; American Academy of Pediatric 
Medicine Subcommittee on the Management of Acute Otitis Media, 2004; Bradley et 
al., 2008).  
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There are three different types of OM (National Institute on Deafness and other 
Communication Disorder, 2002; Klein and Pelton, 2012b; Bluestone and Klein, 
1983) They are Acute Otitis Media (AOM) (inflammation of the middle ear); Otitis 
Media with Effusion (OME) (fluid & mucus remain after AOM inflammation); and 
Chronic Suppurative Otitis Media (CSOM) (perforation of the tympanic membrane).  
In terms of morbidity, OM is the most frequent occurring diagnosis in children in 
general practice (Congeni, 2003). Its incidence varies with the incidence of risk 
factors such as Eustachian tube dysfunction, bacterial and viral load, immune 
response and host and environmental factors (see below).  
 
Most children who develop OM initially exhibit behaviors and symptoms such as 
pulling or rubbing of the ear, fever, irritability, poor feeding, restlessness at night and 
cough (Bluestone and Klein, 1983; Klein and Pelton, 2012a; Klein and Pelton, 
2012b).  
 
It is estimated that three out of every five children will have suffered from AOM by 
their third birthday, with the peak incidence rate occurring between six and eleven 
months.  Between 50% and 85% of all children experience at least one episode 
(Rovers et al., 2004).  
 
S. pneumoniae is the most common bacterial pathogen causing OM. Accurate OM 
diagnosis is ideally needed to ensure appropriate treatment although approximately, 
80% of AOM cases spontaneously resolve within three days without antibiotic 
therapy. Analgesics such as paracetamol or ibuprofen may be required to reduce 
distress (O’Neil, 1999). 
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Immediate prescription of antibiotics is normally recommended when children 
affected are under two years of age, in children with a frequent history of OM, and 
for those with symptoms that do not resolve or have become worse 72hr after 
diagnosis (Little et al., 2001).  
 
Antibiotics have been prescribed for the treatment of OM since the 1940s. It has for 
some decades been the most common indication for a child to receive an antibiotic, 
accounting for 14% of all antibiotics prescribed to children aged 3 months to 15 
years between 1991 and 2007 in the UK (Thompson et al., 2008). Amoxicillin is the 
recommended first-line antibiotic treatment (Bluestone and Klein, 2001; Gonzales, 
2001).  Although as already observed most cases of OM will resolve spontaneously, 
complications can occur. These may include perforation of the eardrum, hearing 
loss, mastoiditis, meningitis, brain abscesses and blood clots (Klein, 2001).  
 
1.2.1 CLASSIFICATION OF OTITIS MEDIA  
Figure 1.1 shows the physiological setting in which Otitis Media can develop as an 
inflammatory middle ear condition, often after an upper respiratory tract infection 
(URTI) that initially causes symptoms such as sore throat and subsequently spreads 
to the middle ear (Bradley et al., 2008).  
As noted above, there are three different types of OM:  
Acute Otitis Media (AOM): Inflammation occurs in the middle ear causing ottorhea 
(discharge from the ear), bulging tympanic membrane, fever and/or irritability 
associated with fluid and mucus build-up.   
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Recurrent AOM is diagnosed if the child had four or more episodes of AOM within a 
six-month period (National Institute for Health and Clinical Excellence, 2000). 
Figure 1.1: Schematic diagram of the ear 
       (Taken from Doherty, 2008) 
 
 
Otitis Media with effusion (OME): The fluid and mucus remain after AOM 
inflammation has subsided. It also referred to as secretory Otitis Media or glue ear 
(National Institute on Deafness and other Communication Disorder, 2002; Klein and 
Pelton, 2012b). 
 
Chronic suppurative Otitis Media (CSOM): Perforation of the tympanic membrane 
and ottorhea resulting in fluid and mucus to be discharged through the membrane 
(Bluestone and Klein, 1983). 
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1.2.2 BURDEN OF DISEASE 
Otitis Media is one of the most frequent diagnoses in sick children. It historically 
accounts for over one in every ten of all GP child and young adult consultations in 
the UK primary care setting (Congeni, 2003). It has been reported that there are 
more than 63,000 diagnosed cases of pneumococcal OM in England and Wales 
every year (HPA, 2012). Young children are predisposed to AOM due to their 
incompletely developed Eustachian tubes and immature immune systems (Klein and 
Pelton, 2012b). It is estimated that more than two-thirds of children experience one 
or more episodes of AOM by their third birthday: about half experience three or 
more episodes.  It has also been reported that approximately 50-85% of all children 
experience at least one episode of AOM (Taylor et al., 2012; Rovers et al., 2004).  
 
1.2.3 RISK FACTORS 
As mentioned earlier, the onset of OM occurs in association with bacterial and viral 
load alongside factors such as Eustachian tube dysfunction, immune response 
levels and other host and environmental factors (Figure 1.2).  In order to facilitate 
the prevention and management of Otitis Media all such risk factors need to be 
addressed in an appropriate manner. 
 
1.2.3.1 HOST FACTORS 
Young age: An Australian prospective study demonstrated that there is an 
association between the frequency of AOM episodes and the age of the children 
affected.  The younger the age of the child the higher the frequency of episodes 
(Massa et al., 2009).   
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There are two reasons for this. Firstly, an infant’s immune system is still developing, 
making it harder for children to fight infections and justifying the use of antibiotics 
more readily than when older children and young adults are being treated.  
Secondly, children have undeveloped Eustachian tubes.   
 
Figure 1.2: Risk factors involved in the pathogenesis of Otitis Media 
                     (From Rovers et al., 2004)  
 
 
 
As shown in figure 1.3, in younger ages the Eustachian tube is shorter, 
narrower/more horizontal and ‘floppier’ than it is in adult subjects. This impedes air 
flow and, if the child has an infection, organisms can easily reflux from the 
nasopharynx into the middle ear (Bluestone, 1996; National Library of Medicine, 
2012). During the first two years of life, maturation of both the immune system and 
the Eustachian tube will gradually take place. Therefore, the highest incidence rate 
of OM usually occurs in children aged less than two years (Rovers et al., 2004). 
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Figure 1.3: Eustachian tube in a young child compared to an adult  
                      (National Library of Medicine, 2012) 
               
 
Genetic predisposition:  As a majority of children will suffer at least one episode 
of Otitis Media it is not instantly obvious that there is a genetic predisposition to the 
disease. However, evidence from a variety of studies suggests that there is a 
genetic component to susceptibility to OM.  
 
It is, for instance, three times more likely for a child to develop recurrent OM if 
he/she is born into a family where their siblings have had recurrent OM as 
compared to those born into an unaffected family (Teele, Klein and Rosner,1989; 
Uhari, Mantysaari and Niemela, 1996).  
 
Although the latter observation might be linked to environmental factors, twin 
studies also suggest that there is a strong genetic component determining the 
predisposition of a child to OM infection. Monozygotic twins (identical) have a 
greater similarity between their OM histories than dizygotic (non-identical) twins 
(Casselbrant and Mandel, 1999; Rovers et al., 2002). 
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Gender: AOM occurs more frequently in boys than girls “as is true for most 
infectious diseases of childhood” (Klein, 2001). 
 
Race: Children from certain racial/ethnic groups, including Native Americans, and 
American and Canadian Inuits appear to have an increased incidence of severe 
AOM (Klein, 2001). However, this may be an artefact associated with relative 
deprivation levels, and the frequent failure of North American researchers in 
particular to distinguish between class and social justice related factors as opposed 
to inherent race/ethnicity linked traits. 
 
Atopy/allergies: Hypersensitivity reactions and allergies may also predispose to 
OM.  A child with a food allergy may have an abnormal reaction which activates the 
immune system. This may in turn result in inflammatory responses, and increase 
the mucus and fluid in the middle ear during such an episode (Arroyave, 2001; 
Rovers et al., 2004). The affected child may consequently become more vulnerable 
to opportunistic ear infections. 
 
1.2.3.2 BACTERIAL AND VIRAL INFECTION 
As shown in figure 1.4, the most common bacterial pathogens that cause OM are S. 
pneumoniae followed by Haemophilus Influenza and Moraxella Catarrhalis.   Viruses 
(such as Syncytial virus) alone or with bacterial pathogens are believed to be an 
increasing cause of OM (Rovers et al., 2004), although the evidence underpinning 
this assertion is limited.   
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Figure 1.4:  Distribution of bacterial isolates in 2807 children with middle ear 
cultures from children with OM 
 (Taken from Pelton, 2000) 
 
 
 
1.2.3.3 EUSTACHIAN TUBE DYSFUNCTION (ETD) 
The Eustachian tube links the middle ear with the back of the nose. It normally stays 
closed until subjects swallow, yawn or chew. This allows fresh air to enter the middle 
ear and discharge any mucus that is present.  
 
Such actions in addition play a vital role in maintaining a healthy middle ear by 
equalising the middle ear pressure with the air pressure outside the head (ie there is 
a ventilator function). They also protect against ascending secretions or pathogens 
(protective function) and clear secretions towards the nasopharynx (clearance 
function) (Bluestone, 1996; Rovers et al., 2004).  
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In ETD the narrow Eustachian tube is totally or partially blocked. This means that air 
cannot enter into the middle ear. Thus air pressure equalisation is not possible and 
the eardrum is pushed inward and becomes taught and does not vibrate when 
impacted by sound waves (National Library of Medicine, 2008).  
 
Impaired Eustachian tube function is the most important risk factor in the 
pathogenesis of OM (Bluestone, 1996).  Following a respiratory tract infection, the 
Eustachian tube may become congested, leading to the proliferation of pathogenic 
organisms.  
 
1.2.3.4 IMMUNE RESPONSES 
The secretory immunoglobulin IgA and IgG2 help the body to defend against OM 
infection. Secretory IgA inhibits bacterial and viral pathogen adherence and  reduces 
nasopharyngeal  bacterial colonisation,  whilst  IgG2  antibodies  initiate  an  
immunological  response  against  pneumococci  polysaccharide capsules (Kurono 
et al., 1991; Lim and Mogi, 1994).  Therefore low levels of these secretory 
immunoglobulin may increase a child’s risk of OM infection (Stenfors and Raisanen, 
1993; Sanders et al., 1995). 
 
1.2.3.5 ENVIRONMENTAL FACTORS 
Siblings: Having older (and to a lesser degree younger) siblings is one of the most 
important risk factors for developing OM in infants and children (Rovers et al., 2004). 
This relates to, in non-immunised populations, the statistical risk of novel exposure 
to causal organisms. 
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Child-care:  Receiving care outside the home is another important early AOM 
determinant. Rovers et al (1999) undertook a meta-analysis that found a strong 
relationship between attending child-care and the prevalence of OM. Further, a 
study by Ingvarsson et al (1985) found that in such circumstances it is more likely for 
children to develop OM before the age of two years as compared to those aged 
between 2 to 3 years old.  
 
A second relevant factor is the number of children in the child-care environment. 
Marx et al (1995) and Dewey et al (2000) both reported that the relationship 
between attending child-care from early age and OM is significantly affected by the 
group size, which logically correlates with infection risk. 
 
Season: Seasonal climatic variations strongly influence the occurrence of OM in 
children. As is generally true with other pneumococcal-mediated infections in all 
population groups the prevalence rate of OM increases during the north European 
winter. For instance, Rovers et al (2000) reported that the prevalence rate of OM is 
twice as high in winter as summer. 
 
Breast feeding: Several studies have reported that breast-feeding is inversely 
associated with the frequency of OM infections. That is, it provides protection. This 
is due to the fact that the antibody content of human milk will interfere with the 
attachment of bacteria to the nasopharyngial (NP) epithelial cells.  
The immunological components that are present in human milk (including secretory 
immunoglobulin antibodies (sIgA) and lactoferrin) are thought to provide passive 
protection against NP colonization which provides protection against the subsequent 
development of OM (Cripps, Otczk and Kyd, 2005; Sabirov et al., 2009).  
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Exposure to tobacco smoke: Tobacco smoke inhalation is associated with 
vulnerability to S. pneumoniae infection. Children who live in a smoke-filled 
environment are susceptible to ciliary function damage in the paediatric airway 
which increases the probability of their contracting chronic OM (National Institute for 
Health and Clinical Excellence, 2000; Ebby, 2005; Brauer et al., 2006; Cheraghi & 
Salvi, 2009; Wang et al., 2012).  
 
Air pollution: Air pollution is another environmental factor that increases the 
frequency of OM (Kim et al., 1996; Brauer et al., 2006; Zielhuis et al., 1990). The 
mechanisms involved are likely to overlap with, and interact synergistically with, 
tobacco smoke related harm. 
 
1.2.4 PATHOLOGY AND COMPLICATIONS 
Severe and recurrent OM is the major cause of contracted childhood deafness, 
which has ‘knock on’ affects on language and communication skills (Rovers et al., 
2004). It may also affect mental state. 
 
If the eardrum becomes severely weakened a cholesteatoma can occur (Figure, 
1.5).  This involves the accumulation of a protein called keratin within the middle ear. 
In extreme cases it may grow to envelop the ossicles that present in the middle 
space and serve to transmit sounds between air and the cochlea which 
consequently results in conductive hearing loss (Klein and Pelton, 2012b). 
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Figure 1.5: Cholesteatoma (arrow) is a growth of desquamated, stratified, 
squamous epithelium  
                                (From Klein and Pelton, 2012b)  
                                  
 
OM usually occurs by spreading the pathogens from the middle ear cleft to the 
surrounding structure of the ear. Two types of complication may occur: intratemporal 
(which occur within the temple) or intracranial (which occur within the cranium). This 
may result in not only chronic perforation of the tympanic membrane and/or chronic 
suppurative Otitis Media, but also distressing and sometimes potentially disabling or 
fatal disorders like mastoiditis, petrositis, meningitis, brain abscesses, extradural 
abscesses, subdural empyema and suppurative lateral sinus thrombosis (Klein, 
2001).  
 
1.2.5 DIAGNOSIS 
The diagnosis of AOM is usually based upon a combination of observed symptoms 
and physical findings. They include ear pain, ear tugging or rubbing, otorrhoea, 
fever, excessive crying in the younger age group, poor appetite, headache and 
vomiting.  
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A related history in contexts like hearing difficulties, together with information on 
social interaction, behaviour, function in the educational setting and speech and 
language development can also be important to deriving an initial diagnosis and to 
differentiating between different types of OM, in addition to which specific 
examinations are normally needed.   
 
It has been argued that all GPs or alternative health professionals should have an 
appropriate training as to how they use otoscopes to detect the presence of the 
middle ear inflammation. The level of accuracy in detecting the presence of middle 
ear fluid using this technique should be no less than 80% to 90% (Scottish 
Intercollegiate Guidelines Network, 2012).  
 
1.2.6 CLINICAL MANAGEMENT 
Most cases of Otitis Media are self-limiting. That is, they spontaneously resolve 
without the need for any intervention (Glasziou et al, 1997). Nevertheless, in some 
cases active treatment is necessary. The two main interventions available are a) 
antibiotic therapy and b) myringotomy, with or without the surgical insertion of 
tympanostomy tubes.  
 
1.2.6.1 TYMPANOSTOMY TUBES AND MYRINGOTOMY 
Myringotomy (myringa is the Latin word for the eardrum) involves making a small 
incision in the eardrum to relieve pressure caused by an excessive buildup of fluid in 
the middle ear. In order to prevent recurrent infections and the possible perforation 
of the tympanic membrane (TM) a small tympanostomy tube (TT) can be inserted.  
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There are two different types of TT, constructed of different materials. They are 
namely short–term tubes, which can stay in the TM for 8 to 18 months (more 
recommended for children due to the sensitivity of the ear drum) and long-term 
tubes, which can stay in the TM for more longer periods (Isaacson, 2012).   
 
In the US TT insertion is a frequent reason for children having to receive a general 
anesthetic. About 7% of children in the United States have tympanostomy tubes 
inserted by the age of three (Derkay, 1993; Vaile et al., 2006; Kogan et al., 2000).  A 
study by Rosenfeld and Bluestone (2003) found that even though the impact of 
surgery is variable, children with recurrent AOM who receive TT have avoided – at 
least in the US settings – two diagnosed episodes of AOM a year as compared to 
those not undergoing TT insertion.  
 
1.2.6.2 ANTIBIOTIC ADMINISTRATION  
Historically in the UK, OM has been the primary reason for antibiotic prescribing in 
children.  Amoxicillin is the recommended first-line drug, due to its powerful effect on 
(ie low Minimum Inhibitory Concentration or MIC for) both S. pneumoniae and H. 
influenzae.  However, erythromycin may alternatively be used for those with allergic 
reactions to penicillins, even though it is less effective against H. Influenza. The 
latter causes a quarter to a fifth of all AOM cases. Azithromycin and clarithromycin 
can also be used as alternative treatments that are effective against all the main 
pathogens of AOM (Craig and Andes, 1996; BNF for children, 2012).  
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The antibiotic treatment goal for OM is to sterilise the middle ear fluid. In order to 
achieve this effective concentration must logically be reached for an appropriate 
period of time. Judging this can be problematic, but for uncomplicated ear infections 
five days is normally considered sufficient to clear the infection. Longer durations 
are needed in some cases (BNF for Children, 2012). However, two days medication 
with high-dose antibiotics for OM has been suggested as an alternative approach 
designed to reduce the development of antibiotic-resistance (Oxford Childhood 
Infection Study Group, 2009).  
 
Resistance of S. pneumoniae to penicillin and other beta-lactam based antibiotics 
has been increasing globally (see, for instance, Ruhe et al, 2004, and Vanderkooi et 
al, 2005). Such problems have been identified as high priority concerns by 
authorities such as the immediate past and the current Chief Medical Officers for 
England.  The main mechanism involved is the introduction of mutations in genes 
encoding for penicillin-binding proteins (Albrich et al., 2004). Many factors affect the 
development of antibiotic resistance but prior antibiotic use and a record of frequent 
infection are amongst the most common.  
 
There is a strong relationship between antibiotic consumption and the prevalence of 
the antibiotic-resistance bacteria. The higher antibiotic prescribing countries have 
higher levels of antibiotic-resistance.  It has been claimed, for instance, that 10-40% 
of pneumococcal isolates in the US exhibited penicillin-resistance compared to less 
than 1% from the Netherlands (Albrich et al., 2004; De Neeling et al., 1996; 
Committee on Infectious Diseases, 1997).  
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Moreover, a Finnish study has shown that a reduction of 50% in antibiotic 
prescriptions resulted in a corresponding reduction of resistant bacteria (Seppala et 
al., 1997) and there is also UK community evidence linking prescribing volumes to 
laboratory identified resistance levels. (Note, for example, Howard et al., 2001.) 
 
Systematic review based evidence, UK-based government reports and clinical 
practice guidelines may all have influenced GP antibiotic prescribing for OM. Clinical 
guidelines state antibiotic prescription for AOM to be of limited benefit in most AOM 
cases, and recommend analgesics for children with this diagnosis. There is 
evidence that when these are used for limited periods most of the OM symptoms will 
resolve without the need for antibiotic therapy (Cates, 2003). For example, a multi-
centre randomised control trial including 219 children aged one to six years with 
uncomplicated OM found that ibuprofen or paracetamol significantly reduce earache 
in two days (Bertin et al., 1996).  
 
A recent meta-analysis of ten randomised controlled trials was conducted to 
investigate which age group with OM episodes should be treated with antibiotics. It 
found that these medicines were most beneficial for children younger than two years 
with bilateral acute OM and those with AOM and ottorhea. The authors recommend 
the use of adequate analgesia and an observational approach in children with ‘mild’ 
disease (Sanders et al., 2010).  
 
Even in the 1950s there were doubts about using antibiotics for the treatment of OM. 
A study by the English GP John Fry (1958), for instance, reported that 78% of OM 
episodes resolved without requiring antibiotic treatment.  
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Additionally, a subsequent Cochrane Collaboration systematic review concluded 
that there is a limited role for antibiotics in the treatment of OM, as most of the cases 
resolve without any complication (Glasziou et al., 1997).  Since 2003 in the UK 
delayed antibiotic prescribing has been advocated, in particular for children aged 
two years and above (SIGN, 2003; PRODIGY, 2004; Rovers et al., 2006; NICE, 
2008).  
 
This means that GPs provide the prescription, but advise the parents to delay their 
use in case the symptoms resolve spontaneously. (This practice has implications 
regarded the utility of data sets such as those provided by IMS – see below.). Yet 
most commentators agree about the benefit of using antibiotics for children under 
two years of age, despite the attendant antibiotic resistance risks. Increasing the 
latter must in time increase the prevalence of drug-resistant organisms, and 
consequently drive up morbidity and mortality levels along with health-care costs.  
 
The case for the use of effective S. pneumoniae vaccines in large part rests on such 
observations, along with the fact that even without resistance related problems 
pneumococcal infection can via its role in causing conditions such as meningitis on 
occasions lead to brain damage or death in young people who have not been 
protected by immunisation. 
 
1.2.6.3 VACCINES 
To contain the development and spread of antibiotic-resistant organisms, the future 
management of OM should concentrate more on preventive strategies rather than 
treatment.   
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After studies to prove the safety and efficacy of the vaccine, pneumococcal 
conjugate vaccine (PCV7, 2006) was introduced to the UK childhood primary 
immunisation schedule.  This vaccine links S. pneumoniae derived material with a 
stronger diphtheria bacillus derived antigen to elicit a protective response in subjects 
too young to respond adequately to the previously available polysaccharide based 
vaccines.    
 
Despite evidence such as that shown in Figure 1.6 from American and other 
investigators showing PCV7 to be effective in reducing the number of OM related 
physician consultations and the associated treatment levels in the US environment 
(Grijalva et al., 2006; Zhou et al., 2008; Taylor et al., 2012; Singleton et al., 2009; 
Sox et al., 2008) the full impacts of this intervention have not previously been 
systematically studied in the UK community setting. Later sections of this thesis 
seek to fill this gap in the current literature. 
Figure 1.6: Trends in Otitis Media rates among observational database studies 
presenting data for years before and after 7-valent pneumococcal conjugate 
vaccine introduction in 2000  
(From Taylor et al., 2012)  
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1.3 PNEUMONIA 
Overview 
Pneumonia is a potentially fatal infection of the air sacs (alveoli) and smaller airways 
of the lungs (Fig.1.7), which become inflamed and fill with fluid. This reduces their 
capacity for gaseous exchange.   
Figure 1.7: The location of the lungs and airways in the body  
(National Heart Lung and Blood Institute, 2012) 
 
 
It is one of the most common infectious diseases in young children, with – in this 
country – the majority of infections occurring in the autumn and winter (NICE, 2007).   
     
In the UK, according to data from the Hospital Episode Statistics (HES), up to 1% of 
children aged 0-5 years will contract pneumonia (NICE, 2007). A study by Holmes 
and Woodhead (1999) suggests that in the UK about one third of individuals with a 
pneumonia diagnosis are admitted to hospital.  
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In addition, the HPA recently estimated that in England and Wales each year there 
are 40,000 GP consultations for pneumococcal disease related community acquired 
pneumonia (CAP) (HPA, 2010).  
 
Globally, pneumonia accounts for approaching a fifth of all deaths of children under 
five years old, with an incidence of 0.29 episodes per child-year in low-income 
countries and 0.05 episodes per child-year in high-income countries (WHO, 2013). 
World-wide, approximately 156 million new episodes occur each year. (Forty three 
million in India, 21 million in China, 10 million in Pakistan and 6 million in 
Bangladesh, Indonesia and Nigeria.) Nineteen percent of all deaths in children aged 
less than five years were due to pneumonia, of which more than 70% occurred in 
sub-Saharan Africa and South-East Asia (Kabra, Lodha and Pandey, 2010). 
 
On clinical grounds alone, it can be difficult to diagnose pneumonia. Microbiological 
examination of sputum (or deeper specimens from the lower respiratory tract 
obtained by bronchoscopy, or by lung biopsy), x-ray and blood cultures are 
sometimes recommended to confirm the diagnosis and the causative agent, which 
in the great majority of cases is viral rather than bacterial.  
 
It may perhaps be argued that in the hospital environment treatment should be 
started after the organism causing the infection is identified. However, in the 
community it is rarely possible for this to be achieved, and there is always a 
possibility of patients’ conditions worsening. An alternative way forward can be to 
start on broad spectrum therapy and as necessary become more specific if and 
when additional information is gained.   
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Decisions on therapy are based upon clinical history, and factors such a history of 
exposure to infection, age, underlying disease and previous therapies, a past history 
of pneumonia or related conditions, geographic location, severity of illness, clinical 
symptoms and sputum examination. Once an accurate diagnosis is available 
therapy should be directed at the organism responsible (Purushothama and Chien, 
1996; British Thoracic Society, 2011). The British Thoracic Society Community 
Acquired Pneumonia (CAP) Guidelines recommend that bacterial pneumonia could 
be considered in children aged up to 3 years in the presence of a combination of 
fever >38.5 0C, chest recession and a respiration rate of >50/min (British Thoracic 
Society Standards of Care Committee, 2011).  
 
In most cases, pneumonia can be treated with oral antibiotics such as penicillin. 
Children may be hospitalised for treatment if they have pneumonia caused by 
pertussis or other bacterial pneumonia forms that cause high fevers and respiratory 
distress.  Pneumonia can also lead to complications, which are more frequently 
associated with bacterial rather than viral pneumonia.  Purushothama and Chien 
(1996) noted they may include: 
 Pleural effusion: excess fluid filling the space that surrounds the lung that 
impairs breathing by limiting the expansion of the lungs during inhalation. 
 Empyema: collection of pus within a naturally existing anatomical cavity. 
 Lung abscesses: the collection of pus in newly formed cavities. 
 Pneumatocoeles: cavities in the lungs filled with air that may result from 
pulmonary trauma. 
 Pneumothorax: air/gas present in the pleural cavity. 
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 Pyopneumothorax: pus and air or gas in the pleural cavity - e.g. following 
rupture of a staphylococcal lung abscess in the pleural cavity. 
 Deep vein thrombosis 
 Septicaemia, pericarditis, endocarditis, osteomyelitis, septic arthritis, 
cerebral abscess, meningitis 
 Post-infective bronchiectasis: Inflammation of bronchial and allied tissue 
related to an abnormal build up of mucus in the lung. 
 Acute renal failure  
 
1.3.1 CLASSIFICATION OF PNEUMONIAS 
Pneumonia can be classified in a variety of different ways, most commonly in 
relation to where it was acquired (community or hospital). It may also be categorised 
by the area of lung that has been infected or by the type of organism that caused the 
infection (Dune, 2005). Pneumonia can also be classified on the basis of combined 
clinical and allied factors such as patient age, risk factors for some pathogens, the 
presence of other known lung or systemic disease, and whether the person has 
recently been hospitalised.  
 
1.3.1.1 COMMUNITY ACQUIRED PNEUMONIA (CAP) 
Community acquired pneumonia is the most common type of pneumonia. In 
childhood it is a common cause of hospital admission. However, its severity can 
range from very mild disease to systemic illness ultimately causing death.   
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Hence diagnosis and assessment is critical.  Clinically, it can be defined as the 
presence of signs and symptoms of pneumonia in a previously healthy child who 
has been infected outside hospital. In developed countries pneumonia can be 
verified radiologically.  In the developing world radiological verification may not be 
possible. In such circumstances CAP is also commonly referred to as acute lower 
respiratory tract infection (British Thoracic Society of Standards of Care Committee, 
2011).  
 
1.3.1.2 HOSPITAL ACQUIRED PNEUMONIA (HAP) 
Hospital-acquired pneumonia may be referred to as nosocomial or healthcare-
associated pneumonia (HCAP). It becomes apparent during or within 72 hours after 
the patient been hospitalised for another illness. The infection can be transmitted 
between patients in several ways, including via mechanical ventilation, when it may 
be known as ventilator-associated pneumonia (VAP). HAP is characteristically 
different from CAP in terms of its causes, treatment, and complications. This is 
because the types of pathogen that the patient may be exposed to in hospital are 
often different from those normally encountered in the home/community setting.  
 
It tends to have worse outcomes than community-acquired pneumonia, as hospital-
acquired pathogens may more frequently include antibiotic resistant bacteria 
(American Thoracic Society Documents, 2004).  Patients with underlying illnesses 
are also more vulnerable to virulent and less virulent pneumococcal strains alike.  
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1.3.1.3 CATEGORISATION BY CAUSE 
Historically, based on the type of pathogen and the symptomology of the patients 
involved, pneumonia has been referred to as either typical or atypical.  However, 
The American Thoracic Society does not recommend this classification (Ebby, 
2005). Based on the cause of infection, pneumonia is today classified as:   
 Bronchiolitis obliterans organising pneumonia (BOOP). This was first 
described in the early 1980s. It is also known as cryptogenic organising 
pneumonitis (COP). It is caused by inflammation of the small airways of the 
lungs and it characterised by the presence of granulation tissue inside the 
distal air spaces (Al-Ghanem et al., 2008).  
 Eosinophilic pneumonia. This occurs when eosinophils invade the lungs. It 
quite often occurs in response to infection with a parasite or after exposure 
to certain environmental insults. 
 Chemical pneumonia. This condition can also be known as chemical 
pneumonitis. It is caused by chemical toxins, which may enter the body by 
inhalation or skin contact. If the toxic substance is an oil, this is known as 
lipoid pneumonia. 
 Aspiration pneumonia. Aspiration pneumonia or pneumonitis is caused by 
aspirating oral or gastric contents, either while eating or after reflux or 
vomiting, which causes bronchopneumonia. It is the leading cause of death 
in hospital and patients based in nursing homes.   
 Dust pneumonia. Dust pneumonia is normally caused by exposure to dust 
storms.  The dust progresses into the alveoli of the lungs, stopping the cilia 
from moving and so preventing the lungs from clearing themselves. 
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 Necrotising pneumonia. Necrotising pneumonia includes pneumonias that 
cause significant necrosis (apoptosis or other death) of lung cells. 
Sometimes lung abscesses may occur.  Anaerobic bacteria such as 
staphylococcus aureus, klebsiella pneumoniae and streptococcus pyogenes 
are the predominant causal microbes (Sheppard et al., 2007).   
 Opportunistic pneumonia. This mostly occurs in immunocompromised 
individuals, such as those with AIDS and receiving chemotherapy for cancer. 
The main pathogens mainly responsible include cytomegalovirus and 
pneumocystis and mycobacterium, as well as a range of other pathogens 
(Sheppard et al., 2007).   
 Double pneumonia. This is a traditional term used for acute bilateral lung 
infection, acute respiratory distress syndrome (ARDS). It is more likely today 
to be known as bilateral pneumonia (Girard & Bernard, 2007). 
 Severe acute respiratory syndrome (SARS). This is a highly transmittable 
and form of pneumonia with a high case mortality ratio which first occurred in 
2002 in China. SARS is caused by the SARS corona virus, a previously 
unknown pathogen. The last recorded occurrence was in 2003 (Sheppard et 
al., 2007).  
 
1.3.2 BURDEN OF DISEASE 
Pneumonia is the leading cause of death in children under five years old (Figure 
1.8). Even today it causes more mortality than AIDS and malaria combined, 
accounting for up to 2 million child deaths each year. This represents approximately 
one in five child deaths worldwide and an incidence of 0.05 episodes per child-year 
(Rudan et al., 2004; Kabra Ladha and Pandey, 2010).  
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In the UK, according to data from the Hospital Episode Statistics (HES) records, 
around 1% of all children aged 0-5 years old experience pneumonia (NICE, 2007).  
A study by Holmes et al (1999) suggests that in the UK about one third of people 
with a pneumonia diagnosis are admitted to hospital. In addition, the Health 
Protection Agency (HPA) estimates that in England and Wales each year there are 
40,000 GP consultations for pneumococcal related CAP (HPA, 2010).  
 
 
Figure 1.8: The State of the World's Children 2008, Child Survival UNICEF  
(Adapted from United Nations Children’s Fund, 2007)  
 
 
 
1.3.3 RISK FACTORS 
In order to facilitate the prevention and management of pneumonia, it is necessary 
to understand the risk factors described below. 
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1.3.3.1 HOST FACTORS  
Young age:  As with OM, pneumonia is most commonly found in young 
children (Dunn et al., 2005; Cilla et al., 2008.  A study by Koshy et al (2010) 
found that the highest admission rates for bacterial pneumonia were in the 
youngest age groups (0-4 years old). Also, Michelow et al (2004) found that, 
pneumonia pathogens were found in 92% of children aged under 6 months, 
while a randomised, double blind, placebo-controlled vaccine probe trial in 
Phillipines indicate that a third of young children with a pneumonia diagnosis 
had pneumococcal pneumonia (Lucero et al., 2009). Moreover, a study by 
Myles et al (2009) using a longitudinal, general practice database covering 
the period between 1991 and 2003 found that pneumonia most common in 
children aged under 4 years.   
 
Male gender: As is true for most infectious diseases of childhood, 
pneumonia occurs more frequently in boys than girls (Klein, 2001). In 2007 a 
study by Clark et al found that in the UK incidence rates of pneumonia are 
higher in males than females at all ages (Harris et al., 2011). 
 
Geographical location: In the US, over 1 million children and adults are 
admitted to hospital for pneumonia each year (Center for Disease Control 
and Prevention/CDC, 2009). Outside the developed world a report by the 
United Nations Children’s Fund (UNICEF) stated that, between 2006-2011, 
the highest levels of care-seeking for pneumonia for children aged under 5 
years were found in South Asia and East Asia & the Pacific excluding China 
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with 65% and 64% respectively, followed by 49% in sub-Saharan Africa 
(United Nations Children’s Fund, 2012 – see Figure 1.9.)  
 
Atopy/ allergy: As with other infectious diseases, atopic reactions and 
allergies may also predispose subjects to pneumonia (See Arroyave, 
2001). 
Figure 1.9: Proportion of children under five with suspected pneumonia taken 
to an appropriate health-care provider, 2007–2012. 
(Taken from United Nations Children’s Fund, 2012)  
 
 
* Excludes China. 
1.3.3.2 BACTERIAL AND VIRAL LOAD 
Pneumonia is commonly caused by infection with fungal, viral or bacterial pathogens 
or a combination of such agents (WHO, 2012). Although there are a number of 
viruses associated with CAP the predominant one is, as in the case of OM,  
Respiratory Syncytial virus (RSV). This has been detected in similar proportions of 
children with pneumonia in the community and in hospital (Harris et al., 2011).  
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In the UK, during a six month winter ‘flu season, pneumonia was found in 16% of 
children infected with Influenza A (Laundy et al., 2003).  
However, several other viruses are regularly associated with pneumonia. They 
include Adenovirus, Rhinovirus, Varicella Zoster virus, Cytomegalovirus, Herpes 
Simplex and various Enteroviruses.   
 
Overall, viruses appear to account for more than 30% of CAP cases in childhood. 
They are more frequently identified in children <1 year old (77%) compared with 
over 2 years (59%) (Cilla et al., 2008). However, S. pneumoniae is the leading 
bacterial cause of pneumonia. Prospective studies reported that S. pneumoniae 
accounts for 30‐50% of such cases, followed by Hemophilus influenza. In the latter 
context type b (Hib) has in the past typically caused 10‐30 % of pneumonia cases. 
But it has now almost disappeared in immunised populations.  
 
Mycoplasma and Chlamydia infections are equally common in school aged children. 
Even though S. Aureus and Klebsiella pneumoniae infections are less frequently 
recorded in children they impose a significant morbidity burden and can cause 
severe pneumonia (Nelson, 2000; Rudan, 2008). 
 
It is difficult to quantify precisely the proportion of CAP caused by bacteria as they 
can be difficult to detect. Although, for example, S. pneumoniae is known to be the 
most common bacterial cause of CAP it is comparatively rarely found in blood 
cultures. The available data indicate that it is in practice found in only 4-10% of CAP 
cases (Clark et al., 2007; Cilla et al., 2008) although a review of lung tap studies 
found that S. pneumoniae had been identified in 39% of such cases (Vuori-
Holopainen and Peltola 2001).  
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Yet 90% of children (n=34) in Finland who had a lung aspirate, either by culture or 
by using polymerase chain reaction (PCR) techniques, were found to have S. 
pneumoniae (Vuori-Holopainen et al., 2002).  
In fact, S. pneumoniae causes about a third of radiologically confirmed cases of 
pneumonia in children under 2 years. Haemophilus influenzae type b (Hib) is known 
to be the second most common cause of bacterial pneumonia (WHO, 2012). It is in 
older children that other pathogens such as Chlamydia and Mycoplasma are more 
commonly found (Kurz et al., 2009).  
 
1.3.3.3 GASTRIC ACID INHIBITORS 
The use of gastric acid inhibitors is known to be associated with increased 
pneumonia risk in adults. A single study has suggested this may also be true in 
children (Canani et al., 2006).  
 
1.3.3.4 IMMUNE RESPONSES AND PRE-EXISTING DISEASE 
Most healthy children can fight off respiratory infections with their natural defenses. 
However, those whose immune systems are compromised are at higher risk of 
developing pneumonia. A child's immune system may be weakened due to, for 
instance, malnutrition or an immuno deficiency. For related reasons the risk of 
children contracting pneumonia is also increased in those with pre-existing illness 
such as symptomatic HIV infections and measles (WHO, 2012).   
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1.3.3.5 ENVIRONMENTAL FACTORS  
The following environmental factors also increase a child's susceptibility to 
pneumonia: 
Exposure to tobacco smoke: As mentioned earlier, smoking is associated 
with S. pneumonia infections. Parental smoking significantly contributes to 
child morbidity and mortality associated with this bacterium. Smoke-filled 
environments contribute to the incidence of both upper and lower respiratory 
tract infections (National Institute for Health and Clinical Excellence, 2000; 
Ebby, 2005).  
 
Other air pollution: Indoor air pollution that results from cooking and 
heating with biomass fuels (such as wood or dung) can also increase the 
incidence of pneumonia in children (WHO, 2012). 
 
Season: The season another important environmental factor affecting the 
prevalence of CAP, especially for young children. In the northern hemisphere 
winter sees a predominance of laboratory reported invasive pneumococcal 
disease and hospital admissions due to confirmed pneumococcal infections.  
A study by Melegaro et al (2006) showed that the incidence of CAP in 
December and January is 3-5 times higher than in August.  
In addition another study published in 2009 by Senstad et al. reported a low 
incidence of hospital CAP in summer and a peak in January.  
 
                                                     CHAPTER ONE 
57 
 
1.3.4 PATHOLOGY AND COMPLICATIONS 
Children with CAP may present with complications such as empyema and/or a lung 
abscess. The complications that are most commonly associated with CAP include 
the following:  
Pleural effusions and empyema. Pleural effusions and empyema common 
occur in patients with pneumonia. They are mainly caused by S. 
pneumoniae.  Pleural effusion is defined as a collection of fluid in the space 
between the linings (pleura) of the lung.   
Empyema involves the presence of pus in the pleural space. Excessive 
amounts of fluid and pus can impair breathing by limiting the expansion of 
the lungs during ventilation. These complications are more commonly found 
in patients admitted to hospital. One percent of CAP cases develop pleural 
effusion compared to 40% of cases admitted to hospital (Harris et al., 2011).  
It has, however, been reported that in England the rate of admission with a 
diagnosis of empyema increased over the last decade, most commonly in 
children aged less than 5 years (Buckingham et al., 2003). 
 
Necrotising pneumonias. Necrotising pneumonias (NP) are defined as 
multiple small cavitations without enhancing margins, mainly caused by the 
adenovirus. Certain serotypes of pneumococcal disease are more likely to 
lead to necrotising pneumonia than others (Sheppard et al., 2007; Bender et 
al., 2008). Following a complicated pneumonia diagnosis, NP has been 
increasingly recognised due to the use of CT scans of the chest (Kliegman, 
2006). 
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Septicaemia and other metastatic infections. Pneumonia can also 
accompany other or more extensive systemic infections. Children with 
septicaemia and pneumonia are more likely to need high dependency or 
intensive care management. However, metastatic infections other than 
septicaemia are very rarely associated with pneumonia (Harris et al., 2011). 
 
Haemolytic Uraemic Syndrome. Haemolytic uraemic syndrome (HUS – 
which involves red blood cell destruction and can result in permanent kidney 
damage) is rarely caused by S. pneumoniae. Yet a recent case series study 
reported that out of 43 cases of pneumococcal HUS, 35 presented with 
pneumonia (Waters, 2007). 
 
Long term sequelae. In 2004 a study by Eastham et al. found that children 
who have had an episode of CAP are more likely to suffer from prolonged 
cough (19%), chest wall shape abnormalities (9%) and asthma (23%). 
 
1.3.5 SYMPTOMS AND DIAGNOSIS 
CAP in childhood is a common cause of hospital admission, although its severity 
can range from very mild disease to systemic illness and death. Early diagnosis and 
assessment is therefore critically important. 
 
Most children are initially seen by their GP. If indicative symptoms such as cyanosis, 
difficulty in breathing and/or signs of dehydration are present an immediate referral 
to hospital should be made. But in infants and young children the signs and 
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symptoms of pneumonia can be unspecific. Broad indicators like fatigue, fever, 
chills, headache, coughing, pain in the stomach or chest, vomiting, diarrhea and a 
loss of appetite are common with pneumonia.  
 
Further, even in the case of young children who have been hospitalised after being 
correctly diagnosed with pneumonia, subjects may still experience symptoms for 
weeks after being treated and discharged. Their symptoms may only gradually 
subside in the days and weeks after returning home (NICE, 2007). 
 
In general, a combination of fever and cough is suggestive of pneumonia. Other 
respiratory findings (e.g., tachypnea – unusually rapid breathing – and a sense of 
having to make an increased effort to breath) leading subsequently to coughing may 
also be significant. Coughing may not be a clinical feature initially since the alveoli 
have few receptors involved in cough responses. It begins when the products of 
infection irritate ‘cough receptors’ in the airways. The longer fever, cough, and other 
respiratory findings are present, the greater the possibility of pneumonia.  
 
A definitive diagnosis of pneumonia is usually made not only on symptoms but also 
on radiographic and microbiological diagnosis (NICE, 2007). Most cases of 
pneumonia are initially diagnosed clinically. GPs and paediatricians typically make 
the diagnosis after a physical examination, based on the child's signs and 
symptoms. But when necessary (and normally in the hospital environment)  a chest 
X-ray and blood cultures are recommended, along with other tests such as a 
complete blood count (CBC) and C-reactive protein (CRP). If the responsible 
clinician thinks that the child has pneumonia oxygen saturation levels are also likely 
to be taken, especially if the child is experiencing breathing difficulties. 
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Testing for Respiratory Syncytial virus infections (RSV), flu, and other viral causes of 
pneumonia can also be helpful, as and when the relevant facilities are available. 
Sputum cultures can also be taken. However, this technique is not as helpful in 
infants and young children as it is in other groups because it is often hard to obtain 
an adequate sputum sample (NICE, 2007; Inannelli, 2011).  
 
1.3.6 CLINICAL MANAGEMENT 
As with other infectious diseases, treatment depends on the underlying cause of the 
infection. However, in most cases, pneumonia can be treated with oral antibiotics, 
which can be prescribed by a GP. The vast majority of cases of childhood 
pneumonia can be and are managed effectively within the home.  Hospitalisation is 
mainly recommended in infants aged two months and younger and in cases where 
there is trouble breathing, dehydration, high fever, and the need for oxygen (WHO, 
2012).  
 
1.3.6.1 ANTIBIOTICS  
The management of a child with CAP involves a number of decisions regarding 
treatment with antibiotics.  If it is decided that antibiotics should be used subsequent 
questions may appropriately include ‘which type of antibiotic and by which route?’, 
‘when should the route of antibiotic administration be changed from intravenous to 
oral?’ and ‘for how long should the antibiotic therapy be continued?’. 
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The major problem in deciding whether to treat a child with CAP with antibiotics or 
not is the difficulty in distinguishing between bacterial pneumonia (which would 
benefit from antibiotic treatment) from non-bacterial pneumonia (which would not) 
(Harris et al., 2011).  
 
As already noted, amoxicillin is normally recommended as the first choice for oral 
antibiotic therapy in children of less than five years of age as it is effective against 
most organisms that cause CAP, as well as being well tolerated and cheap (British 
Thoracic Society Standards of Care Committee, 2011). Alternative recommended 
oral treatments can include co-amoxiclav, cefacolor, erythromycin, clarithromycin 
and azithromycin.   
 
A meta-analysis of 27 randomised trials of antibiotic treatment for childhood CAP 
confirmed that amoxicillin is a robust alternative to co-trimoxazole for the treatment 
of ambulatory patients (Kabra et al., 2010). However, world-wide only around 30% 
of children with pneumonia receive the antibiotics they need (WHO, 2012).  
 
Children should ideally be hospitalised if they have pneumonia caused by pertussis 
or other bacterial pneumonias that cause high fevers and respiratory distress. 
Untreated or missed diagnosis of pneumonia can progress to severe and potentially 
life-threatening complications (Purushothama et al., 1996).  
 
Resistance to antibiotics among bacterial pathogens is increasing and is of global 
concern. It is in part driven by the overuse of antibiotics, although even when they 
are used correctly resistance to such medicines will in time tend to emerge.  
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It has the potential to impact on therapeutic choices and there is worldwide concern 
about increasing antibiotic resistance among pneumococcal strains and its eventual 
impact on treatment for pneumonia and invasive pneumococcal disease (Goossens 
et al., 2005).  
 
From 1998 to 2000, the estimated global rate of penicillin resistance in S. 
pneumoniae was about 18%. Rates of resistance to co‐trimoxazole among strains of 
S.pneumoniae and H. influenzae are generally high. In the UK however, penicillin 
resistance is less prevalent.  
 
Pneumococcal penicillin non-susceptibility in pneumococci causing bacteraemia 
increased in the 1990s to 6.7% in 2000, and has since declined to around 4% in 
2007.  Geographical variations range from 1.5% in the East Midlands to 8.0% in 
London area.  This is in contrast to much of mainland Europe. Resistance rates are 
between 25-50% France and Spain (HPA 2010, Harries, 2011).  
 
National campaigns to reduce antibiotic prescribing have led to a reduction in 
prescribing in some countries (Goossens et al., 2006).  Nevertheless, the 
appearance of high-level penicillin and multidrug-resistant S.pneumoniae strains has 
led to an increase in incidence of antibiotic treatment failure (Jacobs, 1999; Barry, 
1999).   
 
In particular, children who have recently received antibiotics are at increased risk of 
acquiring a resistant strain of S. pneumonia. This can lead to additional morbidity, 
mortality and raised health care costs (Jacobs, 1999). 
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A logical approach to reducing the incidence of pneumonia in children and avoiding 
other forms of S.pneumoniae related harm is therefore through prevention by 
vaccination (Hyde et al., 2001; Kaplan and Mason, 2002).  
 
1.3.6.2 VACCINES 
In 2000, PCV7 was licensed in the US for use among infants and young children to 
prevent pneumococcal infectious diseases such as pneumonia. The UK’s routine 
immunisation programme has also offered protection against these infections with 
the introduction of PCV7 in 2006 for children at ages 2, 4 & 13 months old. 
 
In the United States there was after the introduction of PCV7 a reported 39% 
decrease in hospital admission rates for pneumonia in children under 2 years 
(Grijalva et al., 2007).  The HPA/Public Health England has in this country also 
reported a reduction in the rate of IPD cases caused by the seven serotypes in 
PCV7 in children aged under and over 5 year olds since the introduction of the 
PCV7 (HPA, 2009).  
  
A recent study in the UK using HES data found that following the inclusion of PCV7 
in the national childhood immunisation programme, pneumonia hospital admission 
rate in England declined by 20% in children aged 0-15 years within 2 years (Koshy 
et al., 2010). With the introduction of the conjugate pneumococcal vaccine, indirect 
evidence of vaccine efficacy for the prevention of pneumonia can be used to assess 
the contribution of S.pneumoniae to CAP management. 
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In children under 2 years trials have consistently shown a decrease in radiologically 
confirmed pneumonia from 23% in the Phillipines (Lucero et al., 2009) to 37% in the 
Gambia (Cutts et al., 2005) and 25.5% in California (Hansen et al., 2006). The 
observed effect has been most striking in the first year following vaccine introduction 
with a 32%+ incidence reduction, as compared with a lower 23% reduction at the 
end of 2 years (Black et al., 2002).   
 
Although there is robust evidence that the introduction of PCV7 has decreased the 
occurrence of IPD and NIPD due to vaccine serotype bacteria, its impact on the 
overall incidence of OM and pneumonia and related antibiotic prescribing in the UK 
is less clear. An observational cohort study utilising two UK general practice-based 
databases was therefore designed in order to generate a better understanding of 
such questions. However, before this research is described it is relevant to discuss 
further factors underlying the introduction of the vaccine and aspects of its efficacy 
and safety in pediatric use. 
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1.4 SEVEN-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION 
(PREVNAR 7®, PCV7) 
1.4.1 ANTIBIOTIC RESISTANCE AND THE INTRODUCTION OF THE PCV7 
There are two types of antibiotic resistance, inherent and acquired resistance. 
These are caused by either random gene mutations or horizontal gene transfers 
between bacteria. The mechanisms of antibiotic-resistance include modification, 
inactivation or destruction of the antibiotic; reduced effective antibiotic intake; 
increased antibiotic excretion via pump mechanisms; alteration of the drug’s target 
and activation of an alternative metabolic pathway that avoid reliance on processes 
linked to the antibiotic's site of action.  
 
Once resistant bacteria persist spontaneously they can infect individuals in the wider 
community, e.g. schools and workplaces (Standing Medical Advisory Committee, 
1998). Many studies demonstrate the link between the use of antibiotics and the 
development of antibiotic-resistance (Gold and Moellering, 1996) in both inpatient 
(McGowan, 1983) and outpatient settings (Reichler et al., 1992).  
 
Acquired antibiotic-resistance is not present in bacteria that pre-date the antibiotic 
period (Hughes and Datta, 1983) and resistant bacterial strains have continually 
emerged following antibiotic usage (Standing Medical Advisory Committee, 1998). 
The high consumption of antibiotics is recognised as the main cause of emerging 
resistance to antibiotic treatment.  
 
Goossens et al. (2005) compared rates of penicillin prescribing and penicillin-
resistance in 26 countries across Europe. Penicillin consumption was found to vary 
significantly.  
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The highest rate was in France, where the highest levels of resistance were 
recorded, whilst the lowest rates of both prescription and resistance were seen in 
The Netherlands (Figure 1.10).  
Figure 1.10: Correlation between penicillin use and rates of penicillin-resistant 
Streptococcus pneumoniae across European countries in the year 2000  
(From Goossens et al., 2005)  
 
 
Key:  
AT=Austria; BE=Belgium; HR=Croatia; CZ=Czech Republic; DK=Denmark; 
FI=Finland; FR=France; DE=Germany; HU=Hungary; IE=Ireland; IT=Italy; 
LU=Luxembourg; NL=Netherlands; PL=Poland; PT=Portugal; SI=Slovenia; 
ES=Spain; UK=England only  
 
Other studies have documented a link between antibiotic use and resistance at the 
individual patient-level. Steinke et al (2001) demonstrated that the risk of an 
individual being colonised by resistant bacteria increases following recent use of 
antibiotics.  The authors conducted a case-control study of 13,765 people, whereby 
antibiotic exposure in subjects with trimethoprim-resistant isolates was compared 
with antibiotic exposure in subjects with trimethoprim-susceptible isolates.  
 
                                                     CHAPTER ONE 
67 
It was found that exposure to trimethoprim, or any other antibiotic, within the 
previous 180 days increased the risk of colonisation with trimethoprim-resistance 
bacteria.  
 
Nasrin et al (2002) conducted a prospective cohort study of 461 children aged less 
than two years old.  It was found that children who had received a β-lactam 
antibiotic had twice the risk of being colonised with penicillin-resistant pneumococci 
within the two months following treatment compared to those who did not receive a 
β-lactam antibiotic. This risk increased by 4% for each additional day of β-lactam 
use within the six months prior to testing. Furthermore, a recent prospective cohort 
study of 119 children presenting to primary care with acute respiratory tract infection 
reported that the risk of isolating a β-lactamase producing pneumococci from a 
child’s throat doubled at two weeks following treatment with amoxicillin (Chung et 
al., 2007).  
 
A study by Brook and Gober (2005) also confirmed the positive correlation between 
antibiotic use and the development of antibiotic-resistance. The authors investigated 
the antibiotic susceptibility of bacteria isolated from the nasopharynxes of children 
with acute Otitis Media and compared it with children with recurrent Otitis Media that 
had developed between four to six weeks after a previous ear infection that had 
been treated with amoxicillin.  
 
Resistance was found in 12% (37/320) of the isolates obtained from the acute Otitis 
Media group compared to 39% (99/256) from the recurrent Otitis Media group 
(P<0.05).  
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As it has been confirmed that antibiotic use is linked to the development of 
antibiotic-resistant bacteria, it follows theoretically that reducing antibiotic use should 
slow the development of new resistance to antibiotics.   
 
Reduced antibiotic use would also decrease adverse reactions related to antibiotic 
exposure and lower costs associated with antibiotic prescribing, albeit that any 
savings generated would be offset by the costs and possible consequences of the 
measures employed to curb antibiotic usage. 
 
National campaigns to reduce antibiotic prescribing in some countries have, as 
previously reported, led to reduction in prescribing levels (Goossens et al., 2006). In 
the UK specifically Butler et al (2007) demonstrated that amongst laboratory 
samples from general practice populations, lower levels of antibiotic-resistance were 
significantly associated with reduced antibiotic prescribing in the practice.  
 
The appearance of high-level penicillin and multidrug-resistant S. pneumoniae 
strains has led to an increase in incidence of antibiotic treatment failures (Jacobs, 
1999; Barry, 1999).  In particular, children who have recently received antibiotics are 
at increased risk of acquiring a resistant strain of S. pneumoniae, which can lead to 
an increased risk of morbidity, mortality and health costs (Jacobs, 1999).   
Such observations underpin the case for purchasing and supplying PCV7 and its 
successors (Hyde et al., 2001; Kaplan and Mason, 2002).  
 
1.4.2 WHAT IS PCV7? 
In US, the first pneumococcal polysaccharide vaccine was licensed for use with 14-
valent serotype array in 1977.  
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This was followed by a 23-valent serotype product in 1983, offering protection 
against almost 90% of recorded pneumococcal infections. However, these vaccines 
were ineffective in young children under 2 years of age because they induce a T-cell 
independent antibody response that it too limited to be effective in children with 
immature immune responses and hence does not result in become imprinted in their 
immunologic memories.  
  
In February 2000, a new polysaccharide-protein conjugate vaccine was introduced 
in US, following its being licensed by the Food and Drug Administration (FDA) for 
use amongst infants and young children. It was specifically designed to have an 
enhanced immunogenicity in younger children (Kellner et al., 2005; Sleeman et al., 
2001). The mechanisms by which conjugation achieves this end cannot be explored 
in detail here. But they in essence involved linking a weak antigen to a stronger 
antigenic carrier in a manner which confers the immunological properties of the 
latter upon the former. 
    
Following its introduction in the US PCV7 was marketed in Europe and elsewhere, 
and many other countries introduced this vaccine into their immunisation 
programmes (Table 1.5).  
 
Immunisation schedules differ between countries, but the initial dose is usually given 
before the child is six months of age (Gomes et al., 2009). In 2007, the WHO 
recommended that all countries incorporate PCV7 in their national infant 
immunisation programs (WHO, 2007). 
 
PCV7 is a heptavalent vaccine that contains seven serotypes of pneumococcus cell 
membrane sugars conjugated with Diphtheria CRM197 proteins. 
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It is a sterile solution of saccharides of the capsular antigens of S. pneumoniae. 
There are 91 serotypes of pneumococcal bacteria. PCV7 offers protection against 
seven of the most common polysaccharide (chemically activated to make 
saccharides) serotypes that are resistant to antibiotics (4, 6B, 9V, 14, 18C, 19F, and 
23F), each of which is grown separately in a soy peptone broth.   
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Table 1.5: Prevenar introduction in European countries  
(Taken from Gomes et al., 2009) 
 
COUNTRY  EXTENT of VACCINATION 
PROGRAMME  
IMPLEMENTATION 
DATE  
COMMENTS/NOTES
 
 
Austria  Universal  2004 (September)   
Belgium  Universal  2005 (January)   
Bulgaria  NO VACCINATION PROGRAMME    
Cyprus  Universal  2008 (August)   
Czech Republic  Risk Based  2007 (January)   
Denmark  Universal  2007 (October)   
Estonia  NO VACCINATION PROGRAMME    
Finland  Risk Based  2009 (January)   
France  Universal  2006 (June)   
Germany  Universal  2006 (July)   
Greece  Universal  2006 (March)  Fully reimbursed since March 2008  
Hungary  Universal  2008 (October)   
Ireland  Universal  2008 (September)   
Italy  Universal/Risk Based  2005 (May)  Differences on regional basis  
Latvia  NO VACCINATION PROGRAMME    
Lithuania  NO VACCINATION PROGRAMME    
Luxembourg  Universal  2004 (October)   
Malta  Risk Based  2007 (January)   
The Netherlands  Universal  2006 (June)   
Norway  Universal  2006 (July)   
Poland  NOVACCINATION PROGRAMME    
Portugal  NOVACCINATION PROGRAMME   Administered on voluntary basis and 
suggested by the Portuguese society of 
paediatric for children under then 2 
years 
Romania  NOVACCINATION PROGRAMME    
Slovakia  Universal  2008 (April)   
Risk Based  2006 (January)   
Slovenia  Risk Based  2005 (September)  Fully reimbursed since September 2005  
Spain  Risk Based  2001 (June)   
Sweden  Universal  2009 (January)   
UK  Universal  2006 (September)   
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Each 0.5ml dose of the vaccine has been formulated to contain 2 µg of each 
saccharide for serotype 4, 9V, 14, 18C, 19F, and 23F. It also contains 4 µg of 
serotype 6B giving a 16 µg total saccharide per dose, plus approximately 20 µg of 
CRM 197 carrier protein and 0.125 mg of aluminum in the form aluminum phosphate 
adjuvant.  The original manufacturer and other sources claimed that the serotypes in 
PCV7 are responsible for approximately 80% of the most severe pneumococcal 
infections among children under five years of age (Wyeth-Lederal Vaccine, 2000; 
Wuorimaa & Kayhty, 2002; Advisory Committee on Immunization Practices, 2000). 
 
In the UK, PCV7 was licensed in 2001. From 2002 it was recommended for children 
at high risk of pneumococcal disease and in September 2006 it was recommended 
for all infants as part of the routine childhood immunisation programme. The 
perceived benefit of the vaccine introduction is to decrease the incidence of the 
infectious disease caused by pneumococcal bacteria. This consequently protects 
children who are unable to receive the vaccine through herd immunity (DOH, 2006). 
It has since been found to similarly reduce the risk of S. pneumonia in older and 
other immune-compromised adults, adding unexpectedly to the cost effectiveness of 
childhood immunisation. 
 
1.4.3 PCV7 EFFICACY AND SAFETY  
In the US in 2001, one year after the introduction of the PCV7, there was a 69% 
drop in the rate of invasive pneumococcal diseases in children less than 5 years of 
age (Black et al., 2002; Whitney et al., 2003).   
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By 2004, it was reported that hospital admissions for community acquired 
pneumonia had also declined by 39% (95% Confidence Interval CI 22–52) and that 
rates of hospitalisation for pneumococcal meningitis had decreased by 66% (95% CI 
56.3-73.5) in children younger than 2 years of age (Grijalva et al., 2007; Tsai et al., 
2008).  
 
Studies from the US and continental Europe have also shown that the incidence of 
OM and linked antibiotic prescribing rates have fallen since the introduction of PCV7 
for children (Fireman et al., 2003; Poehling et al., 2007; Poehling et al., 2006). 
Moreover, the frequency of tympanostomy tube insertion in young children in the US 
has declined since the introduction of PCV7 (Isaacson, 2012). 
 
The safety profile for PCV7 is accepted as being comparable to that of other infant 
vaccines such as those used to protect against diphtheria, tetanus, pertussis, polio 
and Haemophilus influenzae type b (Hib).  Many studies have shown that PCV7 is 
highly immunogenic, well-tolerated and safe when co-administration for infants at 
age 2, 3 and 4 months, with a booster dose at 12-15 months (Schmitt et al., 2003; 
Oosterhuis et al., 2007; Knuf, 2006). The HPA is monitoring the impact of the 
current vaccination programme weekly, by following IPD admissions in England, 
Wales and Northern Ireland in relevant age groups to evaluate the effectiveness of 
the current schedule. It is also seeking to identify risk factors for vaccine failure and 
monitor evidence of serotype replacement trends.   
 
Between July 2005 and June 2006, the HPA reported 797 cases of IPD in children 
aged less than 5 years old compared to 470 cases by the end of epidemiological 
year 2007/2008 (a decrease of 41%).  
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However, there was no significant reduction in cases in children aged 5 years or 
older (Kaye et al., 2009; WHO, 2007, Whitney et al., 2006).  
 
1.4.4 ADVERSE EFFECTS 
PCV7 is contraindicated in children with known hypersensitivity to the diphtheria 
toxoid or latex. It should not be given to children with thrombocytopenia or 
coagulation disorders that would contraindicate intramuscular injection (Wyeth-
Lederle Vaccines, 2000). In clinical trials, fever >38.0°C, irritability, drowsiness, 
restless sleep, decreased appetite, vomiting, diarrhea, and rash or hives were 
reported more frequently in the PCV7 vaccinated group within two to three days 
compared with the unvaccinated group.  It is has been reported that within 48 to 72 
hours of vaccination patients/vaccinated subjects may also experience oedema, 
pain or tenderness, redness, inflammation or skin discoloration, mass, or local 
hypersensitivity at or around the injection site (Rennels et al., 1998; Black et al., 
2000; Wyeth-Lederle Vaccines, 2000).  
 
1.4.5 WHO SHOULD RECEIVE THE PCV7 VACCINE? 
Before its effective replacement it was recommended that this vaccine should be 
given to all infants from two months of age. This is because infants are at highest 
risk for pneumococcal disease. In the US, the recommended immunisation series 
from the FDA consisted of three doses at two month intervals (2,4,6 months) 
followed by a fourth dose at 12-15 months of age.  
Catch-up vaccination was recommended for children between 2 and 5 years old 
who missed the PCV7 introduction (American Academy of Pediatrics, 2000; Wyeth-
Lederle Vaccines, 2000).   
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In the UK, PCV7 was given at two and four months of age. To provide longer-term 
protection, a booster dose was given at about 15 months of age.  A catch-up 
programme was also recommended for children younger than 2 years old at the 
time of the new schedule’s launch, because these children are at an increased risk 
of pneumococcal disease compared to older children. However, it was decided that 
older children should only be offered the vaccine if they fell into a high-risk group, 
such as those with a heart condition, chronic lung/liver disease, diabetes mellitus or 
a weakened immune system.   
 
Importantly, it has been observed that following the introduction of PCV7 the non-
vaccine S. pneumoniae serotypes may replace vaccine serotypes (Hendrickson et 
al., 2008; Kaye et al., 2009). This gave rise to increasing concerns that PCV7 does 
not contain all of the common and invasive strains. Hence a broader pneumococcal 
vaccine containing thirteen serotypes (PCV13, Prevenar 13) replaced PCV7 in the 
UK in April 2010 (Department of Health, 2010). The HPA suggested that 50% of the 
remaining burden of invasive pneumococcal disease in this country was preventable 
by switching from PCV7 to PCV13 (Kaye et al., 2009). The UK was one of the first 
countries to include PCV13 into its national vaccination programme.   
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1.5 SUMMARY  
Pneumococcal bacteria are responsible for invasive pneumococcal diseases such 
as pneumonia, meningitis, respiratory tract infection and septicaemia, together with 
less dangerous but more prevalent non-invasive diseases such as Otitis Media.  S. 
pneumoniae is the leading cause of bacterial pneumonia in children, and it has been 
observed in approximately a quarter of children hospitalized for pneumonia.   
 
Antibiotics are frequently prescribed as soon as pneumonia is suspected. Untreated 
or missed diagnoses of pneumonia can progress to severe illness with potentially 
life-threatening complications.   
 
OM is a common infection in younger children. Although AOM occurs at all ages, 
this condition, which is defined by the presence of fluid in the middle ear 
accompanied by acute signs or symptoms of middle ear inflammation, is most 
prevalent in infancy. The majority of OM cases do not require antibiotic treatment. 
However, for children with continuous symptoms for more than 3 days or with 
frequent history of OM or younger than two years of age, amoxicillin is the 
recommended first-line treatment in uncomplicated cases.  
 
Very rarely, OM progresses to severe life-threatening outcomes. In part to offset the 
threat of pneumococcal resistance to penicillin and other antibiotics, the UK’s routine 
immunisation programme has offered protection against these infections with the 
introduction of the PCV7 in 2006 for the protection of infants. For unvaccinated 
children aged under 2 years a catch-up programme was also introduced.  
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Studies from the US and continental Europe have shown that PCV7 has had a 
downward impact on the incidence of pneumococcal diseases such as OM and 
pneumonia. In the UK a study was designed in order to answer questions relating to 
the overall prevalence and treatment of childhood S. pneumoniae infections in the 
GP setting.  
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CHAPTER TWO: STUDY DESIGN, RESEARCH TOOLS AND METHODOLOGY  
This chapter presents details of the design, research tools and methodology used 
throughout this thesis. 
 
2.1 STUDY DESIGN 
In order to decide which study design to use for this research, it was necessary to 
weigh up the advantages and disadvantages of the possible options (Table 2.1). 
 
 Table 2.1: Advantages and disadvantages of possible designs  
 
Types of Study                 Advantages            Disadvantages 
Randomised 
Controlled Trial 
(RCT) 
 Can draw conclusions on 
causality and effectiveness 
of treatments 
 Bias and confounding can 
be avoided 
 Multiple outcomes can be 
investigated 
 Expensive  
 Time consuming 
  Requires complex 
design and 
 analysis 
Cohort study  Can discover the time 
sequence of events 
 Can investigate multiple 
outcomes 
 Often expensive 
 Bias could happen 
due to loss of 
 follow-up 
 Limited to one 
 exposure 
  
Case- Control  
Study 
 Can be quick and cheap 
 Can investigate multiple 
exposure 
 Difficult to 
 determine the 
 time sequence of 
event 
 Limited to one 
 outcome 
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To investigate the impact of the PCV7 on pneumococcal diseases such as OM and 
pneumonia a retrospective cohort study design was selected. In order to eliminate 
observer/recall bias and to ascertain the time sequence of events, it is advantageous to 
use a pre-existing database of patient medical records in primary care, rather than 
recruiting naïve subjects. This approach is efficient in terms of time and resources used.   
The databases available are discussed below. 
 
2.2 RESEARCH TOOLS  
Computer based systems have become a vital feature of UK primary care. Most general 
practitioners (GPs) in the United Kingdom use computers to manage their practices in 
terms of storing information on the patient's past illnesses and drug therapy, and to 
write prescriptions for drugs. Ninety six percent of them now access their patients’ 
medical records electronically (Pemberton et al., 2003). This electronic patient 
information can be combined into one database and utilised for medical research 
purposes (Lawrenson et al., 1998).  
 
Most of the UK population’s contacts with the National Health Service (NHS) are 
through general medical practice, where 98% of care episodes are delivered.  The 
advantage of using routine in-practice GP-based databases for research purposes is 
that it is low cost, the databases cover a large population and the data usually spans a 
significant time period (Powell et al., 2003).  Therefore, using a routine database of 
patient medical records is much more efficient in terms of time and resources than 
unnecessarily recruiting patients. This also reduces observer bias and recall bias, and 
reduces inaccuracy and incompleteness because data is captured at the time.  
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In the UK, there are six longitudinal databases of patient medical records. Before 
elucidating the database that will be used in this study, it is worth highlighting or giving a 
brief overview of each database.  
 
QRESEARCH is a database that analyses the accuracy and completeness of data from 
other sources: Prescription Events Monitoring (PEM), Prescription Pricing Authority 
(PPA), General Practice Research Database (GPRD), the IMS Disease Analyzer (IMS 
DA), and The Health Improvement Network (THIN).   QRESEARCH is one of the 
world’s largest computerised databases of anonymised patient health records. It 
contains data from about 10 million patients, from 602 UK general practices. However, 
it is a relatively new database having been created in 2002.  Additionally, data 
regarding 100,000 patients is the maximum that any researcher is able to release from 
the dataset (QRESEARCH, 2009; QRESEARCH, 2012).   
 
PEM and PPA are different types of datasets that do not qualify as observational health 
care databases and are not useful for paediatric medication research studies, due to 
limitations of important data such as vaccination records and age recording for each 
patient respectively.  GPRD and THIN together count as the largest computerised 
general practice’ databases of anonymous patient data, however, it is hazardous to use 
GPRD to study medication in children (Wong and Murray, 2005). IMS DA is a complex 
and secure database in the UK on aspects of studying medicines in children. Therefore, 
in order to conduct this retrospective cohort study, both the IMS DA and THIN 
databases wi l l  be used as both can be used for paediatric drug utilisation, 
pharmacovigilance and pharmacoepidemiological research; and they provide primary 
indications for antibiotic use and immunisation records.  
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THIN and IMS DA have been extensively used and their advantages and limitations are 
widely understood (Wong and Murray, 2005).  The characteristics of each of these two 
databases will now be addressed.  
 
2.2.1 IMS DISEASE ANALYSER (IMS DA) DATABASE 
IMS (formerly known as Intercontinental Medical Statistics) is a UK private international 
healthcare information company, specialising in the collection of anonymised, 
longitudinal, general practice patient medical records and interpretation of anonymised 
patient medical information for research purposes. Established in 1992, IMS holds data 
on over 2 million patients and has information on more than 95 million prescriptions 
from about 125 computerised general practices with more than 500 general 
practitioners (GPs). It represents approximately 2% of the total UK census population.  
Of the 2 million patients, almost 40% have at least ten years of follow-up data available 
(De Lusignan et al., 2002; Wong and Murray, 2005). IMS data provides information on 
patient demographic and clinical details including both the reason for GP consultation 
and the indication for the actual prescription. 
 
2.2.1.1 RECORDABLE INFORMATION  
Contributing GPs are provided with guidelines that define an electronic record of all 
patients’ consultations. This includes (De Lusignan et al., 2002; Wong and Murray, 
2005): 
 • Demographics, including date of birth and gender of patient.  
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• Indication coded by GPs via Read Codes and then mapped to ICD-10 codes by a 
  team of experts in medical classification and adjusted for internal consistency.  
• Treatment, including drug substance, drug class, formulation, strength, dosage and 
   frequency, coded via the ATC classification system.  
• Treatment linked to indication.  
• Treatment linked to cost.  
• Test results linked to diagnosis.  
• Referrals and procedures, e.g. X-rays, surgery.  
GPs enter the data into the database via a computer package (Torex-Meditel System 
5). This allows linkage of prescription and clinical indication data (De Lusignan et al., 
2002). However, the level of completeness of these data varies from one GP to another 
according to the level of detail the GP records (Linsell et al., 2006).    
 
In the IMS DA UK database, there are four different data tables. These include: 
patients, problems, notes and therapy data. The ‘Patients’ table data includes age, sex, 
date of registration, etc. The ‘Problems’ table contains all patients’ diagnoses using 
(ICD-10 and Read) codes and text. In the ‘Notes’ table, data comprises all details from 
patients’ consultations, such as diagnoses, prescriptions, referrals and test results. And 
in the ‘Therapy’ table data consists of medications and doses prescribed and issued to 
patients. All data relating to each individual patient are linked via a unique patient 
identification number. However, the data are fully anonymised and no identifiable 
details, such as postcode or NHS number, are recorded.  
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The general practices contributing data to IMS DA UK operate via fully electronic 
patient medical records. Prescriptions, referrals and tests can only be generated by 
entering the patient’s details and the relevant treatment/procedure code into the 
database.  Moreover, drugs prescribed by hospital doctors or other specialists will not 
appear in IMS DA data unless the treatment is to be continued. Thus the data is likely to 
be relatively complete. 
 
2.2.1.2 DATA QUALITY, COMPLETENESS AND REPRESENTIVNESS 
Checks are employed in order to monitor the quality of information submitted by all 
contributing GPs. Data quality markers are used to ensure that the data contained 
within the IMS DA UK database is of specified quality standard.  Hence, in order to be 
included and retained within IMS DA UK, GPs must meet a minimum data quality 
score.  The score is based upon ten different assessment criteria, as outlined in Box 
2.1 (De Lusignan et al., 2002; Clayton, Thompson and Meade, 2008). These scores 
are then reported back to the contributing general practices on a quarterly basis in 
order to highlight the areas of data recording that require improvement. 
 
This feedback system has been shown to significantly improve the quality of data 
contained within the IMS DA UK database.  A newsletter addressing coding issues 
within IMS DA UK, compiled by an expert panel of GPs, is also distributed to 
contributing GPs every six months.  GPs receive approximately £400 per year as 
an incentive to meet the minimum data quality scores for all ten assessment criteria 
(De Lusignan et al., 2002). A validation study demonstrated that the IMS DA database 
has reliable, consistent and complete data (Lawrenson et al., 1998).  
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Box 2.1: The ten data quality markers used within the IMS DA UK database   
(Taken from De Lusignan et al., 2002) 
 
1)  Percentage of registered patients for whom there has been a change in 
     record over the previous twelve months 
2)  Percentage of patients with year of birth and gender recorded 
 
3)  Percentage of problems or diagnoses with Read Code of level 3 or lower 
 
4)  Percentage of notes linked to problem or diagnosis 
 
5)  Percentage of notes in which Read Code is level 3 or lower 
 
6)  Number of prescriptions issued per week per 1,000 registered patients 
 
7)  Complete dose and regimen details related to dose-effect or adverse drug  
      reaction 
 
8)  Proportion of acute prescriptions issued linked to a problem or diagnosis 
 
9)  Proportion of repeat prescriptions linked to a problem or diagnosis 
 
10) Ratio of acute prescriptions issued to chronic prescriptions 
 
 
The patient population contained within the data is demographically similar to that of the 
total UK population at any given point in time in terms of age and gender. Although 
there is under-representation of smaller practices, the practices included in the IMS DA 
are broadly representative of general practices across the whole of the UK (Wong and 
Murray, 2005).  
 
2.2.1.3 IMS DA STRENGTHS AND LIMITATIONS 
The following is a summary of the strengths and limitations of the IMS DA database: 
Strengths:  
 Large computerised database  
 Data are reliable, consistent and complete. 
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 Representative of the total UK population by age and gender distribution. 
 Largely representative of general practices in the total UK census population.  
 Prescriptions are directly linked to the clinical indication, for both acute and 
chronic conditions. 
 Additional information can be sought via GP questionnaires, such as vaccination 
record  
 Availability of denominator data enables researchers to calculate prevalence 
and incidence rates (excellent research tool for pharmaco-epidemiological 
research). 
 Free from observer and recall bias. 
 Minimal training required prior to using it as a research tool (Lawrenson et al., 
1998; Wong and Murray, 2005). 
Limitations:   
 Possible coding errors/misclassification.  
 Presence of missing data.  
 No information on socio-economic status or ethnicity.  
 No information on whether prescriptions are dispensed or taken.  
 Data collection is not for research purposes and hence, not geared towards 
answering specific research questions (Lawrenson et al., 1998; Strom, 2006).  
 
2.2.1.4 ETHICAL APPROVAL  
All studies that use IMS DA UK data must be approved by the Independent Scientific 
and Ethical Advisory Committee (ISEAC). 
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2.2.2 THE HEALTH IMPROVEMENT NETWORK (THIN) DATABASE 
The Health Improvement Network (THIN) database is an anonymised primary care 
patient record from information entered by GPs, used to support drug safety and 
epidemiological studies. It was set up in November 2002, and is a collaboration 
between two companies with an established name in primary care computing: EPIC, a 
non-profit making organisation that facilitates access to electronic research data, and 
Cegedim, a European healthcare software and research company who develop and 
supply the Vision general practice computer system to over 1800 GP practices in the 
UK.  
 
The data are collected weekly by THIN and sent monthly to EPIC who, supply the data 
to researchers for studies approved by the nationally accredited ethics committee, 
South East Multicentre Research Ethics Committee (SE-MREC) (Cegedim, 2012).  
 
2.2.2.1 RECORDABLE INFORMATION 
THIN collects anonymous patient data, this include past history and prescriptions from 
practices using a system called, the Vision practice management system, where it has 
already been recorded in the normal routine of the practice. Data collected from the 
practice system are anonymised at the collection stage; thus, no identifying information 
will be available to THIN.  The data are organised in files by individual practice and 
progressed to provide researchers with access to demographic, medical, and 
prescription information at an individual patient level.   
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In addition, there is information on referral to specialists, diagnostics, and laboratory 
results, some lifestyle characteristics with other measurements taken in the GP 
practice. Moreover, In the THIN database, there are six different data tables - see table 
2.2 below. 
 
More than 330 practices using Vision software have joined the scheme. Currently, the 
THIN dataset contains data from over 514 general practices with a total of over 10 
million patients of which approximately 2.4 million are actively registered with the 
practice’s medical records and can be followed prospectively. The remaining patients 
will still have historical data but have either left the practice or died. Most of these 
contributing practices have recorded several years of data on their system (UCL, 2012; 
Cegedim, 2012). 
 
2.2.2.2 DATA QUALITY, COMPLETENESS AND REPRESENTIVENESS  
As well as establishing a new primary care research data resource, THIN is improving 
the data recording of contributing practices. In addition to providing free training to the 
practices, THIN data are subjected to computerised validation to measures the 
completeness and accuracy of recording. These results are fed back to the practices 
with more information on how to improve quality and correct omissions. They are also 
supported by free training seminars to address any issues and encourage more efficient 
use of their computer systems.  
The comprehensive information on data quality of individual practices is shared with 
researchers so that, if appropriate, they can select subsets of practices with strengths in 
specific areas of data collection. 
                                                      CHAPTER TWO 
88 
Table 2.2: Main file types of THIN data  
(Taken from University College of London (UCL) The Health Improvement Network 
(THIN) Research team, 2012). 
 
PATIENT Age, sex, registration date when entering the practice, and date 
when leaving the practice 
MEDICAL Medical diagnoses, date of diagnosis, and location (e.g., GP’s 
office, hospital, consultant) of the event and an option for adding 
free text; referrals to hospitals and specialists. 
THERAPY All prescriptions along with the date issued, formulation, strength, 
quantity, and dosing instructions, indication for treatment for all 
new prescriptions (inferred from cross reference to medical events 
on the same date), and events leading to withdrawal of a drug or 
treatment. 
ADDITIONAL HEALTH  
DATA (AHD) 
Vaccinations and prescription contraceptives; miscellaneous 
information such as smoking, height, weight, immunizations, 
pregnancy, birth, death, and laboratory results. 
POSTCODE VARIABLE 
INDICATORS (PVI) 
Postcode linked area based socio-economic, ethnicity and 
environmental indices 
 
CONSULTATION 
 
Date, time and duration of consultation 
 
STAFF 
  
Gender and roles of staff who entered the data 
 
A complete computerised record of the patient’s healthcare is recorded whilst the 
patient is registered with their GP. Significant historical events are entered from a 
summary transferred from the paper notes.  However, the THIN dataset is created from 
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data collected from the GP’s medical record system and will imitate only those events 
that are supposed to be relevant to the patient’s care.  
 
During consultation, all medical conditions and symptoms reported to GPs are recorded 
on the computer. These consultations build up long computerised the patient’s medical 
histories. Medical conditions are recorded using the Read code. This is a hierarchal 
system, and the codes may be cross-referenced to the International Classification of 
Diseases (ICD10). Information of the type of specially is routinely recorded on referrals 
to secondary care.  
 
Secondary information received by the GP is recorded and entered retrospectively; this 
includes details on hospital admissions, discharge medication and diagnosis, outpatient 
consultation diagnosis, investigation and treatment outcomes. In terms of GP 
prescriptions, prescribing is particularly well recorded since the computerised entry 
made by the doctor is also used as the prescription form with a copy being printed for 
the patient to present it at the pharmacy.  
 
The Read code classification is used to code specific diagnoses, and a drug dictionary 
based on data from the MULTILEX coding system classification is used to code drugs. 
Prescriptions not issued from the computer, such as controlled drugs, immunisations, 
private prescriptions, and drugs prescribed during home visits should all be entered, but 
there is a possibility of under-recording with such items (UCL, 2012; CEGEDIM, 2012). 
In most cases a medicine prescribed for the first time can be temporarily related to the 
medical event record (symptom or diagnosis) even though there is not a permanent link 
between a therapy record entry and an entry in the medical records.    
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Also as in IMS DA database drugs prescribed by hospital doctors or other specialists 
will not appear in the THIN data unless the treatment is to be continued. However, due 
to the constraints of specialist/hospital prescribing budgets many prescriptions issued 
outside of the GP practice will usually only be enough to cover the first 7 days.  After 
this time the patient will be required to visit their GP for a further prescription, and again 
for any subsequent ones. These therefore will be entered into THIN data.  
 
Since the database holds comprehensive prescribing and disease information it allows 
healthcare researchers to be able to study the natural history of disease, monitor drug 
safety and carry out any risk management studies. Prescribing analysis can examine 
therapy/treatment indication and use.  The data collected is audited regularly and the 
participating general practices are subjected to a number of quality checks. The quality 
of the information in the database has been validated in many of independent studies 
and has been found to be high (Maguire et al., 2008; Mayles, 2009).  
 
2.2.2.3 THIN DATABASE STRENGTHS AND LIMITATIONS  
The following text offers a summary of the strengths and limitations of the THIN 
database (UCL, 2012; Cegedim, 2012): 
Strengths:  
 It is population-based data, representative of the majority of the population 
within the UK.  
 It allows maximum scope for researchers in terms of study design (i.e. cohort, 
case-control, and case-series). 
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 It is representative of general practices in the UK census population. 
 The data includes some longitudinal data, allowing long-term follow-up of patient 
histories, making longitudinal studies possible. 
 Reduces time and costs as data does not need to be collected. 
 Control subjects can be from the same population source. 
 Relatively rare exposures or outcomes of any medication can be examined. 
 It is not subject to recall bias or researcher bias, as there is no reliance on 
patient recall or researchers to collect the data. 
 
Limitations: 
 Coding errors/ misclassification. 
 Missing data. 
 Prescriptions are not directly linked to the clinical indication. 
 No information on ethnicity, occupation, employment, and/or socio-economic 
status.  
 Not appropriate for studies examining over the counter drugs. 
 Not appropriate for studies looking at laboratory test results. 
 Not appropriate for studies requiring follow-up of over 5.5 years. 
2.2.2.4 ETHICAL APPROVAL 
All studies that use THIN data must be approved by the Scientific Review Committee 
(SRC).  
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2.3 JUSTIFICATION OF THE DATASETS USED IN THIS STUDY 
The advantages and limitations of the THIN and IMS DA UK databases were 
considered when determining their utilisation within this study. Table 2.3 demonstrates 
the differences. 
Table 2.3: Comparison of the THIN and IMS DA UK databases  
 
                      
                       Characteristics 
                            Database 
THIN IMS DA UK 
Year established for the database 2002 1992 
Percentage of UK population represented ~ 5% ~2% 
Total number of patients ~10 million ~3 million 
Number of patients currently registered ~2.4 million ~1 million 
Prescribing and indication data directly 
linked 
No Yes 
The availability of primary and secondary 
care data  
Yes Yes 
Access to patients’ entire medical history 
while registered in the database 
Yes No 
 
A major limitation of both THIN and IMS DA UK, which is common to any routinely 
collected medical database, is coding misclassification. This relates to how GPs record 
diagnoses.  Another limitation is that collected data is not geared towards a specific 
research question, unlike in a prospective study.  
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Thus, although, the aforementioned databases may not be comparable for all subjects, 
using a database of patient medical records such as the THIN and IMS DA UK 
remained the most efficient means of obtaining data for the purpose of this research.  
 
Both THIN and IMS DA contains information on demographics, prescriptions, diagnoses 
and referrals.  Although, indications are not directly linked to prescriptions in THIN they 
are linked in IMS DA.  However, THIN has information on hospital admission and 
results of laboratory tests.  Both the THIN and IMS DA UK are excellent research tools 
for examining the incidence of pneumococcal diseases.  Best practice for this type of 
analysis suggests that any trends in disease incidence should be confirmed in two 
independent databases, therefore both were used.  
 
2.4 DEFINITIONS AND STATISTICAL METHODS  
The following section provides a description of the epidemiological definitions and 
statistical methods used throughout this study.  
2.4.1 AGE CLASSIFICATION  
The classification of children into age-groups provides a means of investigating age-
related differences in disease incidence and antibiotic prescribing trends. Age-groups 
for this study were defined as 0-1 years, 2 to 5 years, 6 to 10 years and 11 to 15 years.   
 
The International Conference of Harmonisation (ICH) guidelines, recommend 
classifying age-groups as preterm newborn infants, term newborn infants (0 to 27 
days), infants and toddlers (28 days to 23 months), children (2 to 11 years) and 
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adolescents (12 to 16/18 years), based upon physiological and developmental 
considerations (International Conference of Harmonisation, 2000).  However, in this 
study a narrower age-grouping is applied. This enables a more detailed reflection of the 
age-related differences in disease incidence and antibiotic prescribing than would have 
been possible if the ICH age-group classification was applied.  
 
2.4.2 INCIDENCE  
Incidence is a measure of the number of new events occurring during a given time 
period in a specified population. The incidence rate refers to the rate at which these 
new events occur and takes the dynamics of the population into account, whereby the 
numerator is the number of new events in a defined time period and the denominator is 
the population at risk of the event during the relevant period, expressed as child-years 
(Last, 2001).  
                                               Number of new events in a defined time period 
Incidence rate =  
                                    Number of people at risk of event during this time period  
 
Descriptive analysis will be conducted for patient demographics and prescription data 
throughout the study. To describe the study cohort, the age and gender distribution and 
total person-years of patients will be calculated.  
 
Antibiotics are generally used to treat bacterial infections such as acute Otitis Media and 
pneumonia (recorded in the IMS DA and THIN database respectively) so a child may be 
infected and receive antibiotics more than once within the same year. Thus, each 
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episode of illness and prescription will be counted as a new infection and a new 
prescription and it will contribute to the numerator more than once in any given year. 
 
2.4.2.1 INCIDENCE RATE CALCULATION FOR OM DIAGNOSIS AND ANTIBIOTIC 
TREATMENT FOR OM 
Diagnoses of OM will be based on Read Code classifications. To obtain insight into the 
medical conditions of the children and how they are being treated, all indications for 
antibiotic prescriptions will be investigated in the IMS DA.  Antibiotic prescribing 
patterns for OM will be compared with the total antibiotic trend during the study period. 
Annual, age and gender-specific incidence rates for OM and antibiotic prescribing will 
be calculated per 1000 person/child years. 
 
                                                         Number of OM episodes in a particular year   
Incidence rate for OM =                        
                          Number of person-years in paediatric population in a particular year 
 
 
Also, within the IMS DA, antibiotics listed under the ATC therapeutic levels main group 
J01 (antibacterial for systemic use) will be utilised in the data analysis.   
 
                                   Number of antibiotic prescriptions for OM in a particular year 
Incidence rate of AB prescribing=   
                             Number of person-years in paediatric population in a particular year 
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2.4.2.2. INCIDENCE RATE CALCULATION FOR PNEUMONIA DIAGNOSIS AND 
ANTIBIOTIC TREATMENT FOR PNEUMONIA 
Pneumonia diagnosis will be classified on Read Code (Appendix 7). To obtain an 
insight into the medical conditions of the children and how they are being treated, all 
indications for antibiotic prescriptions will be investigated in the THIN database. 
Antibiotic prescribing patterns for pneumonia will be compared with the total antibiotic 
trend during the study period.  Annual, age, and gender-specific incidence rates for 
pneumonia and antibiotic prescribing will be calculated per 1000 person-year population 
of the THIN data. 
           Number of pneumonia episodes in a particular year                         
Incidence rate for pneumonia= 
                       Number of person-years in paediatric population in a particular year 
 
 
 
In the THIN database, antibiotics are listed under the BNF code (antibacterial for 
systemic use), which is based on data from the MULTILEX classification and will be 
utilised in the data analysis. 
 
                   Number of antibiotic prescriptions for pneumonia in a particular year 
Incidence rate of AB prescribing=   
                  Number of person-years in paediatric population in a particular year 
 
Incidence rate will be calculated using Poisson distribution with a 95% confidence 
interval (CI). A chi-squared test or 2 test will be used to compare the prescribing trends 
before and after the introduction of PCV7.  Data manipulation and analysis will be 
conducted using STATA/SE 11.0 for Windows (Statistical Software: Release 9.1. 
College Station, TX, USA).  
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2.4.3 CONFIDENCE INTERVALS 
Confidence intervals are a range of values for the interested constructed 
variable. It provides a range (confidence interval) of sampling error amount that is 
present in a study, and this range has a specified probability (confidence level) of 
including the true value of the variable.  
 
Moreover, if the confidence interval is narrow, this indicates good precision that any 
effect outside of this range will be ruled out of the study. However, if the confidence 
interval is wide, this indicates poor precision.  
This usually occurs if the study’s size is relatively small. If the confidence interval does 
not include the no-effect/null value (1.0) then the result is deemed statistically 
significant and vice-versa (Webb el al., 2005, Davies & Crombie, 2009).  The 
confidence interval used in this study is the 95% confidence interval (95% CI). This 
provides a  range that the reader can be 95% confident that it contains the true 
value of the interested variable, which was based on the Poisson distribution 
(possibility distribution of a number of events occurs in a specific period of time), as the 
analyses were concerned with child-year incidence rates of infection diseases (Webb 
et al., 2005, Davies & Crombie, 2009, Last, 2001).  
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2.4.4 P-VALUES 
P-values provide a measure of the probability of whether an observed association might 
be due to any chance occurrence during the study period. In most epidemiological 
studies, and throughout this study, a result with a probability value of less than 5% 
(P<0.05) is considered unlikely to have occurred by chance and is, thus, deemed 
statistically significant (Last, 2001).  Moreover, in relation to confidence intervals, if the 
95% CI does not include the no-effect/null value (1.0), then the corresponding P-value 
will be <0.05 and the result termed as statistically significant and vice versa (Webb, 
Bain and Pirozzo, 2005).  
 
2.5 METHODOLOGY  
Overall this study can be viewed as involving four study strands (Table 2.4).  Initially, a 
systematic review and meta-analysis were performed. Following this review the study 
aims and objectives were defined.  
Table 2.4: The Study Strands - Respective Methodologies and Data Sources 
 
Study Strand Methods Data Source 
1. Literature Review Systematic Review 
Meta-Analysis 
Randomised Controlled 
Trials 
2. Study of GP based 
vaccination records 
Validation study IMS DA, COVER and 
questionnaire 
3. OM study Retrospective cohort study IMS DA 
4. Pneumonia study  Retrospective cohort study THIN 
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However, for the purposes of clarity each of the study strands will now be addressed in 
turn, and their respective aims, objectives and methods discussed. 
 
2.5.1 Study strand ONE – Systematic Review and Meta-analysis  
2.5.1.1 Definitions  
A systematic review is a way to combine the results from different, published or 
unpublished studies. These are mainly the results of clinical trials that deal with the 
same conditions or same type of therapy. Systematic review has through time become 
an integral part of evidence-based medicine and an important method because of its: 
 Efficiency: systematic review of pre-existing studies is more time saving and 
economically efficient than performing a whole new studies of a certain 
intervention for instance. It summarises all available results and stops 
unnecessary studies being performed. 
 Consistency: the results of a systematic review can be generalised to a bigger 
and wider population than any one single study. 
 Precision: in combination with meta-analysis this can give greater ability to 
detect effects that are of interest. 
 Reduction: systematic reviews have the ability to reduce large amounts of 
information into a manageable size. 
The demand of evidence-based medicine has grown and became so big that a group of 
clinicians, consumers and methodologists have created what is called The Cochrane 
Library.   
                                                      CHAPTER TWO 
100 
This is a platform for systematic reviews performed by the Cochrane collaboration. 
Additionally the Cochrane Library includes different evidence based health care 
databases (Egger et al., 2001; Hemingway& Brereton, 2009).  
 
In order to assess the reliability of any systematic review and individual trials two 
guidelines have been designed.   These are the Consolidated Standards for Reporting 
of Trials (CONSORT) and the Quality Of Reporting Of Meta-analyses (QUORUM) 
(Needleman, 2000).  They help to standardise the reporting of clinical trials and meta-
analyses. 
 
2.5.1.1.1 Consolidated Standards for the Reporting of Trials (CONSORT) and the 
Quality of Reporting of Meta-analyses (QUAROUM).  
Consolidated Standards for Reporting of Trials (CONSORT) 
The CONSORT guideline has been developed by a group of journal editors, clinical 
researchers and biostatisticians. From 1996, 70 biomedical journals using randomised 
controlled trials (RCTs) adopted this guideline. 
It consists of different items that should be included in a RCT publication listed in a 
checklist. These items include a clearly described hypothesis, protocol, randomisation, 
blinding, follow up and analysis.    Moreover, it can provide a clear guidance on how to 
construct better trials, which in turn should improve the quality of future research. It is a 
way to get authors to be transparent when it comes to reporting a RCT. This is 
important for the reader to be able to understand interpretations, study design, and 
assessment of validity. For this sole purpose, a checklist and flow diagram have been 
designed to help researchers when setting up a RCT (Needleman, 2000; Turpin, 2005). 
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Quality of Reporting of Meta-analyses (QUAROUM) 
The QUAROUM is another guideline, which has been developed to improve the quality 
of reporting of research methods. To aid evaluation of any systematic review, the 
QUAROUM guideline has also set out a checklist and flow diagram (Needleman, 2000; 
Turpin, 2005). The checklist includes asking if any information is missing which can be 
linked to biased estimates of treatment. This is important information for the reader to 
judge the reliability and the relevance of included studies.  
 
The flow diagram gives directions in how to describe the flow of patients through the 
entire trial. This includes how they are allocated, how they are randomised and by 
whom. If the trial is blinded, it should be stated who is blinded to it. It asks for 
descriptive information regarding four different stages of a RCT: enrollment (how many 
participants there are in each group), intervention allocation (explain the nature of 
intervention), follow up and analysis (Petrie & Sabin, 2009). 
 
2.5.1.1.2 Meta-analysis 
Meta-analysis is a statistical method whereby analysis combines data from different 
studies with the same outcome in order to improve the reliability of the results.  The first 
step in doing a statistical meta-analysis is performing a systematic review as explained 
earlier. To conduct a meta-analysis requires a comprehensive search strategy using 
several electronic databases (Crombie, Davies, 2009).  
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2.5.1.1.3 Intent to treat (ITT)   
The idea behind the intent to treat strategy is to include all subjects in a group, 
regardless of whether they were withdrawn from the trial, missed a dose, did not 
complete the whole treatment, or did not comply entirely with the inclusion criteria 
(Hollis & Campbell, 1999). This is an important component when looking at 
effectiveness, and if not performed, the effectiveness of a treatment may be 
overestimated. Therefore, it takes into account all enrolled patients. 
 
2.5.1.2 Systematic literature review of the study 
A recent review of pneumococcal conjugate vaccines did not adequately address the 
efficacy of PCV7 in the paediatric population (Huss et al., 2009). Therefore, a 
systematic review was undertaken to investigate the efficacy of the vaccine, its level of 
adverse events in children aged 0-10 years, and to review the current literature in order 
to assess what is already known.  
 
2.5.1.2.1 Aims & objectives: 
The aim of this systematic review was to investigate the efficacy and adverse effects of 
PCV7 in children aged between 0-10 years. The outcomes of interest are described 
below:  
 Primary outcome: the efficacy of PCV7 in preventing pneumococcal 
diseases. The serotype specific antibody concentrations, geometric mean 
concentration (GMC) were investigated.  
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 Secondary outcome: the adverse effects of PCV7. The local and systemic 
adverse drug events associated with the PCV7 were investigated. 
 
2.5.1.2.2 Methods  
2.5.1.2.2.1 Search strategy:  
A systematic review of the literature published between January 1990 to January 2010 
was undertaken using the following electronic sources: PubMed, EMBASE, the 
Cochrane Central Register of Controlled Trials (CENTRAL), the Meta-Register of 
Controlled Trials (www.controlled-trial.com), WHO Clinical Trial Register 
(http://www.who.int/ctrp/en/) and the Clinical Trials Government database 
(http://www.clinicaltrials.gov/).  
 
Hand searching was also carried out to examine the reference lists of identified studies. 
The search strategies for the literature review are described in Table 2.5. 
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Table 2.5: Search terms will be used to search relevant articles from electronic 
databases 
Condition  Drug  Population      Study Design 
Invasive 
pneumococcal 
diseases (IPD) 
OR Otitis Media 
OR acute Otitis 
Media OR Otitis 
Media effusion 
OR middle ear 
infection OR 
middle ear 
inflammation OR 
respiratory tract 
infection OR 
bronchiectasis  
OR pneumonia 
OR meningitis 
OR neisseria 
meningitidis  OR 
meningococcal 
OR 
pneumococcal 
meningitis OR 
bacteraemia  
A
N
D 
7-valent 
pneumococcal 
conjugate 
vaccine OR 
heptavalent 
pneumococcal 
conjugate 
vaccine OR 
PCV7 OR 
Prevnar OR 
pneumococcal 
vaccine OR  
PCV OR 
pneumococcal 
immunisation 
OR 
pneumococcal 
immunization 
OR 
pneumococcal 
vaccination  
A
N
D 
infants OR 
children OR 
child OR 
neonates OR 
baby OR 
babies OR 
paediatric OR   
pediatric OR 
toddlers      
A
N
D 
randomised-controlled 
study OR randomised 
controlled trial OR 
randomized controlled 
trial OR randomized 
controlled study OR 
cohort study OR panel 
study OR double blind 
method OR double blind 
trial OR single blind trial 
OR triple blind trial OR 
blind trial OR randomised 
double blind placebo 
controlled trial OR 
randomized double blind 
placebo controlled trial 
OR single blind method 
OR single masked 
method OR single blind 
procedure OR controlled 
clinical trial OR crossover 
studies OR crossover 
trials OR crossover 
designs  
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2.5.1.2.2.2 Study selection criteria: 
Inclusion Criteria 
 Literature published from randomised controlled trials (RCTs), investigating the 
efficacy and side effects of 7-valent pneumococcal conjugate vaccine (PCV7) to 
prevent pneumococcal infections. 
 Children aged 0-10 years.  
 No language restrictions.  
 
Two reviewers (Aisha El-Turki, Abir Ali) independently performed the electronic 
searches in January 2010. Any articles that clearly did not meet eligibility criteria in the 
systematic review were rejected on initial review. A standardised data extraction form 
was used to record all data from the papers meeting the inclusion criteria for review 
(Egger et al., 2001). The standardised form included study design, trial duration, mean 
age of participants, gender, number of participants in treatment and placebo group, 
interventions, and the assessment of intention-to-treat (ITT) analysis. The QUORUM 
(Quality of Reporting of Meta-analysis) guidelines were used for reporting the results of 
the systematic review (Moher et al., 1999; Moher et al., 2001; Needleman, 2000). 
 
2.5.1.2.2.3 Dealing with missing data 
The reviewers directly contacted the study authors three times to obtain missing 
information in the articles. If the reviewers were unable to obtain the missing 
information, the missing data were given replacement values.   
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For example, where standard deviations (SD) were not reported, these were obtained 
from standard errors (SE), confidence intervals, t values or p values (Higgins and 
Green, 2009).  
2.5.1.2.2.4 Statistical analysis 
The meta-analysis used a random effects model with RevMan 5.0.20 (Oxford, UK: The 
Cochrane Collaboration, 2009). Due to the low number of included studies, funnel plot 
analyses were unable to be performed in order to assess publication bias. 
 
2.5.2 Study strand TWO – Validation Study  
2.5.2.1 Background 
In the UK, children are vaccinated at GP practices and their immunisation records are 
recorded in the GP computer systems. In addition to GP practices, other healthcare 
professionals such as practice nurses, health visitors, and school nurses can also 
administer vaccines to children (Immunisation against infectious disease, 2006). For 
those children who are vaccinated by other health care professionals outside GP 
practices, their immunisation records may not be recorded in the general practice 
computer system.  Therefore, immunisation records may be under-recorded in GP 
practices.   
 
In January 1987, the Cover of Vaccination Evaluated Rapidly (COVER) scheme was 
first set up to monitor immunisation coverage data for children in England and Wales 
(White et al., 1995).  
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In May 2002, data started to be collected from Primary Care Trusts (PCTs)  in England 
and all the immunisation records were collected amongst children aged one, two and 
five years old from the PCTs.  Prescribing trends of PCV7 taken from IMS DA will be 
compared with national statistical data [Cover of Vaccination Evaluated Rapidly 
(COVER)], which estimates the vaccine (PCV7) coverage reached approximate 90-95% 
of children (NHS Immunisation Statistics, 2012). COVER is a national programme to 
monitor immunisation coverage data in children.  
 
This analysis will enable us to expand and integrate knowledge of OM and pneumonia 
and their management in children in the wake of the PCV7 programme; also, it can 
provide a comprehensive understanding of the efficacy of PCV7 use in UK primary 
care. It is believed that no previous studies have been carried out to validate 
immunisation records in GP practice taken from the IMS DA. Therefore, a validation 
study was conducted through GP questionnaires to investigate immunisation recording 
in children aged 0-2 years in general practice. 
 
2.5.2.2 Aims of the study 
 To investigate PCV7 immunisation recording in children aged 0-2 years in 
general practice.  
 To compare the percentage of immunisation recording in general practice 
(recorded in IMS DA) with COVER programme data. 
 To investigate the association between vaccine consumption and the incidence 
of OM in children aged 0- 2 years old by using individual patient-analyses.  
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2.5.2.3 Methods 
2.5.2.3.1 Study design  
This study was designed to investigate PCV7 immunisation recording in children aged 
0-2 years in general practice. A letter (4 December 2010) was sent to GPs with a 
questionnaire asking a single question: has this child had the Prevnar 7® vaccine? 
(Appendix 1a &1b).  All children who were born in 2008 were identified and their 
records were followed for 2 years.  
 
To validate the study, firstly, the percentage of PCV7 vaccinated children born in 2008, 
in the IMS DA database was calculated and compared with the COVER data.   
Secondly, children of the same age (0-2years) without a PCV7 record in the primary 
care setting, in IMS DA database, were validated through the questionnaire sent to their 
General Practitioners.  
 
2.5.2.3.2 Study population  
Prior to sending the questionnaire to the GPs, the overall number of questionnaires 
required for this study had to be estimated using Epi InfoTM version 3.5.1. This is open 
source software designed for epidemiological research. It offers resources for use in 
counting and measurement in descriptive and analytic studies, undertaking stratified 
analysis with exact confidence limits, matched pair and person-time analysis, sample 
size and power calculations, and other evaluation statistics (CDC, 2013).  
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In IMS DA database, there are approximately 18,000 children aged 0-2 years registered 
per year. Based on the COVER data (HPA, 2009), it was assumed that 10% of children 
(1,800) will be without a PCV7 immunisation record. A worst-case scenario was that 5% 
of these patients were immunised but unrecorded. Therefore, the sample size needed 
to detect this worst-case scenario would be 138 patients, with 95% confidence interval 
(Table 2.6). If the questionnaire response rate was 80%; then 173 questionnaires would 
be needed.  
 
                              Table 2.6: Sample size calculation (WHO, 2009) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identification of children without PCV immunisation records in the IMS DA database 
were identified by searching for prescription and event codes corresponding to 
vaccination listed in (noteread44or5code) (Appendix 2) and ATC code (J07A7).   
                  Sample size calculation 
Total Population Size:  1,800 
Expected Frequency:  2.50% 
Worst Acceptable:  5.00% 
Confidence level required  Sample size 
80%  62 
90%  100 
95%  138 
99%  226 
99.9%  342 
99.99%  445 
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This identified all vaccinated and unvaccinated children registered with the IMS DA 
Database between 1st January 2008 and 31st December 2010, aged between 0-2 years 
(born in 2008 and followed for the following two years (up to 2010).  Ethical approval for 
this study strand was obtained from ISEAC and a summary of their consent is at 
Appendix 3. 
 
2.5.3 Study strand THREE – OM Cohort Study  
2.5.3.1 Aims and objectives 
The aim of this study strand:  
To describe the incidence rates of OM and antibiotic prescribing patterns in children 
and adolescents before and after the introduction of PCV7 between 2002 and 2010 in 
the UK primary care setting stratified by age and gender. 
Objectives:  
1) To determine the annual incidence of OM diagnosed in the UK primary care 
setting.  
2) To determine the annual incidence of OM diagnosed in primary care stratified by 
age and gender.  
3) To estimate antibiotic prescribing patterns associated with OM.  
4) To estimate antibiotic prescribing patterns associated with OM by age and 
gender. 
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2.5.3.2 Methods  
2.5.3.2.1 Study design  
A retrospective cohort study was conducted on data between 2002 and 2010 taken 
from IMS Disease Analyzer (IMS DA) database. Information held on the database 
includes patient demographics, indications for treatment and prescription details.  
 
Prescribed drugs are coded based on the Anatomical Therapeutic Chemical (ATC) 
classification (European Pharmaceutical Market Research Association, 2010) 
(Appendix 4) and medical diagnoses are coded to Read Code (Appendix 5). Ethical 
approval for this study strand was obtained from the Independent Scientific and Ethical 
Advisory Committee (ISEAC) and the summary of their comments are included 
(Appendix 3). 
 
2.5.3.2.2 Study population 
Inclusion criteria 
Children and adolescents aged 0 to 18 years with OM diagnoses between the 1st of 
January 2002 and the 31st of December 2010 were identified.  For inclusion, all patients 
needed to be registered with a GP who contributed data to the database for at least 6 
months (except children less than 6 month of age). Children temporarily registered with 
their general practice were excluded to avoid duplication of event data and inaccurate 
child-year calculations, as these children were most likely registered in another practice.  
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2.5.3.2.3 Data extraction 
Cases of OM were identified by searching the entire collection of electronic records of 
all children and adolescents in the IMS DA data over the study period for those who had 
diagnostic codes relating to a diagnosis of OM or middle ear infection with read-code. 
All codes were validated by Professor Mike Sharland.  
 
Antibiotic prescriptions for OM were identified by searching the IMS DA database for all 
therapy codes corresponding to antibiotics (i.e. drugs listed under the ATC therapeutic 
main group J01, antibacterial for systemic use). Drugs for treatment of tuberculosis and 
leprosy were not included.  Patient ages were recorded at the date the antibiotic was 
prescribed.  
  
2.5.3.2.4 Data analysis 
OM is an acute infection that can recur and if not treated properly it may develop into 
OME and/or CSOM from the same episode. In instances of repeat infection antibiotic 
resistance may develop, so a child may have to receive treatment more than once for 
the same episode.  Therefore, each episode of more than 30 days due to OM and each 
antibiotic prescription counted as a new infection and a new prescription. This thirty day 
screening period was set on the advice of Professor Mike Sharland.  
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In addition, as OM is more commonly observed in the younger age group, data were 
split into the following age ranges in order to investigate the incidence of OM by age (<2 
year old, 2-5 years old, 6-10 years old, 11-15 years old and 16-18 years old). Age and 
calendar year-specific incidence rates were calculated for OM diagnosis and antibiotic 
prescribing for OM, per 1,000 child-years at risk in the IMS-DA. The incidence rate of 
OM diagnosis/ antibiotic prescriptions for OM was defined as the number of the 
disease/ treatment event divided by the total number of child-years at risk of OM in a 
paediatric population (aged 0 to 18 years) in a particular year.  
 
Ninety-five percent confidence intervals were generated using Poisson approximation. 
Additionally, a chi-square test (Cochran-Armitage test for trend) was used to examine 
the yearly trend of incidence rate of OM, as well as, the antibiotic prescribing for OM. A 
P-value of less than 0.05 was considered statistically significant.  
To evaluate the effectiveness of PCV7 for pneumococcal diseases an Interrupted Time 
Series (ITS) design was used. It is an experimental method used to determine the 
impact of a complex intervention. It is a set of data which is used to study change in a 
variable over time that consists of a time-ordered sequences of measurements.  
 
Data are collected at multiple instances over time, before and after an intervention, to 
detect whether the intervention has an effect significantly greater than the underlying 
secular trend. Also time series enable the timing and the nature of change to be 
examined (Matowe et al., 2003). For more details see Figure 2.1. 
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In this study, the causal hypothesis was that observations made after the introduction of 
the vaccine will have a different level and/or slope as compared with previously. 
(Grijalva et al. (2007) used this method of analysis in their studies.) 
 
Figure 2.1: The effect sizes estimated by time series regression analysis of an 
interrupted time series design. (Taken from Ramsay et. al., 2003) 
 
 
Interrupted Time Series analysis using segmented regression modeling was employed 
to examine the impact of PCV7 on OM incidence before and after its introduction and to 
control for seasonal effects, by comparing the quarterly change of OM episode in 
children aged less than 2 years old before and after the introduction of PCV7.  Data 
from IMS DA was extracted. PCV7 was introduced to UK practice in September 2006, 
so the study period was defined as pre-PCV7 (2003-2005) and post-PCV7 (2007-2009). 
The year 2006 was defined as a transitional period.  
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Slope change is a comparison of the pre-PCV7 and post-PCV7 when the quarterly OM 
episode level is plotted over time in months.  All data management and analysis was 
carried out using Stata version 11.0 (Statistical Software: Release 11.0 College Station, 
TX). 
 
2.5.4 Study strand FOUR – Pneumonia Cohort Study  
2.5.4.1 Aims and objectives 
Even though a reduction in pneumonia incidence and antibiotic prescribing for 
pneumonia has been demonstrated in other countries, it still remains unclear if there 
have been any changes in pneumonia management in UK General Practice since the 
introduction of PCV7. 
The aim of this study strand is:  
To describe the incidence rates of pneumonia and antibiotic prescribing in children and 
adolescents before and after the introduction of PCV7 between 2002 and 2010 in the 
UK primary care stratified by age and gender. 
Objectives:  
 To determine the annual incidence of pneumonia diagnosed in the primary care 
setting.  
 To determine the annual incidence of pneumonia diagnosed in primary care 
stratified by age and gender.  
 To describe antibiotic prescribing patterns associated with pneumonia.  
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 To describe antibiotic prescribing patterns associated with pneumonia by age 
and gender. 
2.5.4.2 Methods  
2.5.4.2 1 Study design  
A retrospective cohort study was conducted using The Health Improvement Network 
(THIN) database. Information held on the database includes patient demographics, 
indications for treatment and prescription details. Descriptive analysis will be conducted 
for patient demographics and prescription data.  
 
With THIN database, antibiotics are listed under the BNF code (antibacterial for 
systemic use), based on data from the MULTILEX classification, which will be utilised in 
the data analysis (appendix 6). Diagnoses of pneumonia will be classified based on 
Read Code (refer to appendix 7).  Ethical approval for this study was obtained from the 
Scientific Review Committee (SRC). A summary of their comments is included at 
Appendix 8. 
 
2.5.4.2.2 Study population 
Children and adolescents aged 0 to 15 years with pneumonia diagnoses between the 
1st of January 2002 and the 31st of December 2010 were identified. For inclusion, all 
patients needed to be registered with a GP who contributed data to the database for at 
least 6 months. 
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2.5.4.2.3 Data extraction 
Pneumonia was identified by searching the entire collection of electronic records of all 
children in THIN database over the study period for those who had diagnostic codes 
relating to a diagnosis of pneumonia with a respective read-code. Over the study period 
all codes were validated by one of our clinical team (Prof. Mike Sharland).  
 
Antibiotic prescriptions for pneumonia were identified by searching THIN database for 
all therapy codes corresponding to antibiotics (i.e. drugs listed under BNF code for 
antibacterial for systemic use respectively). Patient ages were recorded at the date the 
antibiotic was prescribed.   
 
2.5.4.2.4 Data analysis 
As long as pneumonia is one of the most common infectious diseases in young children 
and as antibiotics are prescribed when pneumonia is suspected, resistance by the 
bacteria may occur, so a child may receive antibiotics more than once for the same 
episode. Therefore, each episode of more than 30 days due to pneumonia and each 
antibiotic prescription were counted as a new infection and a new prescription. The 
thirty days screening period was set on the advice of one of our clinical team based on 
his clinical expertise (Prof. Mike Sharland).  
 
As pneumonia is more commonly observed in younger age group, data were split into 
the following age ranges in order to investigate the incidence of pneumonia stratified by 
age (<2 year old, 2-5 years old, 6-10 years old and 11-15 years old).  
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In the THIN database, the incidence rate of pneumonia was defined as the number of 
each pneumonia episodes divided by the person year in the paediatric population (aged 
0 to 15 years) in a particular year.  The incidence rate of prescribing was defined as the 
number of antibiotic prescriptions divided by the person-year paediatric population 
(aged 0 to 15 years) in a particular year.  
 
The incidence rate was calculated using Poisson distribution with a 95% confidence 
interval (CI). A chi-square test was used to compare the prescribing trend before and 
after the introduction of PCV7. A P-value of less than 0.05 was considered statistically 
significant. Data manipulation and analysis was conducted using STATA/SE 11.0 for 
Windows (Statistical Software: Release 9.1. College Station, TX, USA). 
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CHAPTER THREE: SYSTEMATIC REVIEW & META-ANALYSIS 
This chapter addresses the results of the systematic review and meta-analysis that 
were performed for this study in order to investigate the efficacy of the vaccine and 
the respective adverse events caused by the vaccine in children aged 0-10 years.  
 
3.1 RESULTS 
Based on the initial search strategies (discussed in Chapter 2), 447 articles were 
identified. The title, abstract or the full text article were then reviewed for relevance, 
and 438 articles were excluded for various reasons (refer to Figure 3.1). Of these, 9 
articles were deemed relevant for scrutiny of the full text article. However, at this 
point 7 studies were excluded; with 2 studies remaining which were included as they 
met the inclusion criteria (refer to Table 3.1). Meta-analysis could be performed on 
the two studies and all calculations were performed according to ITT.   
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Figure 3.1: Identification and selection of eligible trials for inclusion in the 
systematic review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
   Eligible articles 
        2 articles 
Articles identified  
n= 447 
PubMed n= 201, EMBASE= 79, WHO= 22, Cochrane= 36, Meta-Register= 78, 
Clinical trial registered= 31 
Excluded after screening titles and 
abstracts n=438 
 Duplicates  n= 56 
 Not relevant  n=229 
 No publication  n= 39 
 Not randomized clinical trial  n=6  
 Other vaccines  n= 21 
 Still ongoing studies  n=3 
 Other indication  n=3 
 Nasopharyngeal colonization  n=14 
 Reviews  n=23 
 Combination vaccines  n=29 
 Costs effectiveness studies  n=3 
 Others (fact sheets, commentary)  
n=12 
 
Potentially eligible articles 
n= 9 
 5 articles did not report geometric 
mean concentration (GMC) for the 
all 7 serotypes  
 1 articles had no available data 
 1 other language (French, couldn’t 
be translated) 
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The reported characteristics and main findings from the 2 eligible individual studies 
are described in Table 3.1. 
Table 3.1: Data extracted from the included studies 
 
 
Author Cheng Li, R et al 
Year 2008 
Location China 
Objective Primary objective was to evaluate the safety of PCV7 versus control 
group given at 3,4, and 5 months 
 
Secondary objective to evaluate the immunogenicity of PCV7 given 
concurrently with DTaP versus control 
Study Design Open label, controlled, randomized study 
Population 800 previously unimmunized Chinese infants of 3-4 month of age 
Outcome Safety assessment: child is monitored for 30 min after injection, local 
and systematic side effects are looked at.  
 
Parent to fill out diary for 4 days after vaccination.  
 
To decide immunogenicity, 3 ml blood retrieved from 55 infants from 
every group. 
Results After immunisation, increase in GMC in groups 1 and 2 but decline in 
group 3.  
 
Local reactions: Erythema , induration/swelling and tenderness.  
 
Systematic: fever, irritability, decrease appetite, disrupted sleep, 
drowsiness, vomiting and diarrhea 
Conclusion Included in meta-analysis 
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Author Black et al. 
Year 2000 
Location USA 
Objective Primary objective is to evaluate the efficacy of PCV7 against any 
invasive disease caused by vaccine serotype. 
 
Secondary objective is to evaluate the efficacy of PCV7 against 
clinical OM visits and episodes 
Study Design Randomized double-blind trail 
Population 37,868 infants 
Outcome AOM episode 
Results No evidence of any increase of disease caused by non-vaccine 
serotype. 
 
Local reactions: redness, swelling and tenderness. 
 
Systematic reaction: fever 
Conclusion Included in meta-analysis 
 
The Meta-Analysis  
Within the meta-analysis of the 2 included papers, the local Adverse Drug Reactions 
(ADRs) used in the analysis were tenderness, redness and swelling. Tenderness 
was defined as tenderness felt by injection site which did not interfere with leg 
movement (injection given in hip). Redness was defined as a red area < 2.5 cm 
around the injection site and swelling was defined as a swelling < 2.5 cm. The 
systematic ADR was fever of >38 °C. Forest Plots were generated for each ADR.  
 
What is a “Forest Plot”? 
Results of meta-analyses are usually reported using forest plots. A forest plot is a 
graphical display of the included studies’ results. They were first used in 1970.  
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It consists of two columns: one displays the study names (left hand column) and the 
other displays the corresponding mean for the measure of effect (e.g. an odds ratio) 
and its confidence interval. The point estimate is displayed as a square whose size 
is proportional to the weight assigned to the study. The confidence interval is 
displayed as a horizontal line extending on both sides of the mean. In case of using 
an odds ratio as a measure of effect, the plot will have a natural logarithmic scale to 
enable presenting the confidence interval symmetrically around the mean. This 
ensures that values greater than 1 are not over-emphasized. The combined 
measure of effect obtained from the meta-analysis is represented on the plot as a 
diamond, the lateral points of which indicate the confidence interval around the 
mean estimate. 
 
The forest plot also has a vertical line corresponding to “no effect” (i.e. no difference 
in effect between the study arms). If the horizontal line representing the confidence 
interval for any individual study crosses this line, this demonstrates that the effect 
size does not differ from no effect, at the given level of confidence, for the individual 
study (i.e no difference in effect between the study arms).  The same applies to the 
combined measure of effect representing the meta-analysis result: if the point of the 
diamond overlaps the line of no effect, the overall meta-analysis result cannot be 
said to differ from no effect at the given level of confidence (Schünemann et al., 
2008; Schriger et al., 2010). 
 
Local ADRs 
In this study, forest plots have been generated for each ADR after the 3 consecutive 
vaccine doses (see figures 1-12).  
The forest plots present the heterogeneity between the studies and the precision of 
each study individually as well as in comparison with one another.   
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The following figures show the forest plots of meta-analysis conducted on the two 
included studies. Each study is represented by a block, which is proportional to 
mean precision of the treatment in each study.  
The 95 % confidence interval corresponds to the horizontal lines and the width of 
the centre of the diamond shape represents the average treatment effect across the 
two studies. 
 
Tenderness 
Fig 1: Tenderness post dose1 
 
The first forest plot (Fig 1) describes the tenderness after first dose of PCV7. This 
includes a total of 19231 subjects with and odds ratio 1.52 [95% CI; 0.56, 4.15]. The 
p value of the Chi-squared test has evidence of statistical variability between the two 
studies, with the value showing considerable heterogeneity in the outcome variable 
(I2=80%).  
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Fig 2: Tenderness post dose 2 
Forest plot in this figure (Fig 2) has a total of 19 187 subjects and describes 
tenderness after the second dose of PCV7. The odds ratio in this plot is 1.36 [95% 
CI; 1.29, 1.44].    
It also shows that the p value of the Chi-squared test has no evidence of statistical 
variability between the two studies, with the value showing no considerable 
heterogeneity in the outcome variable (I2=0%).  
Fig 3: Tenderness post dose 3 
This figure describes tenderness after the third dose of PCV7. This includes a total 
of 19179 subjects with and odds ratio 1.34 [95% CI; 0.80, 2.25].   
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The p value of the Chi-squared test has no evidence of statistical variability between 
the two studies, with the value showing no considerable heterogeneity in the 
outcome variable (I2=19%).  
 
The following figures (4, 5 and 6) represent the forest plots for redness after first, 
second and third dose of PCV7 respectively.  
 
 
Redness  
Fig 4: Redness post dose 1 
 
After the first dose, the total number of subjects is 19231; odds ratio 2.12[95% CI; 
0.99, 4.57]. The Forest plot figure displays that the p value of the Chi-squared test 
shows evidence of statistical variability between the two studies, with the value 
showing considerable heterogeneity in the outcome variable (69%).  
 
 
 
                                                 CHAPTER THREE 
127 
Fig 5: Redness post dose 2 
After second dose, the total number of subjects was 19187; odds ratio 1.59 [95% CI; 
1.48, 1.71], The Forest plot figure shows that the p value of the Chi-squared test has 
no evidence of statistical variability between the two studies, with the value showing 
no considerable heterogeneity in the outcome variable (I2=0%).  
 
Fig 6: Redness post dose 3 
After the third does, the total number of subjects is 19179; odds ratio 1.56 [95% CI; 
1.47, 1.67] .The Forest plot figure shows that the p value of the Chi-squared test has 
no evidence of statistical variability between the two studies, with the value showing 
no considerable heterogeneity in the outcome variable (I2=0%).  
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Figure 7,8 & 9 represent the forest plots for swelling after the first, second and third 
dose of PCV7 respectively.  
 
Swelling 
Fig 7: Swelling post dose 1 
After the first dose, total number of subject 19231 and odds ratio is 2.49 [95% CI; 
2.28, 2.71]. The Forest plot figure shows that the p value of the Chi-squared test has 
no evidence of statistical variability between the two studies, with the value showing 
no considerable heterogeneity in the outcome variable (I2=0%).  
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Fig 8: Swelling post dose 2 
After the second dose, the total number of subjects is 19187 and odds ratio is 1.88 
[95% CI; 0.85, 4.17].  
The Forest plot figure shows that the p value of the Chi-squared test has no 
evidence of statistical variability between the two studies, with the value showing no 
considerable heterogeneity in the outcome variable (I2=70%).  
 
Fig 9: Swelling post dose 3 
After the third dose the total number of subjects is 19179 and the odds ratio is 1.49 
[95% CI; 1.08, 2.06]. The Forest plot figure shows that the p value of the Chi-
squared test has no evidence of statistical variability between the two studies, with 
the value showing no considerable heterogeneity in the outcome variable (I2=15%).  
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Figure 10, 11 & 12 represent the forest plot for the systematic ADR (fever) following 
the first, second and third dose of PCV7 respectively.  
 
Systematic ADR (Fever >38 °C)  
Fig 10: Fever post dose 1 
The total number subjects is 19230 and odds ratio is 0.53 [95% CI; 0.05, 5.92] after 
the first dose. The Forest plot figure shows that the p value of the Chi-squared test 
has evidence of statistical variability between the two studies, with the value 
showing considerable heterogeneity in the outcome variable (I2=95%).  
 
Fig 11: Fever post dose 2 
                                                 CHAPTER THREE 
131 
After the second dose the numbers were 19187; 1.23 [95% CI; 0.26, 5.87]. The 
Forest plot figure shows that the p value of the Chi-squared test has evidence of 
statistical variability between the two studies, with the value showing considerable 
heterogeneity in the outcome variable (I2=92%).  
 
Fig 12: Fever post dose 3:  
After the third dose the numbers where 19179; 0.63 [95% CI; 0.07, 6.01]. The Forest 
plot figure shows that the p value of the Chi-squared test has evidence of statistical 
variability between the two studies, with the value showing considerable 
heterogeneity in the outcome variable (I2=89%).  
 
3.2 DISCUSSION  
The aim of this systematic review was to examine the efficacy of the heptavalent 
pneumococcal conjugate vaccine (PCV7) as a primary outcome. The secondary 
outcome was to investigate the ADRs related to PCV7. This was a systematic 
review of controlled clinical trials i.e., PCV7 groups were compared to a control 
group. The control group in the two included studies received a meningococcal 
conjugate vaccine.   
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As for the efficacy of the vaccine, this could unfortunately not be ascertained due to 
the lack of data for the control groups in the two respective studies. Attempts to 
contact authors have were made but data was not attainable. 
 
It is problematic to evaluate the efficacy of the PCV7 since different methods were 
used in the included studies. Many articles have investigated the efficacy on the 
number of infection episodes that PCV7 has prevented compared to unvaccinated 
groups (control group). Eskola et al. (2001) states that the efficacy of PCV7 in 
preventing Otitis Media was relatively low, reducing cases of any cause by 6% “(95 
percent confidence interval, -4 to 16 percent [the negative number indicates a 
possible increase in the number of episodes]), culture-confirmed pneumococcal 
episodes by 34 percent (95 percent confidence interval, 21 to 45 percent), and the 
number of episodes due to the serotypes contained in the vaccine by 57 percent (95 
percent confidence interval, 44 to 67 percent). The number of episodes attributed to 
serotypes that are cross-reactive with those in the vaccine was reduced by 51 
percent, whereas the number of episodes due to all other serotypes increased by 33 
percent”(Eskola et al., 2001, p 403).  
 
Another way of assessing efficacy is to investigate the immunogenicity the vaccine 
provides for each serotype, as the incidence of different pneumococcal diseases 
varies according to the serotype it is caused by. The World Health Organisation has 
reported that the minimum concentration which is considered immunogenic is 0, 20 
– 0, 35 µg/ml for children (Capeding et al., 2008). Thus the levels of geometric mean 
concentration of an antibody can be another indicator to evaluate the efficacy of 
PCV7. 
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In addition, as mentioned earlier, the serotype 19A was the leading cause for 
invasive pneumococcal diseases in children less than 5 years of age. However, this 
cannot be evaluated due to the lack of sufficient data in this review.  
 
The meta-analysis was successfully conducted on the ADRs of the vaccine. The 
ADRs of PCV7 in three doses prior to the booster were assessed. The results 
clearly demonstrated that the control group had more ADRs than PCV7 vaccinated 
children, indicating that the PCV7 is well tolerated with no serious ADRs.  However 
due to the few articles included, it is difficult to draw a conclusion on the safety of 
PCV7 in children.  
 
As for the systemic ADRs (e.g. fever), it is apparent that the PCV7 group 
(vaccinated children) reported more fever than the control group.  This is an 
expected side-effect of the vaccine; however fever can be very abstract and it is 
difficult to evaluate the association with PCV7.  
 
It is difficult to analyse the heterogeneity of only two studies; conclusions made 
cannot be generalised. For the local ADRs, there is a trend in the heterogeneity; 
there is a clear drop in heterogeneity (τ). For all three ADRs: tenderness, redness 
and swelling, the τ is higher in the first dose but drops for the second and three 
doses. It is evident that there has been some sample attrition in the studies which 
may contribute to the heterogeneity being similar in the last two doses. The authors 
did not provide any information to why there was attrition in the studies. 
 
The results for the systematic ADR of fever showed that the heterogeneity varied 
and was relatively higher than the local ADRs, this has also been seen at different 
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doses. This may be due to the different sampling and measurement of fever in each 
individual study.  
 
A quality assessment of two included articles was carried out using the CONSORT 
statement (Appendix 9).  The included articles were considered high quality to carry 
out the meta-analysis. The results needed for meta-analysis were reported, such as 
randomisation, allocation, intervention, inclusion criteria and population. There is 
some concealment of information, which may address the questions of bias, for 
example the article by Cheng et al (2008), did not report the number of patients who 
dropped out after first dose, as well as the reason for the withdrawal.  In addition, 
both included articles did not report the data for the control group on the serotype 
specific GMCs which makes it difficult to carry out the comparison for this 
measurement.   
 
Finally, publication bias could not be examined via a Funnel Plot (a statistical 
method used to detect publication bias in systematic reviews and meta-analyses, via 
plotting intervention effect estimates from individual studies against the size of each 
investigation – Cochrane, 2006), since this analysis needs at least 10 studies.  
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3.3 HYPOTHESIS, AIMS AND OBJECTIVES 
Following the literature review and meta-analysis, the study hypothesis, aims and 
objectives were confirmed as follows:  
 
3.3.1 HYPOTHESIS 
The incidence rate of pneumococcal diseases and respective antibiotic prescribing 
post the introduction of the PCV7 in children and adolescents will be lower as 
compared to the rates observed prior to its introduction.  
 
3.3.2 AIMS 
To investigate whether the introduction of PCV7 has had an impact on the recorded 
occurred pneumococcal diseases (OM and Pneumonia) and the volume number of 
antibiotics prescribed to treat these conditions in children and adolescents. 
 
3.3.3 OBJECTIVES 
Primary objective: 
To characterise the annual incidence rates of OM and pneumonia and antibiotic 
prescribing trends for these diseases in children and adolescents, between 2002 
and 2010 in the UK primary care setting before and after the introduction of PCV7.   
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Secondary objectives:  
1) To compare the percentage of children recorded as receiving PCV7 in 
the IMS DA with the national statistical data (COVER).  
2) To validate the IMS DA immunisation records in children aged 0-2 years 
through questionnaires sent to GP. 
3) To investigate the association between the vaccine consumption and the 
incidence of OM in children aged 0- 2 years old by using individual 
patient-analyses. 
                                                CHAPTER FOUR 
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CHAPTER FOUR: VALIDATION STUDY 
This chapter presents the findings of the validation study performed to investigate 
PCV7 immunisation recording in children aged 0-2 years in general practice. This 
study strand compared the percentage of immunisation recording in general practice 
(recorded in IMS DA) with COVER data. To validate the study, firstly the percentage 
of PCV7 vaccinated children born in 2008, in the IMS DA database was calculated 
and compared with the COVER data.  Secondly, children of the same age (0-
2years) without a PCV7 record in the primary care setting, in IMS DA database, 
were validated through a questionnaire sent to their general practitioners. 
 
4.1 RESULTS 
In the IMS DA data, 12,740 vaccination records of PCV7 for children born in 2008 
were identified, 2,497 children had no vaccination records.  From those children 
without PCV7 vaccination record 173 children (7%) from 53 practices were randomly 
selected (the estimated overall number of questionnaires required for this study, 
chapter 2). The GP questionnaire was then sent to those practices. There were 2 
practices unable to return the questionnaires as one practice had stopped 
contributing their data to IMS DA, and the other practice encountered a technical 
problem.  A total of 117 questionnaires were returned (68%; 117/173) (Chart 4.1).  
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Chart 4.1: Questionnaire Responses 
 
 
                                                          
 
 
 
 
 
 
 
 
 
 
 
   
 
 
  
 
 
 
 
      117 questionnaires received 
76 child having PCV7 
record  
34 children with no PCV7 
record  
  
           110 (with & without PCV7 record) 
 
4 children been unable  
to decrypt 
1 practice (1  
child)  has left  
panel 2 children moved 
before any vaccine 
given 
 1 had only 1st dose 
 1 had only  2nd & 3rd doses 
 2 deleted by IMS 
 1 had only  1st & 2nd doses 
 
 1 fictitious patient 
 3 deleted by IMS 
 2 temporary resident  
   173 questionnaires sent to 53 practices 
56 not responded 
28 children confident with no 
PCV7 record 
71 children confident fully 
vaccinated with PCV7 
9 without 
any record  
25 with no 
PCV7 record 
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Table 4.1 displays the vaccination records of the 173 children by region. One 
hundred percent of children in Yorkshire region, 87.5% of children in Mersey region 
and 73% of children in North West Thames region had been vaccinated yet they had 
no vaccine records in the data.  In contrast, in Wessex, the result shows that 78% of 
the children were truly un-vaccinated.   
Table 4.1: Vaccination records by region 
 
Region L P CMBV NPR NGR UD Vac.  
  
 
Unvac. Total 
East Anglian 0 0 0 1 0 1 0 2 
North Western 0 0 0 3 0 0 1 4 
Mersey 0 0 0 2 0 21 3 26 
Northern 0 0 0 2 0 0 1 3 
Oxford 0 0 0 2 0 1 0 3 
North East 
Thames 
0 0 0 0 0 1 1 2 
Wales 0 0 0 1 0 0 0 1 
South 
Western 
0 0 0 17 2 5 5 29 
South West 
Thames 
0 0 2 9 1 4 4 20 
South East 
Thames 
0 0 0 1 0 0 0 1 
Trent 0 0 0 7 0 1 0 8 
Wessex 0 0 0 1 0 2 7 10 
West Midlands 1 2 0 9 1 8 1 22 
Yorkshire 0 0 0 0 0 8 0 8 
North West 
Thames 
0 0 7 1 0 24 2 34 
Overall  1 2 9 56  4 76          25  173 
 
 
 
PL= Left Practice 
CMBV= Children Moved Before Vaccination 
NPR= No Patient Record, assumed not vaccinated 
NGR= No GP reply 
UD= IMS unable to decrypt 
Vac. = Vaccinated with PCV7    
Unvac. =Unvaccinated with PCV7, not included in other category    
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4.2 DISCUSSION 
Overall, the percentage of PCV7 vaccinated children in the IMS DA database is 
slightly lower as compared to that in the COVER data (83% and 90%-95%). 
However, out of the 117 children with no PCV7 record in the IMS selected data, 
65% of these had in fact received the PCV7 but this had not been recorded in the 
IMS data set.  This indicates that, the administration rate of PCV7 was higher than 
that reported by IMS. As can be seen from the table 4.2, most geographical regions 
need to improve their practices’ vaccination records.   
 
According to the percentage of the vaccination records in the data, there is a 
potential under-recording of the immunisation history of the children in the IMS 
database.  This could be due to the fact that, healthcare professionals other than 
GPs can also administer the vaccine to children, and these professionals may not 
have direct access to the patients’ electronic record.  In addition, where the vaccine 
is given (irrespective of who it is given by) GPs may not always record the 
vaccination of the child as The Quality and Outcomes Framework (QOF) scheme 
does not include vaccination as an indicator (Dixon et al., 2011).  
 
There is therefore reason to conclude that health authorities and general practices 
need to develop strategies to improve their computerised vaccination records. One 
way of achieving this could be by assigning more clinicians read/write access to 
primary care IT systems and records. If all relevant health professionals were to 
have the facility to record their patients’ immunisations, organisations like IMS would 
be able to offer more reliable databases to investigate the impact of vaccines on the 
incidence of related conditions.  
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This topic is considered further in chapter 7 of this thesis. But more immediately the 
evaluation reported here has established that individual patient-level data analyses 
based on IMS data cannot reliably be employed to investigate the association 
between the incidence of OM and PCV7 usage, due to the under-recording of 
childhood immunisation in current NHS GP records. A cohort study based design 
using Interrupted Time Series techniques was therefore employed in the work 
described in the next chapter. (See also chapter 2 for the underpinning methodology 
used). 
 
4.3 CONCLUSION 
This validation study has shown that it is not appropriate to use the recorded IMS 
patient-level data to analyse the effectiveness of PCV7.  A cohort study based 
design using Interrupted Time Series techniques is the appropriate methodology. 
 
                                               CHAPTER FIVE 
142 
CHAPTER FIVE: THE IMPACT OF PCV7 ON THE INCIDENCE OF OM AND 
ANTIBIOTIC PRESCRIBING FOR OM IN CHILDREN AND ADOLESCENTS 
BETWEEN 2002 AND 2010 
This chapter presents the results of the study strand that investigated the incidence 
rates of OM and antibiotic prescribing patterns in children and adolescents before 
and after the introduction of PCV7 between 2002 and 2010 in the UK primary care 
setting stratified by age and gender.  As described in chapter 2 a retrospective 
cohort study was conducted on data between 2002 and 2010 taken from IMS 
Disease Analyzer (IMS DA) database. 
5.1 RESULTS  
There were 799,126 (49% female; n=395,363) children and adolescents aged 0 to 
18 years in the IMS DA contributing 4,020,777 person-years between January 2002 
and December 2010. Of these, a total of 151,599 (19%; 151,599/799,126) had a 
diagnosis of OM. Half of them were female (51%; 77,102/151,599). Table 5.1, 
shows the demographic of children diagnosed with OM between 2002 and 2010. 
 
Figure 5.1 shows that the number of OM episodes gradually declined over the years 
in both boys and girls. Amongst those children with an OM diagnosis, approximately 
40% (n=59,950; 59,950/151,599) of them had received an antibiotic prescription. 
Overall, the incidence of OM episodes significantly decreased by 36% from 85.5 
per1000 person-years (95% CI: 84.6-86.4) in 2006 to 54.9 per1000 person-years 
(95% CI: 54.1-55.6) in 2010 (P<0.05).  A similar trend was seen in the incidence of 
antibiotic prescribing for OM.  It also significantly decreased between 2006 and 
2010, from 26.3/1000 person-years (95% CI: 25.8-26.8) to 13.4/1000 person-years 
(95% CI: 13.0-13.8) respectively (P<0.05). This represented a standardised decline 
of 49%. 
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              Table 5.1: Demographic of children and adolescents diagnosed with OM, aged 0-18 years in IMS DA, 2002-2010. 
 
 
Year 
Boys Girls 
Number of patients Number of episodes Person-years Number of patients Number of episodes Person-years 
   2002     17,454 23,248 263777.9 17,749 23,247 254243 
2003 17,930 24,041 258312.5 18,357 23,868 248746.9 
2004 15,940 21,283 244468.2 16,505 21,657 235088.5 
2005 15,197 20,399 233251.9 15,873 20,799 223886.7 
2006 14,326 18,817 226924.2 14,930 19,225 218008.5 
2007 12,669 16,614 219137 13,722 17,620 210379.6 
2008 11,089 14,499 211939.1 11,767 15,175 203246.9 
2009 9,228 12,047 201208.5 9,635 12,359 192740.3 
2010 7,819 10,087 191773.4 8,253 10,514 183644.6 
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Figure 5.1: Incidence of OM diagnosis and antibiotic episodes for the treatment of OM in children and adolescents 
aged 0-18 years, by year, derived from IMS DA 
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Of the included children with OM episodes, diagnosis varied between each age group 
(Fig. 5.2). From 2002 onwards and up to the end of the study period, the incidence of 
OM reduced with age. The lowest recorded incidence was in adolescents/young adults 
aged 16-18 years. The highest incidence was in children aged less than 2 years, 
although this group experienced a 15% decline in the rate of OM diagnoses from 
181.6/1000 person-year (CI: 176.4-186.9) to 155.8/1000 person-year (CI:149.6-162.3) 
between 2006 and 2010. It is of note that for the same age group there was between 
2009 and 2010 a slight increase of 11% from 138.3/1000 person-year (95% CI:136.5-
142.2) to 155.8/1000 person-year (CI:149.6-162.3) respectively.  
 
For the other age groups, there was a notable decline observed in the incidence of OM 
diagnosis between 2006 and 2010. In children aged between 2 and 5 years old there 
was a 31% decrease, from 176.9/1000 person-years (95% CI: 174.0-179.9) to 
121.6/1000 person-years (95% CI: 118.9-124.3). Likewise there was a 36% fall 
amongst those aged between 6 and 11 years old from 88.8/1000 person-years (95% 
CI: 87.1-90.5) to 56.7/1000 person-years (95% CI: 55.2-58.2); a 43% fall in those aged 
12-15 years old from 45.9/1000 person-years (95% CI: 44.7-47.1) to 26.2/1000 person-
years (95% CI: 25.3-27.2); and a 32% decline in those aged between 16 and 18 years. 
In the latter group the diagnosis rate declined 28.2/1000 person-years (95% CI: 27.1-
29.4) to 19.2/1000 person-years (95% CI: 18.2-20.2).   
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    Figure 5.2: Age group- specific incidence of OM diagnosis, by year, derived from IMS DA 
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The annual incidence of antibiotic prescribing for the treatment of OM also varied 
between age groups during the study period (Fig. 5.3).  In line with OM incidence the 
highest treatment incidence was also seen in children aged less than two years old, 
followed by children aged between 2 and 5 years old.  Following the introduction of the 
PCV7 there was between 2006 and 2010 a 36% decline in the incidence of antibiotic 
prescribing for OM in children aged less than 2 years, from 65.7/1000 person-years 
(95% CI: 62.6-68.9) to 42.4/1000 person-years (95% CI: 39.2-45.8).  
 
A 43% decrease was observed in children aged between 2 and 5 years old, from 
55.9/1000 person-years (95% CI: 54.3-57.6) to 31.6/1000 person-years (95% CI: 30.2-
45.8). In those aged between 6 and 11 years there was a 52% decline from 25.9/1000 
person-years (95% CI: 25.1-26.9) to 12.5/1000 person-years (95% CI: 11.8-13.2) while  
in those aged 12-15 years it was 53%, from 13.2/1000 person-years (95% CI: 12.6-
13.8) to 6.1/1000 person-years (95% CI: 5.7-6.6). Finally in young adults aged between 
16 and 18 years there was a 40% drop, from 7.5/1000 person-years (95% CI: 6.9-8.1) 
to 4.5/1000 person-years (95% CI: 4.0-4.9) between 2006 and 2010. 
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Figure 5.3: Incidence of antibiotic prescribing for OM for children and adolescent aged 0-18 years, by age group, 
derived from IMS DA 
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With regards to gender the overal l  incidence of OM diagnosis was slightly higher in 
females compared to males (Fig. 5.4). Between 2002 and 2010 in females the 
incidence of OM decreased during the study period by 37% from 91.4/1000 person–
years (95% CI: 90.3-92.6) to 57.3/1000 person-years (95% CI: 56.2-58.4). In males it 
fell by 40% from 88.1/1000 person–years (95% CI: 87.0-89.3) to 52.6/1000 person-
years (95% CI: 51.6-53.6) in the same period.  
 
Likewise between the years 2006 and 2010 the incidence of OM in females decreased 
by 35% from 88.2/1000 person–years (95% CI: 86.9-89.4) to 57.3/1000 person-years 
(95% CI: 56.2-58.4) respectively. In males it decreased by 37% from 82.9/1000 
person–years (95% CI: 81.7-84.1) to 52.6/1000 person-years (95% CI: 51.6-53.6). 
 
Antibiotic prescribing rates for the treatment of OM in children were similar between the 
two sexes throughout the study period (Fig 5.5). Between 2002 and 2010 the incidence 
of antibiotic prescription for females declined progressively, by a total of 63% from 
35.9/1000 person–years (95% CI: 35.4-36.9) to 13.4/1000 person-years (95% CI: 12.8-
13.9) Roughly the same percentage reduction was observed in males. Likewise, 
between 2006 and 2010, the incidence of antibiotic prescribing in females declined 
by about half from 26.8/1000 person–years (95% CI: 26.1-27.4) to 13.4/1000 person-
years (95% CI: 12.8-13.9) and similar reduction was also observed in males.   
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  Figure 5.4: Incidence of OM episodes for children and adolescent aged 0-18 years, by gender, derived from IMS DA 
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Figure 5.5: Incidence of antibiotic prescribing for OM for children and adolescent aged 0-18 years, by gender, 
derived from IMS DA 
             
 
 
0
5
10
15
20
25
30
35
40
2002 2003 2004 2005 2006 2007 2008 2009 2010
In
c
id
e
n
c
e
 o
f 
O
M
 p
e
r 
1
0
0
0
 p
e
rs
o
n
-y
e
a
rs
 
Year 
Female Male Overall
PCV7 introduced 
 
                                                                CHAPTER FIVE 
152 
 
Figure 5.6 shows the quarterly incidence of OM diagnosis for all age groups. Overall, OM 
incidence peaked in the first quarter of each year. However, there was a significant decline of 
31% from the 3rd quarter of 2006, when it stood at 54.2 per1000 person-years (95% CI:52.8-
55.6), to 37.3 per 1000 person-years (95% CI: 36.1-38.6)  in the 3rd quarter of 2010 (P<0.05). 
 
Figure 5.7 shows that between 2006 and 2010 the 3rd quarter incidence of OM declined 17% for 
children aged less than two years old, from 129.14 per1000 person-years (95% CI:121.2-136.9) 
in 2006 to 106.83 per 1000 person-years (95% CI:97.5-116.1) in 2010. The equivalent decline 
was 26% for children aged between 2 and 5 years from 84.7 per1000 person-years (95% 
CI:80.9-88.6) in 2006 to 63.1 per1000 person-years (95% CI:59.4-66.8)in 2010 and 33% for 
children aged between 6 and 11 years. In this last age group OM incidence dropped from 56.7 
per1000 person-years (95% CI:54.3-59.1) in 2006 to 38.2 per1000 person-years (95% CI:36.0-
40.2) 2010. In addition a 35% decline was seen in children aged between 12 and 15 years, from 
34.3 per1000 person-years (95% CI:32.3-36.6) to 22.2 per1000 person-years (95% CI:20.3-
24.0). In subjects aged between 16 and 18 years old there was a 22% decline from 21.8 
per1000 person-years (95% CI:19.8-23.7) in 2006 to 17.1 per1000 person-years (95% CI:15.3-
18.9) 2010. 
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 Figure 5.6: Quarterly incidence of OM episodes in children and adolescents aged 0-18, derived from IMS DA  
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     Figure 5.7: Quarterly incidences of OM episodes in children and adolescents by age group, derived from IMS DA 
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As mentioned earlier, to compare the quarterly change on OM episode in children aged 
less than 2 years old before and after the introduction of PCV7. ITS using segmented 
regression modeling found that for children aged <2 years old there was a significant 
decline in the level of OM incidence following the introduction of the heptavalent 
vaccine (P= 0.001). Yet despite this there was not a significant difference in the trend of 
incidence of OM following the introduction of the vaccine (P=0.727) (table 5.2). The 4th 
quarter was used as the reference group in these calculations, as in the UK OM 
incidence always peaks at this time of the year (Fig 5.7). 
Table 5.2: Segmented regression model for children with OM episodes age less 
than 2 years old  
 
 
Parameter  IRR IRR (95% 
Lower CI) 
IRR (95% 
Upper CI) 
 
 
p 
baseline trend  1.00 0.99 1.00  0.092 
level change after PCV7 
intervention 
 0.84 0.76 0.93  0.001 
trend change after PCV7 
intervention 
 1.00 0.99 1.01  0.727 
Quarter 1 vs. 4  0.86 0.81 0.92  <0.001 
Quarter 2 vs. 4  0.71 0.67 0.76  <0.001 
Quarter 3 vs. 4  0.55 0.51 0.59  <0.001 
 
 Key: 
 IRR = Incidence Rate Ratio, which in this instance compares the condition incidence  
            rates before and after the introduction of PCV7 at a given point in time.  
baseline trend: original trend of the mean OM incidence, independently from all   
intervention 
level change after PCV7 intervention: immediate impact of the intervention on the 
mean OM incidence 
trend change after PCV7 intervention: change in trend of the mean OM incidence 
after the intervention 
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5.2 DISCUSSION 
 
5.2.1 SUMMARY OF MAIN FINDINGS AND COMPARISON WITH OTHER STUDIES 
This chapter has presented the findings of the first UK national study to investigate the 
impact of PCV7 on the incidence of OM and antibiotics prescribed for OM using a UK 
primary care database.  Since the introduction of the vaccine in 2006 this research 
strand found a significant decline in the incidence of OM diagnoses (36%) and also in 
antibiotic prescribing (49%) for the treatment of OM in children and adolescents aged 
between 0-18 years old. Although initial reductions in reported OM cases predated the 
introduction of the vaccine, an accelerated trend was seen after the introduction of the 
vaccine – see, for instance, Table 5.2 above. The incidence of OM antibiotic treatment 
follows the same pattern as the incidence of OM episodes, but with much lower 
incidence. Overall, only a third of the children diagnosed with OM were prescribed 
antibiotics.  
 
After the introduction of the PCV7 antibiotic prescribing for the treatment of OM in UK 
primary care fell to a much lower level than that found in a previous study that used 
GPRD data and was undertaken before the free mass availability of immunisation. 
Thompson et al. (2008) showed that between 1990 and 2006 in the GPRD 1,210,237 
episodes of OM were identified amongst a population of 464,845 children. In two-thirds 
of these instances (68%) an antibiotic prescription was issued on the same day. Such 
indicates that PCV7 has had an impact on OM as well as on antibiotic prescribing for 
OM. This in theory at least should have decreased the incidence antibiotic resistance.  
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Despite clinical guidance to the contrary, a proportion of GPs may have continued 
habitually to prescribe antibiotics for children consulting with OM despite the fact that 
many cases are self-limiting and spontaneously resolve without antibiotic treatment 
(Glasziou et al., 1997). Such higher than average usage of antibiotics could be due to 
several factors (Thompson et al., 2008). For instance, some GPs may be more 
concerned than others to avoid the development of potential complications, which are 
more likely to occur in vulnerable populations (Kumar, Little and Britten, 2003). Also, 
articulate parental pressure for antibiotics may at times lead doctors to prescribe 
regardless of whether or not they believe antibiotic treatment is strictly necessary 
(Britten and Ukoumunne, 1997; MacFarlane et al., 1997; Bauchner,  Pelton and Klein, 
1999; Mangione-Smith et al., 1999; Kumar, Little and Britten, 2003; Coenen et al., 
2006).  
Randomised controlled trials and observational studies have indicated the effectiveness 
of PCV7 in children of all ages. In the US, for instance, several studies have shown that 
PCV7 has reduced the incidence of OM as well as the level of antibiotic use in children 
(see Fireman et al., 2003; Poehling et al., 2007).  Similarly, studies from continental 
Europe (Finland, Italy, and France) have reported decreases in AOM rates and 
antibiotic use in children who were administered PCV-7 (Eskola et al., 2001; Cohen et 
al., 2006).  Following on from the above this study demonstrates a 15% decline in the 
incidence of OM in children aged <2 years old and a 31% fall in children aged between 
2 and 5 years old in the UK primary care setting. 
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Such figures are encouraging for observers concerned with the reduction of S. 
pneumonia related morbidity. However, the reported levels of disease decline found in 
this study are not as great as those observed in some other studies.  For instance, one 
retrospective cohort study evaluated the vaccine effectiveness in the US outpatient 
setting via analyses of two national health care surveys (NAMCS & NHAMCS) during 
the period 1994 to 2003. It was found that after the introduction of PCV7 in 2001, OM 
visit rates declined by 20% in children aged <2 years (Grijalva et al., 2006).   
 
In 2009 another study by Grijalva et al. in the US assessed the annual visit rates for OM 
and antibiotic prescription rates for OM for children aged less than 5 years, between 
1995 and 2006 using the same health care data sources. This study reported that the 
annual visit rate for OM had declined by 33%. This fall was accompanied by a 
corresponding 36% decrease in antibiotic prescribing for OM.  
 
In this study the decline in incidence of antibiotic prescription for OM exceeds the 
effects reported in Grijalva et al., 2009. The results show that following the introduction 
of PCV7 antibiotic prescribing for OM has declined by 43% in the UK primary care.  In 
the older age groups (ages 6-11, 12-15 &16-18), OM incidence decreased by 36%, 
43% & 32% respectively. Additionally, the study shows marked reduction in OM 
episodes in older children, who were above age of vaccination. This suggests a 
reduction in the carriage of the infective agent. 
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Overall, when comparing age groups this study’s results show that the burden of OM 
and the rate of antibiotic prescription for OM decreased significantly with increasing 
age.  This could be related to the fact that younger children have immature immune 
systems and anatomically undeveloped Eustachian tubes, which before immunisation 
put them at particular risk of infection.   
 
Although between 2006 and 2010 the burden of OM and the antibiotic prescribing for 
OM decreased in all age groups, in 2010 there was a significant increase in the 
incidence of OM and antibiotics prescribed for OM for children aged less than 2 years. It 
is possible that this increase in the incidence of OM at this point was due to serotype 
replacement. A non-vaccine S. pneumoniae serotype may have become active, 
increasing disease incidence specifically for those aged less than two years. Other 
authors have observed that following the introduction of PCV7 non-vaccine 
S.pneumoniae serotypes to a degree replace vaccine serotypes (Hendrickson et al., 
2008 & WHO, 2009).  Indeed, the threat of serotype replacement disease in part led to 
the introduction of PCV13 into the UK childhood primary immunisation schedule in April 
2010,  
 
In terms of gender, although there were fluctuations in the incidence of the diagnosis 
and in antibiotic prescribing for OM before the introduction of the vaccine and a 
significant decline post introduction of the vaccine, the rates observed were 
consistently higher in females. One possible explanation for this is that females are at 
raised risk because of anatomical as opposed to immune system linked variables. 
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In addition, this study investigated the incidence of the disease on a quarterly basis. 
The results show that seasonal variation is one of the main factors affecting the 
incidence of OM.  
 
The seasonal variation found was an increased incidence in the winter months, as is 
true for many other infectious diseases (e.g. measles, influenza, whooping cough) 
(Grassly & Fraser, 2006; Zielhuis et al., 1990).    
 
As already noted, ITS analyses were employed in this study, and segmented 
regression modelling was used to assess the impact of PCV7 and control for seasonal 
effect.  There was a statistically significant drop in the level of mean OM incidence 
immediately after the introduction of PCV7, but no significant change in trend. As 
mentioned earlier, this apparently paradoxical finding was probably associated with a 
declining incidence of OM established before the introduction of the vaccine, coupled 
with contingent phenomena such as serotype replacement.  
 
5.2.2 POSSIBLE REASONS FOR THE REDUCTION OF OM INCIDENCE PRIOR TO 
THE INTRODUCTION OF THE VACCINE 
The findings presented in this chapter show that, before the introduction of the vaccine 
in 2006, there was unexpected decline in the incidence of OM diagnosis in general 
practice between 2003 and 2004, followed by another decline from 2005 to 2006. The 
reason behind these events is unknown. Apart from random variations in incidence they 
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could perhaps have been due to increased host immunity to infection, or they could 
reflect a true reduction in the nature of the disease itself.  
 
There are consistent findings from other UK national studies to support this study’s 
results.  In as early as 1982 Quinn observed that over time the streptococcal infections 
that are the most common causes of OM appear to be becoming less virulent (Quinn, 
1982).  
 
A previous study by Fleming et al (2003) conducted a time-trend analysis of respiratory 
tract infection diagnoses (including OM) and antibiotic prescribing for patients of all 
ages between 1994 and 2000. Respiratory infection data was obtained from the Weekly 
Returns Service of the Royal College for General Practitioners, which are surveillance 
network covering approximately 600,000 patients from general practice in England and 
Wales. Antibiotic prescribing information was derived from Prescribing Analysis and 
Cost (PACT) data. The authors reported a reduction in respiratory tract infection 
diagnoses, including OM, from 1995 until 2000. Parallel trends were observed in total 
antibiotic prescribing (Royal Collage of General Practitioners, 2007).  Moreover, 
evidence provided by the Health Protection Agency (2008), shows that since 1999 
laboratory reports of Respiratory Syncytial virus have continually reduced.  
 
As mentioned earlier, environmental factors could also be one of the risks influencing 
the pathogens that cause OM. Improvements in people’s behaviour towards tobacco 
smoking, such as reducing smoking in confined areas, and improving basic hygiene 
could have contributed to the reduction of infections in children (Fleming et al., 2003).  
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In 2003 a Scottish Intercollegiate guideline Network stated that “…there is likely to be a 
causal relationship between parental smoking and both acute and chronic middle ear 
disease in children …” (Scottish Intercollegiate guideline Network, 2003, p3).  
 
Another factor that could have influenced Otitis Media treatment trends is changes in 
healthcare-seeking behaviour. A Standing Medical Advisory Committee (SMAC, 1998) 
report recommended a Campaign on Antibiotic Treatment (CAT) in the NHS primary 
care setting.  It advised, firstly, that antibiotic prescriptions should not be given for 
simple coughs and colds or for viral sore throats; secondly, prescribing over the phone 
should be limited; and, thirdly, that antibiotic prescribing for uncomplicated diseases 
should be limited to three days if the patient is fit.   
 
These recommendations were combined with a National Advice to the Public (NAP) 
campaign, together forming the CATNAP campaign. The NAP campaign aimed to 
educate the public/parents. It discouraged them from unnecessarily consulting their 
GPs, sought to lower their expectations for antibiotic prescriptions for OM and advised 
them to seek out advice on symptomatic relief from their community pharmacists 
instead of visiting GP practices. Patients/parents may have therefore have become 
better informed with regard to the symptoms and treatment of OM, consequently 
resulting in fewer consulting their GP for OM incidents.  
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5.3 STRENGTHS AND LIMITATIONS OF THIS STUDY 
It is believed that this study is the first paediatric population-based cohort study 
undertaken to assess the incidence of OM and antibiotic prescribed for OM in children 
and adolescents in the UK primary care.  
 
The strengths of this study are that, firstly, the IMS DA contains robust data from 
primary care across the whole of the UK, so the overall estimate of OM incidence is 
likely to be representative of the UK paediatric population as a whole. Secondly, in the 
IMS database antibiotic prescriptions are directly linked to a Read Coded clinical 
indication by the GP at the time of consultation. This direct linking of therapy and 
indication data enables trends in antibiotic prescribing for OM to be investigated in 
relation to patterns of OM and for the appropriateness of the choice of antibiotic to be 
assessed.  
 
The major limitation of the study, which is common in all studies based on routinely 
collected clinical data, is the inability to confirm diagnosis. The case categorisations 
used were based on the codes entered by the GPs.  Not all data of interest may have 
been recorded in the IMS DA.  
 
Furthermore, it is unknown whether a diagnostic code changes during the study time 
span contributed to the significant reduction in OM diagnosis and prescribing through 
under-recoding. Further work is needed in order to understand how GPs make the 
diagnosis and the decision to prescribe. 
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5.4 CONCLUSION 
This study identified an overall fall of more than a third in OM diagnosis and antibiotic 
prescribing for the treatment of OM in children between 2006 (the date of introduction of 
the vaccine in this country) and 2010. However, some of this reduction predated the 
introduction of PCV7. Several factors appear to have influenced this finding.  
Interrupted Time Series analysis using segmented regression modelling shows that 
there was a significant decline in the incidence of OM at around the time vaccination 
commenced, but that the overall trend was unaffected. This is suggestive of several 
causal factors being at work being simultaneously. It is of note that ITS based 
calculations have not previously been used in studies of the impact of PCV7 
immunisation on the incidence of OM.   
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CHAPTER SIX: THE IMPACT OF PCV7 ON THE INCIDENCE OF PNEUMONIA AND 
RELATED ANTIBIOTIC PRESCRIBING IN CHILDREN BETWEEN 2002 AND 2010                  
 
Although the previous chapter’s results have shown a reduction in both OM diagnoses 
and antibiotic prescribing following the introduction of PCV7 in UK general practice, the 
vaccines impacts on incidence and treatment of pneumonia remain unclear. Therefore, 
an observational cohort study based on THIN database was undertaken to assess the 
effects of the introduction of PCV7 on the burden of disease due to pneumonia and the 
associated antibiotic prescribing for children.  This chapter reports its findings.   
 
6.1 Results  
For the period 2002 and 2010 there were a total of 1,410,663 children aged 0 to 15 
years old (726,766 male/ 683,897 female) in the THIN database population, contributing 
5,732,111 person-years of follow-up data. Table 6.1 shows the information relating to 
children diagnosed with pneumonia between 2002 and 2010.  In this cohort, 5,261 
(5,261/1,410,663; 0.4%) had a diagnosis of pneumonia. Of these nearly a half were 
female (n=2,383), and just over a quarter (27%; 1,425) received an antibiotic 
prescription.  
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Table 6.1: Children diagnosed with pneumonia, aged 0-15 years in THIN, 2002-2010 – episode numbers and person 
years of exposure 
 
 
Year 
Boys Girls 
Number of patients Number of episodes Person-years Number of patients Number of episodes Person-years 
  2002     
284 292 309260.6 236 244 285706.2 
2003 
267 282 314125.8 209 214 292113.1 
2004 
288 299 324136.2 261 264 303273 
2005 365 376 332278 281 290 313148.3 
2006 365 379 334845 291 316 317324.3 
2007 296 306 337126.4 255 257 321457.9 
2008 305 311 338076.7 263 269 323188.7 
2009 305 311 335684.3 263 269 320812.6 
2010 314 322 321889.7 258 260 307664.3 
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Between 2002 and 2010 the lowest incidence of pneumonia diagnosis amongst children 
was seen in 2003 with 0.82/1000 person-years (95% CI: 0.74-0.89) (Fig. 6.1). But it 
increased by 30% to 1.07 per 1000 person-years (95% CI: 0.98-1.14) in 2006.  The 
incidence of pneumonia episodes then decreased by 21% between 2006 and 2007, 
from 1.07 per 1000 person-years (95% CI: 0.98-1.14) to 0.85 per 1000 person-years 
(95% CI: 0.78-0.92). Following this the rates then started to gradually climb to an 
incidence in 2010 of 0.92 per 1000 person-years (95% CI: 0.85-1.00).   Overall, 
however, the number of pneumonia episodes recorded from 2006 onwards declined by 
14% from 1.07 per 1000 person-years (95% CI: 0.98-1.14) in 2006 to 0.92 per 1000 
person-years (95% CI: 0.85-1.00) in 2010 (P<0.05).   
 
Similarly, the incidence of antibiotic prescribing for pneumonia treatment in subjects 
aged 0-15 years declined by 10% from 0.29 per 1000 person-years (95% CI: 0.25-0.33) 
in 2006 to 0.26 per 1000 person-years (95% CI: 0.22-0.29) in 2010 (P<0.05).    
  16
8 
Figure 6.1: Incidence of pneumonia diagnosis and antibiotic prescribing for pneumonia treatment in children aged 
0-15years, derived from the THIN database.  
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The number of pneumonia episodes varied between each age group (Fig. 6.2). From 
2002 onwards and up to the end of the study period, the incidence of pneumonia 
episodes fluctuated by age group until it reached the lowest incidence for children aged 
between 11 and 15 years old.  The highest age specific incidence was found in the 
youngest age group (under two). However, the incidence rate for children under 2 years 
old decreased 29% between 2006 and 2010, from 3.1 per 1000 person-years (95% CI: 
2.7-3.5) in 2006 to 2.2 per 1000 person-years (95% CI: 1.9-2.6) in 2010.   
 
In addition, between 2006 and 2010, a 16% decrease was observed in the incidence of 
pneumonia in children aged between 2 and 5 years old, from 1.9 per 1000 person-years 
(95% CI: 1.7- 2.2) to 1.6 per 1000 person-years (95% CI: 1.4-1.8). However, between 
2009 and 2010 the incidence of pneumonia in the 2-5 year old group slightly increased, 
from 1.4 per 1000 person-years (95% CI: 1.2-1.6) to 1.6 per 1000 person-years (95% 
CI: 1.4-1.8).  
 
The recorded incidence of pneumonia decreased in children aged 6-10 years old by 
28% between 2006 and 2010, from 0.71 per 1000 person-years (95% CI: 0.6-0.8) in 
2006 to 0.5 per 1000 person-years (95% CI: 0.4- 0.6) in 2010. Yet it increased in this 
age group by 8% between 2009 and 2010, from 0.47 per 1000 person-years (95% CI: 
0.38-0.57) to 0.51 per 1000 person-years (95% CI: 0.42-0.62).  Moreover, the incidence 
of pneumonia in those aged between 11 and 15 years increased by 77%, from 0.06 per 
1000 person-years (95% CI: 0.03-0.11) in 2006 to 0.26 per 1000 person-years (95% CI: 
0.19-0.35) in 2010.   
  
1
7
0 
   Figure 6.2: Age group- specific incidence of pneumonia diagnosis, by year, derived from the THIN database.  
 
 
 
  
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
2002 2003 2004 2005 2006 2007 2008 2009 2010
N
u
m
b
e
r 
o
f 
e
p
is
o
d
e
s
 p
e
r 
1
0
0
0
 p
e
rs
o
n
 y
e
a
rs
  
Year 
<2 years 2-5 years 6-10 years 11-15 years
PCV7 introduced 
 
                                                     CHAPTER SIX 
 
171 
 
The annual incidence of antibiotic prescribing for the treatment of pneumonia also 
varied between age groups during the study period (Fig. 6.3).  From 2002 to 2009, it 
was highest in children aged less than two years old, followed by those aged between 
two and five years old. This is in line with the reported incidence rates for pneumonia 
itself. However, in 2010, the antibiotic prescribing rate was higher in children aged 
between two and five years than in all other groups.  
 
In children aged less than two years old, there was a 44% decline in the incidence of 
antibiotic prescribing for diagnosed pneumonia between 2006 and 2010, from 0.73 
items per 1000 person-years (95% CI: 0.55-0.95) to 0.41 per 1000 person-years (95% 
CI: 0.28-0.58).  However, in children aged between two and five years there was slight 
increase of 2% in the overall incidence of antibiotic prescribing for this condition 
between 2006 and 2010. It rose from 0.46 prescription items per 1000 person-years 
(95% CI: 0.36-0.58) to 0.47 per 1000 person-years (95% CI: 0.37-0.59). Against this, if 
the period 2006 to 2009 is taken there was a 26% decline in the incidence, from 0.46 
per 1000 person-years (95% CI: 0.36-0.58) in 2006 to 0.34 per 1000 person-years 
(95% CI: 0.26-0.44) in 2009.  
 
Since 2002 there has also been a fluctuating trend in antibiotic prescribing for children 
aged from 6-10 years old, with a peak in 2006 of 0.27 per 1000 person-years (95% CI: 
0.20-0.35). There was then a decrease of 37% to 0.17 per 1000 person-years (95% CI: 
0.12-0.24) in 2009. However, antibiotic prescribing for this group slightly increased (by 
6%) to 0.18 per 1000 person-years in 2010 (95% CI: 0.13-0.25).   
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Interestingly, in children aged 11-15 years old, antibiotic prescribing for pneumonia 
increased substantially during the study period. Between 2006 and 2010, the incidence 
increased 75%, from 0.02 per 1000 person-years (95% CI: 0.007-0.05) to 0.08 per 1000 
person-years (95% CI: 0.05-0.1).  
 
In children aged 11-15 years old antibiotic prescribing for pneumonia also increased 
during the study period. Between 2006 and 2010 it increased by 75%, from 0.02 
prescriptions per 1000 person-years (95% CI: 0.007-0.05) to 0.08 per 1000 person-
years (95% CI: 0.05-0.1) respectively.  
  
1
7
3 
Figure 6.3: Incidence of antibiotic prescribing for pneumonia for children aged 0-15 years, by age group, derived 
from the THIN database.  
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With regard to gender, overall the incidence of pneumonia diagnosis was slightly higher 
in males compared to females (Fig. 6.4). From 2002 until 2010, the incidence in both 
genders fluctuated.  The incidence in males peaked in 2006, falling by 19% from 1.13 
antibiotic items per 1000 person-year (95% CI: 1.02-1.25) in 2006 to 0.92 per 1000 
person-year (95% CI: 0.82-1.04) in 2009. However, there was a subsequent slight 
increase to 1.00 per 1000 person-year (95% CI: 0.9-1.1) in 2010.  Similarly with females 
a peak was seen in 2006, then rates fell by 14% from 0.99 per 1000 person-year (95% 
CI: 0.88-1.1) to 0.85 per 1000 person-year (95% CI: 0.75-0.95) in 2010.  
 
Additionally the annual incidence of antibiotic prescribing for the treatment of 
pneumonia was slightly higher in males compared to females during the study period 
(Fig. 6.5). Between 2006 and 2010, the incidence decreased by 7% in males from 0.29 
per 1000 person-year (95% CI: 0.24-0.36) in 2006 to 0.27 per 1000 person-year (95% 
CI: 0.24-0.36) in 2010.  In females the incidence of antibiotic prescribing decreased by 
15% from 0.27 per 1000 person-year (95% CI: 0.22-0.34) in 2006 to 0.24 per 1000 
person-year (95% CI: 0.18-0.30) in 2010. 
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 Figure 6.4: Incidence of pneumonia episodes by gender and year, aged 0-15 years, derived from the THIN database.  
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Figure 6.5: Incidence of antibiotic prescribing for pneumonia for children aged 0-15 years, by gender, derived from 
the THIN database.  
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Figure 6.6 shows the quarterly incidence by year of pneumonia diagnoses for all age 
groups. Overall, the incidence of pneumonia increased in the first quarter of the year. 
However, there was a marked decline (20%) from the 3rd quarter of 2006 from 
0.56/1000 person-years (95% CI: 0.53-0.79) to 0.45/1000 person-years (95% CI: 0.35-
0.55) in 2010.  Between 2006 and 2010 the 3rd quarter incidence of pneumonia declined 
49% for children aged less than two years old, from 1.48/ 1000 person-years (95% CI: 
0.98-2.15) in 2006 to 0.76/ 1000 person-years (95% CI: 0.43-1.26) in 2010 (Fig. 6.7).  
 
The corresponding findings in the other age groups were 29% for children aged 
between 2 and 5 years old from 1.07/ 1000 person-years (95% CI: 0.77-1.45) in 2006 to 
0.76/ 1000 person-years (95% CI: 0.52-1.08) in 2010; and 10% for children aged 
between 6 and 11 years old from 0.39/ 1000 person-years (95% CI: 0.24-0.61) in 2006 
to 0.29/1000 person-years (95% CI: 0.16-0.48) in 2010. However, for children aged 
between 12 and 15 years old the 3rd quarter incidence increased by 77% from 0.05/ 
1000 person-years (95% CI: 0.01-0.16) in 2006 to 0.22/1000 person-years (95% CI: 
0.11-0.39) in 2010.   
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  Figure 6.6: Quarterly incidence of pneumonia episodes in children aged 0-15, derived from the THIN database.  
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 Figure 6.7: Quarterly incidences of pneumonia episodes in children, by age group, derived from the THIN database.  
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6.2 DISCUSSION 
6.2.1 Summary of main findings and comparison with other studies 
This chapter presents the findings of the research strand that investigated the impact of 
the PCV7 on the incidence of pneumonia and respective antibiotic prescribing using a 
UK primary care database.  Overall the total number of children diagnosed with 
pneumonia in general practice was low (0.4%).  This study’s findings show that, year by 
year, the number of pneumonia episodes was slightly higher than the number of 
children affected. This indicates that a small number of the children will have 
experienced more than one recorded pneumonia episode within a year i.e. they 
suffered recurrent infections.  
This study shows that between 2002 and 2010 the greatest fall in the incidence of 
pneumonia diagnosis was seen in 2003. This predated the introduction of PCV7. Such 
a trend might have been due to decreased disease virulence (Fleming et al., 2003). 
However, it is also of note that in 2003 a Haemophilus influenza b (Hib) booster vaccine 
was introduced for younger children to increase their immunity against Hib infection 
(HPA, 2012). Haemophilus influenzae and S. pneumoniae can both be found in the 
upper respiratory tract (Pettigrew et al., 2008). It may be that the Hib booster vaccine 
could have decreased the rate of respiratory tract infections, including those classified 
by GPs as pneumonias. 
 
Nevertheless, the overall incidence of pneumonia diagnosis gradually increased by 
30% between 2003 and 2006 (prior the introduction of PCV7) but then declined by 21% 
in 2007 (post the introduction of PCV7).  
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The incidence rate for pneumonia diagnosis in the research described here is 
comparable to a recent study in the UK reported in 2010 by Koshy et al. This used the 
Hospital Episode Statistic (HES) database to identify the impact of PCV7 on childhood 
hospital admissions for bacterial pneumonia and empyema in England during a 12 year 
period (1997- 2008).  
 
According to this source the hospital admission rate for children aged <15 years old 
with bacterial pneumonia increased by 31% from 1997 to 2005 and by 19% from 2004 
to 2006. However, it declined by 19% following the addition of PCV7 in 2006 to the 
national vaccination programme. The authors suggested that the sharper increases 
prior the introduction of the vaccine in the incidence of bacterial pneumonia admission 
rates were unlikely to be an indication of the true rises of the disease itself but were 
more likely due to other factors such as changes in health-seeking behaviour. 
Furthermore, they noted, the HPA reported that prior to 2006, the number of isolated 
pneumonia cases were stable (Koshy et al., 2010).  
 
This study shows that from 2007 the incidence of pneumonia diagnosis has gradually 
increased, peaking in 2010. The interpretation offered here is that it is unlikely that this 
has been due to serotype replacement, and more likely that it is due to low herd 
immunity in older children/young adults. The results presented in this thesis show that 
between 2006 and 2010 the incidence of pneumonia diagnoses in the primary care 
setting appears to have gradually declined in children aged less than 2 years old (see 
Figure 6.2). This finding is consistent with the available HPA/PHE data on vaccine 
serotype infection, as shown in Fig. 6.8.  
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However, with the non-vaccine serotypes the picture is less clear cut (Fig 6.9). It can be 
concluded that in overall terms PCV7 (and its successor PCV13) has reduced the 
incidence of pneumonia amongst infants aged less than 2 years old, the target 
population of the programme. However, this was not true in the older unvaccinated age 
groups.  
 
Figure 6.8: Cumulative weekly number of reports of Invasive Pneumococcal 
Disease due to any of the seven serotypes in Prevenar 7™: Children aged < 2 
Years in England and Wales by Epidemiological Year: July-June (2005- To Date) 
(HPA, 2013a).  
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Figure 6.9: Cumulative weekly number of reports of Invasive Pneumococcal 
Disease due to any of the seven serotypes NOT in Prevenar 7™: Persons aged 
under 2 years in England and Wales by Epidemiological Year: July-June (2005- 
To Date) (HPA, 2013b).  
 
 
 
Other studies offer similar but more significant results. As already highlighted, in the US 
it has been reported that a 39% decline in pneumonia admission rates for children aged 
<2 years old occurred between 2001 and 2004 (National Inpatient Sample data were 
used – Grijalva et al., 2007). Also, the HPA (now PHE) reported in this country a 
marked reduction in the rate of IPD cases caused by the seven serotypes in PCV7 
since the introduction of the vaccine. Moreover, in 2013, a study by Ladhani et al., using 
enhanced national surveillance data in England and Wales, reported that even infants 
aged less than 3 months have derived benefit from PCV7’s introduction.  
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In addition, for those ages between 2-5 years old, 6-10 years and 11-15 years, the 
incidence of pneumonia apparently declined from 2007 to 2009, but slightly increased in 
the next year. The older age group was expected to be protected from pneumonia 
through herd immunity. A recent study found that although hospitalisation rates for 
childhood pneumococcal pneumonia substantially decreased between 2001 and 2007 
(by 61% in children aged less than 2 years and 26% in those aged 2-4 years old) the 
rate of pneumonia complicated by empyema increased two-fold in children aged <2 
years. It rose from 3.5 cases per 100,000 children between 1996-1998 to 7.0 per 
100,000 between 2005-2007. It also increased by 2.8 times in children aged 2-4 years 
old (from 3.7 per 100,000 children in 1996-1998 to 10.3 per 100,000 in 2005- 2007 – 
Grijalva et al., 2010). Such trends may help explain the increased incidence of 
pneumonia in the older age groups in this study’s data.   
Overall, when comparing the various age groups, the results of this analysis show that 
the burden of pneumonia and antibiotic prescription for pneumonia apparently 
decreased with increasing age. The highest incidence was seen in children aged less 
than 2 years old.  In general, the incidence of antibiotic treatment follows the same 
trend as the incidence of pneumonia itself. 
 
Pneumonia has always been one of the primary causes of antibiotic prescribing in 
children, so it was postulated at the start of the study that the incidence of antibiotic 
prescribing for pneumonia would correlate closely with the incidence of pneumonia 
itself.  
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However, the low incidence of antibiotic prescription in the data could be due to GPs 
becoming increasingly likely to refer children to hospitals for treatment, particularly if 
there are concerns relating to factors like the development of complications. They may 
also seek hospital care if there are uncertainties over the choice of antibiotic at the 
initiation of treatment as the infecting organism is almost never known at this point. It 
may also be relevant to note that if there as a need for intravenous antibiotic treatment 
this is only available in hospitals (British Thoracic Society Standards of Care 
Committee, 2002 & 2010). 
 
In terms of gender, allthough, there was a fluctuation in the incidence of diagnosis and 
antibiotic prescribing for pneumonia before the introduction of the vaccine and 
apparent decline one year post its introduction, incidence rates were consistently 
higher in males than females. A recent study in the UK also found that males with 
bacterial pneumonia have higher hospital admission rates than females in all age 
groups (Koshy et al., 2010).  
 
In addition, this study investigated the incidence of the disease on a quarterly basis.  
The results underline the fact that seasonal variations are one of the key factors 
affecting the incidence of pneumonia. Despite the availability of antibiotics and 
vaccines, invasive pneumococcal diseases in the UK are more prevalent during the 
winter months (Clarke et al., 2006; Zielhuis et al., 1990).  
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This pattern of seasonal variation is also mirrored in other infectious diseases (e.g. 
measles, influenza and whooping cough) (Grassly and Fraser, 2006). Because in this 
study the overall incidence of pneumonia did not significantly decline it was not 
possible to use ITS analysis in the same way that it was employed in the previous 
chapter on OM to analyse the impact of the vaccine in the pneumonia context. 
 
6.3 CONCLUSION 
This study strand identified that the overall number of pneumonia episodes and level of 
antibiotic prescribing for pneumonia declined by 14% and 10% respectively in the UK 
between 2006 and 2010. Nevertheless, the Health Protection Agency (now Public 
Health England) has recognised that since the introduction of the initial vaccine the 
incidence of disease due to non-vaccine serotypes has been increasing and that 
serotype replacement is therefore a concern.   
 
The cumulative incidence of serotypes 7F, 19A and 22F in particular led the HPA and 
its advisors to recommend the introduction PCV13 into the national childhood 
vaccination programme in 2010. Taken in its totality this thesis has increased 
knowledge of the impact of PCV7 on the incidence of OM and pneumonia and related 
antibiotic prescribing for children and adolescents in the primary care setting in the UK.   
This work has also systematically evaluated the efficacy of the vaccine by investigating 
the serotype specific antibody concentrations, geometric mean concentration (GMC) 
and the local and systemic adverse drug events associated with PCV7 from published 
RCTs, utilising a systematic review and meta-analysis methodology (see Chapter 3). 
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 In addition, a pharmaco-epidemiological study was performed utilising two large health 
care databases (The Health Improvement Network database and IMS Disease 
Analyzer). IMS DA was utilised to investigate immunisation recording in children aged 
0-2 years in general practice (Chapter 4) and it was also employed for a retrospective 
cohort study to evaluate the annual incidence of OM diagnosed in the primary care 
setting and the antibiotic prescribing patterns associated with OM in both children and 
adolescents (Chapter 5). The THIN database was used to conduct a retrospective 
cohort study to estimate the incidence of pneumonia and associated antibiotics in 
children in the primary care setting.   
 
The final chapter below builds on this body of work to consider the clinical and wider 
health policy implications of its findings and to provide recommendations for future 
research.  
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CHAPTER SEVEN: OVERALL DISCUSSION 
 Overview 
 
The findings presented in this thesis can be taken to confirm the effectiveness of the 
PCV7 in preventing vaccine serotype related childhood pneumococcal diseases in the 
UK context.  The vaccine is beneficial in preventing invasive pneumococcal disease 
and it has also played an important role in reducing rates of non-invasive conditions 
associated with S. pneumoniae, most notably Otitis Media in children. The original 
research reported here found that the overall number of (all cause) pneumonia 
episodes and antibiotics prescribed by GPs for pneumonia in children and young adults 
declined by 14% and 10% respectively between 2006 (the year of introduction of the 
PCV7) and 2010.  In addition, the study identified an overall fall of more than a third in 
OM diagnosis and antibiotic prescribing for the treatment of OM in children between 
2006 and 2010.   
 
Given that the PCV7 has now been replaced by the PCV13 (which may in turn – in part 
because of possible increases in the incidence of currently non-vaccine serotype 
disease – be superseded by further vaccine changes in the future) this discussion 
seeks to raise a series of important practice and policy related issues that are as yet 
unanswered.  It will also make comparisons with other studies conducted in this area, 
both globally and regionally.  The impact and value of the collation of routine 
surveillance data will in addition be considered, and a focus placed on the actual and 
possible pathogenic (serotype) changes that may in part have led to the need for the 
PCV13 vaccine’s introduction.   
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Examples of the types of question addressed include ‘if currently more prevalent 
serotypes are effectively eliminated due to vaccine use, what happens to the incidence 
and virulence of illness caused by other remaining S. pneumoniae serotypes?’  and 
‘what are the implications of vaccine use in the very young and young for the health of 
the older (near or post retirement) population?’ People over 65 are more at risk of not 
only death but also prolonged morbidity because of S. pneumoniae infection than any 
other section of the adult population. 
 
7.1 Comparisons with other studies and settings 
This study’s findings are similar to those of other studies undertaken in the UK and 
Western Europe. However, it is known that in countries such as the United States much 
higher rates of IPD incidence have been recorded.  In America the reported IPD 
incidence in children under 2 years of age prior to PCV7 introduction was, for example, 
far higher (160-180 per 100,000 children) than in the UK (35.7 per 100,000) or in 
Western Europe overall (20-35 per 100,000) (Poehling et al., 2006; Ladhani et al., 
2013b).  Such data imply differences in the health gain related value of vaccination 
programmes in different settings. 
 
It is possible that the higher observed US incidence has been due to a higher proportion 
of relatively deprived ‘at risk’ populations (e.g. in the Alaskan Native, American Indian 
and black/African American communities) coupled with a lower threshold for performing 
blood cultures in febrile children, especially in the out-patient setting.   
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It is of note that Ladhani et al (2013b) found that in infants under 90 days old the IPD 
incidence in England was comparable to the US population figures (13.0 per 100,000 
compared to 11.8 in the US study). They speculated that this is because infants are 
more likely to develop severe IPD, to be admitted to hospital, and to have lower 
thresholds for having blood cultures taken both here and in the US.   
 
Furthermore, in the US study PCV7 serotypes initially accounted for 71% of IPD in 
young infants.  PCV7 introduction in 2000 led to a 39% (P <0.001) overall and 67% 
(P=.004) PCV7 serotype specific IPD reduction within 3 years compared with reductions 
of 25% and 83% respectively in the Ladhani et al (2013b) study, where the pre-vaccine 
proportion of PCV7 IPD infections was 44%.   
 
Importantly, the US study cohort had a higher proportion of black/African American  
infants (34%, compared to only 6% in the Ladhani et al work) who are said to be at a 
raised risk of IPD.  The fall in infant IPD in the US study occurred primarily among black 
Africans (from 17.1 to 5.2 per 100,000 live births, P=0.001) with a far smaller impact 
among white infants (from 9.6 to 6.8 per 100,000 live births, P=0.11) (Poehling et al., 
2006).   
 
7.2 Are there regional variations within the UK? 
Aspects of this question demand further research. Clarke et al (2006) reported higher 
rates of IPD in Scotland and serotype variations across the UK.  In Scotland the overall 
reported incidence of IPD is 11 cases per 100,000 populations in subjects aged up to 1 
year and 45 cases per 100,000 in those aged over 65 years. By contrast in England 
                                     CHAPTER SEVEN 
191 
 
and Wales the overall incidence of IPD is 8.6 per 100,000 populations, with the highest 
reported burden among the very young and older people, in whom it is in excess of 30 
per 100,000.  
 
The 10 most common pneumococcal serotypes associated with IPD in England and 
Wales are 14, 9, 6, 19, 23, 8, 1, 4, 18, and 7. The most common serotypes in Scotland 
are 14, 8, 9V, 1, 3, 22F, 23F, 6B, 18C and 19F (Clarke et al., 2006). Such differences 
suggest that in the future it may be beneficial to tailor S. pneumoniae vaccines more to 
specific regional, national or sub-regional/local protection needs. 
 
7.3 The value of routine surveillance and GP record data sets 
Microbiology laboratories in England and Wales voluntarily report all clinically significant 
pneumococcal isolates to what is now the PHE Centre for Infections via a computerised 
surveillance system called CoSurv.  Laboratories are also encouraged to send 
serotypes to the Respiratory and Systemic Infection Laboratory (RSIL) for serotyping.  
Yet currently reporting is not required by law and the system remains a voluntary one. 
Therefore not all pneumococcal isolates are sent to RSIL and CoSurv, and some 
isolates may be sent to one reporting stream and not the other.  In an uncertain number 
of other cases GPs treat CAP cases on the basis of clinical signs and symptoms alone, 
without the causal agent ever being clearly identified. 
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In Scotland, however, reporting of S. pneumoniae bacterium infections is mandatory 
under the Part 2 of the Public Health Act (Scotland) of 2008. This part of the Act came 
into effect on 1 January 2010.  To support notifications, clinicians send reports 
electronically via SCI Gateway.  But although reporting of S. pneumoniae is a statutory 
requirement, IPD itself is not a statutorily notifiable disease. Surveillance is therefore 
based on local laboratory reports of S. pneumoniae from invasive body sites (i.e. mainly 
blood and cerebral spinal fluid).  
 
In 1999, an enhanced surveillance scheme was introduced, which is jointly managed by 
HPS and the Scottish Meningococcus and Pneumococcus Reference Laboratory 
(SMPRL). Data gathered in this part of the UK are posted to the website 
http://www.hps.scot.nhs.uk/resp/pneumococcaldisease.aspx (last accessed 16.7.13), 
enabling researchers and interested clinicians to view the number of cases of IPD per 
year by quarter and by age group. 
 
Since 1996, a dataset for all invasive pneumococcal infections reported in England and 
Wales has also been in existence. This links computerised reports sent to the HPA and 
isolates referred to RSIL for serotyping.  It consists of cases where S. pneumoniae has 
been identified by culture or more rarely by antigen detection or polymerase chain 
reaction (PCR) in a normally sterile site.  From January 2006 PCR facilitated diagnosis 
has been performed by the HPA on cerebrospinal fluid and pleural fluid samples from 
patients with suspected meningitis or empyema, with serotyping performed via a 
pneumococcal polysaccharide antigen assay that detects 14 serotypes.   
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After the introduction of PCV7 in September 2006 all patients with IPD were followed up 
for vaccination history and clinical presentation, improving diagnosis of cases (Miller et 
al., 2011).  Serotypes 6A and 6C were routinely distinguished from one another from 
May 2009 onwards.  The value of such routine surveillance data is considerable.  
Relevant datasets have enabled researchers to ascertain the impact and efficacy of the 
PCV7, particularly in the context of more serious disease (Miller et al., 2011; Ladhani et 
al., 2013a; Ladhani et al., 2013b).   
 
Miller et al (2011) found that 5,809 cases of IPD were reported in 2009-2010 in England 
and Wales, giving an overall incidence of 106 per 100,000 populations. This when 
compared with the adjusted average annual incidence of 16.1 in 2000-2006 gives an 
overall reduction of 34% (95% CI 28-39).  Vaccine type (VT) disease decreased in all 
age groups, with reductions of 98% in individuals younger than 2 years and by 81% in 
those aged 65 years or older.   
 
Non-vaccine type (NVT) disease increased by 68% in individuals younger than 2 years 
and by 48% in those aged 65 years or older, giving an overall reduction in IPD of 56% 
in those younger than 2 years and 19% in those aged 65 years or older.  Using HPA 
data Ladhani et al (2013a) calculated that between September 2006 and March 2010 a 
total of 1,342 IPD episodes occurred in 1,332 children.  In a further study Ladhani et al 
(2013b) also found that prior to PCV7 introduction IPD incidence in infants aged less 
than 90 days was 13.0 (95% CI, 12.0-14.0) per 100,000 live births and PCV7 serotypes 
accounted for 44% (154/349) of serotyped isolates.   
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These data indicated that PCV7 introduction resulted in an 83% (95% CI, 66-91%, P 
<.001) reduction in PCV7 IPD and a declining trend in overall IPD by 2009-2010. Taken 
with the results presented in Chapters 5 and 6 of this thesis, such figures mean that 
there can be little doubt as to the efficacy of the conjugate PCV vaccines in preventing 
relevant serotype illness in children and others in the UK, albeit that the overall picture 
in general practice is complicated by a variety of factors. 
 
Robust surveillance data will continue to be needed to assess the epidemiological effect 
of multivalent pneumococcal disease vaccines.  A recommendation for the future would 
be to fully enshrine the reporting of IPD into a regulatory framework across the whole 
UK in order to create complete data sets, and prevent the underreporting of cases. 
Such a measures could also curb non-diagnosis, incomplete diagnosis and potential 
condition mismanagement in primary care as well as in hospital care. 
 
Nevertheless, a note of caution is required. Miller et al (2011) highlighted the complexity 
of interpreting disease trends in changing clinical, diagnostic and surveillance 
environments.    They have drawn attention to the difficulty of interpreting IPD data from 
different countries, and of comparing the effect of programmes at different stages of 
maturity and with surveillance systems targeting different sets of patients.  For example, 
they argue that the extent to which findings from surveillance studies in the UK can be 
extrapolated to populations such as those in developing countries where bacterial 
carriage and IPD incidence rates are much higher than in Europe and the US, and 
where the coverage of prevalent serotypes by PCV7 is lower, is far from clear.   
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Understanding the full effects of higher valency vaccines will also arguably require 
robust surveillance systems and good knowledge of the invasiveness potential of non-
PCV serotypes (see below), highlighting their prevalence in carriage as well as their 
prevalence in IPD. This distinction appears to have been overlooked in surveillance 
systems to date (Miller et al., 2011).  Additionally Clarke et al (2006) raised another 
issue that has been overlooked in surveillance to date, namely the possibility of 
simultaneous carriage of more than one pneumococcal serotype. The extent to which 
simultaneous carriage of different serotypes occurs is unknown and there is arguably a 
need for future systems to identify all the causative serotypes involved in individual 
cases of IPD.   
 
A final point to emphasise under this heading is that although aggregated GP record 
based data sets such as the IMS DA and THIN products used in this research clearly 
have some utility, their value in relation to detailed research and/or disease surveillance 
should not be over-stated. Their strengths and weakness reflect those of general 
medical practice itself. Although they can provide robust overall measures of volumes of 
activity and drugs prescribed in response to broad categories of symptomatic illness 
they do not necessarily provide deep insight as to exactly what is being treated, or 
indeed whether or not prescribed items such as antibiotics are actually dispensed or 
taken by those for whom they were intended (see further remarks below). 
 
 
 
                                     CHAPTER SEVEN 
196 
 
7.4 Pathogenic changes over time 
There are presently some open questions as to the extent to which, as some previously 
successful serotype strains are eliminated via vaccine use, others will become more 
infectious or virulent (or both) in order to exploit the new  opportunities available. It is, 
however, already known that serotype replacement disease does occur in response to 
vaccination programme roll-outs.  As referred to earlier, Miller et al (2011) found that 
after the PCV7 vaccine’s introduction more NVT serotypes increased in frequency than 
decreased. This is entirely consistent with vaccine induced serotype replacement.   
 
Worryingly, in certain countries – including Spain, the Netherlands, France in the EU – 
and in some indigenous populations in the US and Australia, increases in NVT 
infections appear largely to have offset the reduction in VT infections following the 
introduction of PCV7 (Weinberger et al., 2011).  In the Miller et al (2011) study, which 
examined the effects of the vaccine in England and Wales, the key serotypes showing 
replacement were 7F, 19A and 22F.  Yet they found that increased NVT IPD was not 
associated with antimicrobial resistance.  It may be therefore being argued that as yet 
at least serotype replacement disease in the UK has not been strengthened through 
antibiotic resistance.   
 
In addition, Ladhani et al (2013a) have observed that compared with IPD caused by 
PCV7 serotypes (44/248; 17.7%), co-morbidities were less common for the extra 3 
serotypes in the 10-valent vaccine (15/2999; 5.0%) but similar to the 3 additional 
PCV13 serotypes (45/336; 13.4%).  
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Further, they increased for the 11 extra serotypes in the 23-valent polysaccharide 
vaccine (PPV23) (38/138; 27.5%).  Some 52 (3.9%) cases resulted from PCV7 failure.  
Furthermore, co-morbidities were more prevalent in children with IPD caused by non-
PCV13 serotypes, and were associated with an increased case fatality level. 
 
The overall case fatality rate was 4.4%, but this rose to 9.1% in children with co-
morbidities.  It may therefore be hypothesised that serotype replacement disease 
caused by the various vaccines available does not in overall terms increase the risks 
associated with IPD. That is, to date at least disease potency cannot generally be 
shown to have increased.  Nonetheless, serotype replacement disease is complicated 
by the fact that those who contract NVT disease may have additional co-morbidities that 
might affect outcomes.   
 
Ladhani et al (2013a) found that in their study cohort the 3 extra PCV10 serotypes were 
more likely to affect healthy children.  They argued that serotypes 1, 5 and 7 (which are 
included in both PCV10 and PCV13) are known to be highly invasive and to mainly 
affect previously healthy persons. But they appear to cause less severe disease, as 
determined by clinical severity and requirement for intensive care.  Furthermore, a 
meta-analysis of 7 different datasets in children found that serotypes 1, 5 and 7 were 
infrequently isolated among carriage strains but had the highest potential for invasive 
disease, whereas serotypes that were more likely to be carried (e.g. 6B, 19F and 23F) 
were less likely to be invasive (Brueggemann et al 2004). 
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Similarly in a study examining the epidemiology of IPD in the pre-conjugate vaccine era 
(1996-2006) in England and Wales (Trotter et al., 2010) it was found that carrier ratios 
varied substantially by serotype.  As might logically be expected, the higher the 
case:carrier ratio the greater the invasive potential of the serotype.  For some 
serotypes, they found differences in the case:carrier ratio by age (e.g. serotype 18C 
was more invasive in younger children) but for others this ratio was similar (e.g. 
serotype 9V).  The most common serotypes over the time period in children aged less 
than 5 years were serotypes 14, 6B and 19F, whereas serotypes 14, 9V, 1 and 8 were 
most common in those aged 5 years or more.   Additionally, there was greater diversity 
of serotypes in those aged 5 years or more as compared to younger children.   
Importantly, Trotter et al (2010) also noted that serotype distribution can change over 
time without vaccine involvement (i.e. through natural secular changes).  They 
observed increases and decreases in major serotypes, predominantly a decrease in the 
percentage due to serotype 14 and an increase in serotype 1.  Such changes over time 
were also observed in the work of Miller et al (2011).  The reasons for such shifts are 
not known, although it has been postulated that factors related to changes in population 
immunity through natural exposure may be responsible (Trotter et al., 2010). The key 
point to emphasise from the perspective of this thesis and sustained child and public 
health improvement generally is that the situation is dynamic. Regardless of past events 
and achievements, continuing adaptations in immunisation and treatment strategies 
aimed at minimising the harm caused by S. pneumoniae infections may from time to 
time be necessary. 
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7.5 Implications for the very young and older populations 
In relation to the very young Ladhani et al (2013b) noted a reduction in PCV7 serotype 
IPDs achieved through indirect protection in neonates and infants starting from birth.  
Prior to routine pneumococcal vaccination, IPD incidence in infants aged less than 90 
days in England and Wales was 13.0 per 100,000 live births, and PCV7 serotypes 
contributed to 44% of cases.  The introduction of PCV7 led to a significant reduction in 
PCV7 IPD in young infants, most of whom could not (because of the schedule used) 
have directly benefited from vaccination.  Indeed, almost 40% of cases occurred in the 
first week of life, a third of which were in the first 48 hours of life.   The authors state 
that they believe this indirect protection indicates complex interactions between infants, 
siblings, parents and other household contacts, in line with the full range of risk factors 
known to be associated with IPD.   
 
There is evidence that pre-PCV7 neonates who contracted IPD were more likely to be 
infected with a PCV7 serotype if there were at least 2 siblings in the household and/or if 
their siblings attended childcare (Hoffman et al., 2003). It is concluded here that more 
work needs to be undertaken on the risk factors for IPD in pregnancy and strategies to 
prevent mother to child transmission, not least because (like other neonatal pathogens) 
S. pneumoniae is often acquired via the maternal genital tract during the birth process 
(Hoffman et al., 2003).    
 
Questions also remain with regard to the implications of childhood protection for 
pneumococcal disease incidence in elderly populations.  A study by Andrews et al. 
(2012) that evaluated the impact and effectiveness of the 23-valent pneumococcal 
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polysaccharide vaccine (PPV-23) against IPD in older people in England and Wales 
found that IPD caused by the serotypes covered by PCV7 declined in those aged 65 or 
above after 2006, following its introduction in this country. Yet this gain was largely 
offset by an increase in non-PCV7 serotypes.  Furthermore, following the introduction of 
the PPV23 for all 65 and above year olds in England and Wales (in 2003) they found 
“…no discernible impact…” on IPD incidence or PCV7 induced serotype replacement 
(Andrews et al., 2012, p6802).   
 
This is in contrast to the introduction of PCV7 for children, which these authors found 
had produced a “…modest reduction…” in overall IPD in the elderly and large 
reductions in PCV7 serotypes through herd protection (Andrews et al., 2012, p 6805).  
They concluded that the impact on overall IPD incidence in the older population from 
the indirect effects of vaccinating children with PCV7 is more effective than the specific 
PPV23 programme for the over 65s.  Furthermore, they argue that – with the use of 
higher valency conjugate vaccines for child protection, that by definition cover more 
serotypes – additional reductions in IPD in older age groups can be anticipated.  
 
The interpretation of such data offered here is that because those older people most at 
risk from harm due to IPD are likely to have impaired immune responses they are more 
likely to benefit from population wide herd protection effects than from programmes 
targeted specifically at their own age group.  
 
However, this does not mean to say that immunisation for the immuno-competent 
population aged over 50 or 60 using the 23 valent polysaccharide or indeed even more 
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comprehensive vaccines, necessarily lacks – now or in the future –sufficient value to 
justify its costs. More research on the interactions between child and older adult 
pneumococcal diseases is needed to guide policy decisions in this area, alongside work 
designed to verify the hypothesis expressed above and/or to determine whether or not 
the relative immuno-competence of older people can cost effectively be determined in 
primary care or other settings. 
 
7.6 Implications for practice 
The findings reported in this thesis and discussed in this chapter carry with them a 
series of implications for medical, nursing and pharmacy practice.  Firstly, it is arguably 
imperative, given that it is unusual in practice for general practitioners to administer 
vaccines to children, that practice nurses (and where relevant health visitors and school 
nurses) who provide the national childhood vaccination programme should have direct 
access to all appropriate levels of electronic patient record. This would enable them to 
update both immunisation records and where relevant GP based research databases, 
such as the IMS DA.  The validation study offered in Chapter 4 highlights the need for 
improvement in this context. In addition, when vaccines are administered in the private 
system to children registered with NHS GPs then the relevant general practices should 
be informed, and their records updated accordingly.   
 
Second, there is an associated problem in current practice, which is that prescribed 
medications are recorded as being issued with no check as to whether or not they have 
in fact been dispensed, let alone taken.  It may never be possible accurately to confirm 
the latter in the community (as opposed to the hospital) setting, but it would be of value 
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for pharmacists and GP dispensers to be able to record whether items such as 
antibiotics have been supplied as opposed to, for instance, prescriptions being held on 
a contingency basis.  
 
This last is of particular importance, given that the current good practice guidelines for 
OM recommend writing an antibiotic prescription for children with OM symptoms but 
advising parents and careers not to administer the medication unless the symptoms fail 
spontaneously to resolve (see Chapters 1 and 5).   
 
Following on from the above, it is thirdly crucial that GPs are aware of the current 
guidance in this area in order to educate and enable parents to protect their children by 
ensuring that antibiotics are not administered unnecessarily. The latter can increase 
individual risks, as well as the long term collective threat of antibiotic resistance.   
 
Fourth, it may be argued that recognition of IPD within the UK would be aided by more 
blood cultures being performed in children with fevers, in line with other European 
countries and the US (See Chapter 6 and Trotter et al., 2010).  Blood cultures and allied 
tests are currently routinely taken and recorded only when children are being cared for 
as hospital in-patients.  
 
There is a case for believing that such tests ought in contexts such as IPD management 
to be performed more frequently in community (GP and linked) settings, albeit this 
would have some cost implications.  A good case exists for saying that if and when 
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improvements in the available diagnostic technologies occur they should be employed 
in as timely manner as possible.  
 
Fifth, it may in addition be seen as crucial in both community and hospital care that 
blood cultures and bacterial sensitivity tests are repeated where there is recurrent 
pneumonia, in case of alterations in the causative pathogen(s). Lastly, as already 
addressed, it is also important for in-practice surveillance data that all hospital 
laboratories across the UK routinely report and submit clinical isolates to the relevant 
authorities. 
 
7.7 Limitations 
The main limitations of the linked original studies reported here include their focus on 
OM and pneumonia alone; the dominance of England and Wales in the sampled data; 
the under-recording of vaccination in the IMS DA; and the non-utilisation of HPA/Public 
Health England  and Health Protection Scotland surveillance data for comparative 
purposes.  A wider reaching study series might ideally examine additional childhood 
pneumococcal diseases, not just single diseases from the IPD and NIPD categories, 
with more extensive national sampling.  
 
Although the recording of vaccination within the IMS DA was validated in this study, 
using COVER data for comparison and employing supplementary GP questionnaires to 
confirm whether individual children had been fully vaccinated or not, substantial 
questions remain over the use of retrospectively completed GP databases.  These may 
in fact (despite payments for record completion) be far from comprehensive in the 
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immunisation context for the reasons alluded to earlier in this Chapter, and have both 
missing and non-validated data.  
 
Furthermore, in relation to medicines administration studies, although databases like 
the IMS DA can inform researchers whether or not a particular medicine has been 
prescribed, it cannot at present reveal whether the prescription has been dispensed or 
taken.  This limits their value as detailed research tools, albeit they are of value on 
areas like monitoring broad disease and disease management trends. 
 
7.8 Implications for future research 
It may be contended that in future a similar research approach to that employed in this 
analysis would be of use in examining the impact of the PCV13 on OM and pneumonia 
incidence in children and related antibiotic prescribing.  However, if it is accepted on the 
basis of the findings of this study that vaccine administration is of proven value in 
preventing OM cases then a more pragmatic way forward could be designed utilising 
national surveillance data to examine IPD cases in more specific ways.   
 
One important question that presently remains unanswered is ‘how can new strategies 
and vaccines be developed that are better able to prevent pneumonia in children who 
are most susceptible to harm and reduce further the associated death and disability 
burden?’  Continued surveillance and analysis of comprehensive, adequately specified, 
data sets will be essential for monitoring the efficacy of on-going and future vaccines, 
associated serotype replacement disease, and sensitivity to antibiotic treatment and 
trends in related antibiotic resistance.   
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Future studies could also examine further in parallel risk factors in the very young (pre-
vaccination age), in women of child bearing age and in older populations living in the 
community and in residential and nursing care facilities.  Questions relating to maternal 
carriage have not been examined in this thesis, but an additional research question for 
the future might be ‘in what if any circumstances should vaccination against S. 
pneumoniae infections be given in or before pregnancy, in order to prevent mother to 
infant transmission?  
 
7.9 Originality 
The original contributions of this study can be seen as two-fold.  The first was through 
the methodological approach based on utilising general practice based records.  This 
was in part of value because it allowed cross-comparison between the administration of 
the vaccine, the occurrence of OM and pneumonia episodes and the prescribing of 
antibiotic therapy.  A second original contribution was made through the focus of this 
work upon both invasive and non-invasive pneumococcal disease.  
 
Looking at the occurrence and treatment of OM as well as pneumonia was important 
because it has shown the value of vaccination in preventing non-invasive 
pneumococcal disease and the associated use of antibiotic medicines, not just IPD.  
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7.10 Final conclusion 
In the nineteenth century the work of individuals such as Edward Jenner and Louis 
Pasteur began to unlock the potential of immunising techniques to protect individuals 
and populations from infections. This scientific progress is continuing today with further 
improvements in understanding of the detailed mechanisms of the immune system and 
the ways in which it can be manipulated to benefit subjects. In the context of protecting 
children from conditions such as otitis media and pneumococcal pneumonia the recent 
introduction of conjugate techniques - which in the case of S. pneumoniae enable 
infants’ immune systems to respond to weakly immunogenic polysaccharides as they 
do towards more strongly immunogenic proteins – promises important global 
opportunities for health improvement.  
 
The evidence presented in this thesis shows that the introduction of Prevnar 7 in the UK 
reduced the incidence of OM in infants and children, and was also associated with 
reductions in antibiotic prescribing by GPs for this condition. The research reported 
here, together with information from sources such as Public Health England, also 
indicates similar if less pronounced benefits in the context of pneumonia/IPD have been 
derived from the use of Prevnar 7 and its 13 valent successor Prevnar 13.  
 
Employed effectively such vaccines offer the prospect of further national and 
international reductions in not only infant and childhood morbidity and mortality, but also 
contributions to the 21st century task of promoting healthy ageing. However, concerns 
relating to the issues such as serotype replacement exist and have a degree of validity.  
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There is a need for the continued and where possible improved monitoring of 
pneumococcal vaccine effectiveness and the overall consequences of its administration 
on health outcomes and medicines usage. 
 
The key contribution of this thesis is to further confirm the existence and extent of the 
health gains to date achieved via vaccination against S. pneumoniae infection in 
children. Challenges such as the emergence of non-vaccine serotype forms of disease 
may well have to be overcome in future decades, along with in England (and 
elsewhere) problems in areas such as diagnostic and record keeping precision in the 
community setting. But in the final analysis the demonstrated capacity of vaccines such 
as Prevnar 7 and 13 to help further reduce reliance on antibiotics and enhance human 
welfare is of major importance. It deserves informed recognition, and justifies further 
future investment in areas such as immunisation schedule evaluation and development. 
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APPENDICES  
APPENDIX 1A: GP COVERING LETTER AND QUESTIONNAIRE 
Impact of Prevnar® on the burden of disease due to Otitis Media in children in the UK 
 
Dear GP, 
At the Centre for Paediatric Pharmacy Research we are investigating the impact of 7-
valent Pneumococcal Conjugate Vaccine (Prevnar®) in children. In September 2006, 
Prevnar® was introduced into the UK routine childhood immunisation programme. Our 
project aims to characterise the incidence rates of Otitis Media and antibiotic 
prescribing patterns for Otitis Media (OM) in children before and after the introduction of 
Prevnar®. The IMS Disease Analyser (IMS DA) database will be used to investigate the 
impact of Prevnar® on both OM and antibiotic drug prescribing in children aged 0-18 
years.  Different healthcare professionals such as practice nurses, health visitors and 
school nurses can also administer vaccine to children. However, as not all health 
professionals have direct access to the patients’ electronic record, this potentially leads 
to under-recording of the immunisation history. Thus, we would like to validate the 
immunisation record of children aged 0-2 years in the primary care setting, in the IMS 
DA database through questionnaires sent to their GP.  
We have identified a cohort of patients in 2009 on the IMS DA database that did not 
have any immunisation record. We would be grateful if you would complete this 
questionnaire to aid us in this important research. All data received is anonymised and 
will be treated with the utmost confidence and no individual cases will be reported.  
 
 
This project is funded by the Libyan Government for a PhD student and a research 
grant from St. George’s Hospital which is indirectly funded by the Wyeth (manufacturer 
of Prevnar®) to employ a research fellow. As questionnaire may take about few minutes 
to complete, we will offer you £15 for your assistance in this validation study.  
As this is an epidemiological project, it is important that we receive all the information 
requested as this is necessary for meaningful results. 
Your cooperation will be very much appreciated.  
 
Many thanks in advance. 
 
Professor Ian Wong 
Centre for Paediatric Pharmacy Research  
(A collaboration between the School of Pharmacy, Institute of Child Health & Great Ormond 
Street Hospital for Children) 
Level 1, BMA House 
Tavistock Square 
London WC1H 9JP 
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Impact of Prevnar® on the burden of disease due to Otitis Media in children in the UK-
Questionnaire: 
Has this child had Prevnar
®
 vaccine? (Please tick boxes)  
Practice ID Patient ID          Age         Sex Year of birth 
     
 
 Yes                         No 
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APPENDIX 1B: AMENDMENT GP COVERING LETTER 
 
Dear ISEAC members, 
 
Re: protocol:  “Impact of Prevenar on the burden of disease due to Otitis Media in 
children in the UK” (No: 2009/ISEAC/001) 
I would be grateful if the ISEAC would consider and approve the following amendments 
of the above study. 
 
 
1. Validation study 
 
The ISEAC has already approved that a questionnaire would be sent to the GPs to 
confirm immunisation records of selected patients.  
 
However, after further investigation of the immunisation records in the IMS DA, we have 
concluded that it is necessary to defer the questionnaire study. 
 
Prevenar vaccine is given at two months, four months of age and 15months of age. A 
catch-up programme is recommended for those aged <2 years who were not 
vaccinated.  
 
 
To identify all vaccinated/ unvaccinated children born in 2008, it is necessary to follow 
up for at least 2 years and 2010 data are needed. Hence we propose to postpone the 
questionnaire until mid 2011 when the 2010 data are available and fully analysed. 
Many thanks in advance. 
 
 
Professor Ian Wong 
Centre for Paediatric Pharmacy Research  
(A collaboration between the School of Pharmacy, Institute of Child Health & Great Ormond 
Street  
Hospital for Children) 
Level 1, BMA House 
Tavistock Square 
London WC1H 9JP 
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APPENDIX 2: PCV7 NOTEREAD44OR5CODE   
READ_4or5_CODE READ_4or5_TEXT     
65720 Pneumococcal vaccination 
given 
    
.9Oo. Pneumococcal vaccination 
admin 
    
.6572 Pneumococcal vaccination     
.n4b. PNEUMOCOCCAL VACCINE     
.68Ne Consent pneumococcal 
vaccine 
    
.657K Booster pneumococcal 
vaccinatn 
    
.Q5AC Adv reac: pneumococcal 
vaccine 
    
.657N 3rd pneumococcal conjug 
vaccine 
    
.657M 2nd pneumococcal conjug 
vaccine 
    
.657L 1st pneumococcal conjug 
vaccine 
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APPENDIX 3: ETHICAL APROVAL FROM IMS DA   
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APPENDIX 4: ANTIBIOTICS LISTED UNDER THE ATC THERAPEUTIC MAIN 
GROUP J01: FOR ANTIBACTERIAL SYSTEMIC USE  
atc4_code Substance 
J01A0 DOXYCYCLINE 
J01A0 LYMECYCLINE 
J01A0 OXYTETRACYCLINE 
J01A0 TETRACYCLINE 
J01B0 CHLORAMPHENICOL 
J01C1 AMOXICILLIN 
J01C1 AMPICILLIN 
J01C1 AMPICILLIN + FLUCLOXACILLIN 
J01C1 CLAVULANIC ACID + AMOXICILLIN 
J01D1 CEFACLOR 
J01D1 CEFADROXIL 
J01D1 CEFALEXIN 
J01D1 CEFIXIME 
J01D1 CEFPODOXIME PROXETIL 
J01D1 CEFRADINE 
J01D1 CEFUROXIME AXETIL 
J01E0 SULFAMETHOXAZOLE + TRIMETHOPRIM 
J01E0 TRIMETHOPRIM 
J01F0 AZITHROMYCIN 
J01F0 CLARITHROMYCIN 
J01F0 CLINDAMYCIN 
J01F0 ERYTHROMYCIN 
J01G1 CIPROFLOXACIN 
J01G1 LEVOFLOXACIN 
J01H1 FLUCLOXACILLIN 
J01H1 PENICILLIN G 
J01H1 PENICILLIN V 
J01X9 FUSIDIC ACID 
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APPENDIX 5: OTITIS MEDIA READ-CODES 
read_4or5_code read_4or5_text 
0.1492 H/O: chronic ear infection 
.1C3. Earache symptoms 
.1C32 Unilateral earache 
.1C33 Bilateral earache 
.1C3Z Earache symptom NOS 
.2D6. O/E - discharge from ear 
.2D7. O/E - painful ear 
.2D7Z O/E - painful ear NOS 
.2D92 O/E-otoscopy:dull light reflex 
.2D93 O/E - otoscopy:no light reflex 
.2D94 O/E - tympanic membrane pink 
.2D95 O/E - tympanic membrane red 
.2D96 O/E -tympanic membrane bulging 
.2D97 O/E-otoscopy:central perforat. 
.2D98 O/E - otoscopy:posterior perf. 
.2D99 O/E - tympanic membrane tear 
.2D9A O/E -otoscopy:fluid-middle ear 
.2D9B O/E - tympanic membr retracted 
0.3145 Magnifying otoscopy 
0.7434 Myringoplasty 
.F62. Nonsuppurative Otitis Media 
.F621 Acute nonsupp. Otitis Media 
.F622 Chronic serous Otitis Media 
.F623 Chronic mucoid Otitis Media 
.F625 Otitis Media NOS 
.F62Z Chr. nonsupp. Otitis Media NOS 
.F63. Suppurative Otitis Media 
.F631 Acute suppurative Otitis Media 
.F633 Chronic purulent Otitis Media 
.F63Z Purulent Otitis Media NOS 
.F671 Perforation of ear drum 
.F679 Otalgia - earache 
.l6.. *OTITIS MEDIA [no drugs here] 
7312 Repair of tympanic membrane 
73120 Myringoplasty with fat/gelatin 
73121 Revision of myringoplasty 
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read_4or5_code read_4or5_text 
73122 Myringoplasty using biol graft 
73123 Excsn retract pocket tymp memb 
73124 Myringoplasty nec 
73125 Combined appr tympanoplasty 
7312y Repair of eardrum (TM) OS 
7312z Repair of eardrum (TM) NOS 
73133 T-tube insertion tympanic memb 
73160 Tympanoplasty-biological graft 
73161 Tympanoplasty-artif prosthesis 
73162 Revision of tympanoplasty 
73163 Tympanoplasty nec 
73173 Removal tymp membr vent tube 
73175 Incision of eardrum NEC 
73177 Maintenance vent tube eardrum 
73178 Unblocking vent tube tymp memb 
7317A Replace vent tube tymp memb 
7317B Replace grommet tymp membrane 
7K344 Arthroscpc tot med meniscectmy 
A552. Postmeasles Otitis Media 
F5019 Other acute ext.ear infections 
F51.. Nonsupp Otitis Media + eustach 
F510. Acute non supp Otitis Media 
F5101 Acute serous Otitis Media 
F5102 Acute mucoid Otitis Media 
F5103 Acute sanguinous Otitis Media 
F5104 Acute allerg.serous otit.media 
F5105 Acute allerg.mucoid otit.media 
F510z Acute nonsup.Otitis Media NOS 
F511. Chron ot media with eff-serous 
F511z Chronic serous otit.media NOS 
F512. Chron ot med with eff-mucoid 
F5120 Glue ear, unspecified 
F5121 Mucosanguinous chr.otit.media 
F512z Chronic mucoid otitis med. NOS 
F513. Chron ot med with eff-other 
F5130 Chronic allergic Otitis Media 
F5131 Chron ot med with eff-purulent 
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read_4or5_code read_4or5_text 
F514. 
Nonsupp. Otitis Media unspec. 
 
F5141 Serous Otitis Media NOS 
F5140 Allergic Otitis Media NOS 
F5142 Catarrhal Otitis Media NOS 
F5143 Mucoid Otitis Media NOS 
F514z Nonsuppurat. Otitis Media NOS 
F518. Chron ot med with eff-unspec 
F52.. Suppurative Otitis Media 
F520. Acute suppurative Otitis Media 
F5200 Acute supp.otit.media-drum OK 
F520z Acute supp. Otitis Media NOS 
F521. Chron supp ot med-tubotympanic 
F523. Chronic supp.Otitis Media NOS 
F524. Purulent Otitis Media NOS 
F5240 Bilateral supp Otitis Media 
F525. Recurrent acute Otitis Media 
F526. Acute left Otitis Media 
F527. Acute right Otitis Media 
F528. Acute bilateral Otitis Media 
F52z. Otitis Media NOS 
F54.. Other tympanic membrane disord 
F540. Acute myringitis-no otitis med 
F542. Tympanic membrane perforation 
F5420 Tympanic membrane perf.unspec. 
F5421 Tympanic membrane-central perf 
F5422 Tympanic membrane-attic perf. 
F5423 Other marginal tymp.membr.perf 
F5424 Tympanic membr.multiple perfs. 
F5425 Tympanic membr perf > 50% 
F5426 Tympanic memb perf < 50% 
F542z Tympanic membrane perf. NOS 
F54y. Other tympanic membrane disord 
F54y0 Healed tympanic membrane perf. 
F54y1 Atrophic flaccid tymp.memb.NOS 
F54y2 Atrophic nonflaccid tymp membr 
F54y3 Retraction tympanic membrane 
F54yz Other tympanic membr.dis.NOS 
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read_4or5_code read_4or5_text 
F54z. Tympanic membrane disorder NOS 
F5501 
Tympanoscler.-tymp.membr.only 
 
F5614 Otogenic vertigo 
F587. Otalgia 
F5870 Otalgia, unspecified 
F5502 Tympanoscl.-tymp.membr.+ossicl 
F5871 Otogenic pain 
F587z Otalgia NOS 
F5902 Cond.hearing loss-tymp.membr. 
FyuP0 [X]O ac nonsuppurtv otitis med 
FyuP2 [X]O chrn suppurtve otitis med 
FyuP3 [X]Otitis med/bact disease CE 
FyuP4 [X]Otitis Media/viral dis CE 
FyuP5 [X]Otitis Media/oth disease CE 
FyuP8 [X]O margn perfortn/tymp membr 
FyuP9 [X]Oth perfortn/tympanic membr 
FyuPA [X]O spcf disor/tympanic membr 
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APPENDIX 6: ANTIBIOTIC LISTED UNDER THE BNF-C HEADER :ANTIBACTERIAL 
DRUGS 
          Drug Substance Name                  BNF-C Code               BNF-C Header 
Benzylpenicillin 5010101 Benzylpenicillin & phenoxymethylpenicillin 
Phenethicillin 5010101 Benzylpenicillin & phenoxymethylpenicillin 
Phenoxymethylpenicillin 5010101 Benzylpenicillin & phenoxymethylpenicillin 
Flucloxacillin 5010102 Penicillinase-resistant penicillins 
Temocillin 5010102 Penicillinase-resistant penicillins 
Amoxicillin 5010103 Broad-spectrum penicillins 
Ampicillin 5010103 Broad-spectrum penicillins 
Bacampicillin 5010103 Broad-spectrum penicillins 
Ciclacillin 5010103 Broad-spectrum penicillins 
Clavulanic acid 5010103 Broad-spectrum penicillins 
Cloxacillin 5010103 Broad-spectrum penicillins 
Lansoprazole 5010103 Broad-spectrum penicillins 
Pivampicillin 5010103 Broad-spectrum penicillins 
Pivmecillinam 5010103 Broad-spectrum penicillins 
Sultamicillin 5010103 Broad-spectrum penicillins 
Talampicillin 5010103 Broad-spectrum penicillins 
Carfecillin 5010104 Antipseudomonal penicillins 
Pivmecillinam 5010105 Mecillinams 
Cefaclor 5010200 Cephalosporins and other beta-lactams 
Cefadroxil 5010200 Cephalosporins and other beta-lactams 
Cefixime 5010200 Cephalosporins and other beta-lactams 
Cefpodoxime 5010200 Cephalosporins and other beta-lactams 
Cefprozil 5010200 Cephalosporins and other beta-lactams 
Ceftibuten 5010200 Cephalosporins and other beta-lactams 
Cefuroxime 5010200 Cephalosporins and other beta-lactams 
Cephalexin 5010200 Cephalosporins and other beta-lactams 
Cephradine 5010200 Cephalosporins and other beta-lactams 
Bromhexine hydrochloride 5010300 Tetracyclines 
Chlortetracycline 5010300 Tetracyclines 
Clomocycline 5010300 Tetracyclines 
Demeclocycline 5010300 Tetracyclines 
Doxycycline 5010300 Tetracyclines 
Lymecycline 5010300 Tetracyclines 
Minocycline 5010300 Tetracyclines 
Nystatin 5010300 Tetracyclines 
Oxytetracycline 5010300 Tetracyclines 
Tetracycline 5010300 Tetracyclines 
Framycetin 5010400 Aminoglycosides 
Neomycin 5010400 Aminoglycosides 
Azithromycin 5010500 Macrolides 
Clarithromycin 5010500 Macrolides 
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Drug Substance Name BNF-C Code BNF-C Header 
Erythromycin   5010500 Macrolides 
Telithromycin   5010500 Macrolides 
Clindamycin   5010600 Clindamycin 
Lincomycin   5010600 Clindamycin 
Chloramphenicol 5010700 Some other antibacterials 
Colistin sulphate 5010700 Some other antibacterials 
Fusidic acid 5010700 Some other antibacterials 
Linezolid 5010700 Some other antibacterials 
Vancomycin 5010700 Some other antibacterials 
Calcium sulphaloxate 5010800 Sulphonamides & trimethoprim 
Phenazopyridine 5010800 Sulphonamides & trimethoprim 
Phthalylsulfathiazole 5010800 Sulphonamides & trimethoprim 
Sulfametopyrazine 5010800 Sulphonamides & trimethoprim 
Sulphamethoxazole 5010800 Sulphonamides & trimethoprim 
Sulphaurea 5010800 Sulphonamides & trimethoprim 
Trimethoprim 5010800 Sulphonamides & trimethoprim 
Metronidazole 5011100 Metronidazole and tinidazole 
Tinidazole 5011100 Metronidazole and tinidazole 
Acrosoxacin 5011200 Quinolones 
Cinoxacin 5011200 Quinolones 
Ciprofloxacin 5011200 Quinolones 
Citric acid 5011200 Quinolones 
Enoxacin 5011200 Quinolones 
Grepafloxacin 5011200 Quinolones 
Levofloxacin 5011200 Quinolones 
Moxifloxacin 5011200 Quinolones 
Nalidixic acid 5011200 Quinolones 
Norfloxacin 5011200 Quinolones 
Ofloxacin 5011200 Quinolones 
Sodium bicarbonate 5011200 Quinolones 
Sodium citrate 5011200 Quinolones 
Sparfloxacin 5011200 Quinolones 
Temafloxacin 5011200 Quinolones 
Amoxycillin 5011300 Urinary-tract infections 
Fosfomycin 5011300 Urinary-tract infections 
Methenamine 5011300 Urinary-tract infections 
Nitrofurantoin 5011300 Urinary-tract infections 
Pivmecillinam 5011300 Urinary-tract infections 
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APPENDIX 7: READ-CODE FOR PNEUMONIA 
read_4or5_code read_4or5_text 
H062. Acute low respitract infection 
H06z1 Lower resp tract infection 
H2... Pneumonia and influenza 
H21.. Lobar (pneumococcal) pneumonia 
H22.. Other bacterial pneumonia 
H220. Pneumonia - klebsiella pneum. 
H221. Pneumonia - pseudomonas 
H222. Pneumonia - H.influenzae 
H223. Pneumonia - streptococcal 
H2230 Pneumonia due/streptococc,gp B 
H224. Pneumonia - staphylococcal 
H22y. Pneumonia - other specif.bact. 
H22y2 Pneumonia - Legionella 
H22yz Pneumonia - bacteria NOS 
H22z. Bacterial pneumonia NOS 
H23.. Pneumonia - specif.organisms 
H231. Pneumonia - mycoplasma pneumon 
H233. Chlamydial pneumonia 
H23z. Pneumonia - spec.organism NOS 
H24.. Pneumonia + Infect.disease EC 
H240. Pneumonia + measles 
H243. Pneumonia + whooping cough 
H246. Pneumonia + aspergillosis 
H24y. Pneumonia+other infect.dis.EC 
H24y2 Pneumonia + pneumocyst.carinii 
H24y7 Pneumonia + varicella 
H25.. Bronchopneumonia,organism unsp 
H26.. Pneumonia, organism unspecif. 
H260. Lobar pneumon-unspec organism 
H261. Basal pneumon-unspec organism 
H262. Postoperative pneumonia 
H270. Influenza + pneumonia 
H2700 Influenza + bronchopneumonia 
H28.. Atypical pneumonia 
H2y.. Pneumonia or influenza OS 
H2z.. Pneumonia or influenza NOS 
H5303 Abscess of lung with pneumonia 
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read_4or5_code read_4or5_text 
H5400 Hypostatic pneumonia 
H564. Bronchioliti oblit organ pneum 
H56y1 Interstitial pneumonia 
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APPENDIX 8: ETHICAL APPROVAL LETTER FROM THIN (SRC) 
 
 SRC Feedback  
Researcher Name: Dr Macey Murray  
Organisation: London school of Pharmacy  
SRC Reference Number: 11-031  
Date: 19/10/2011  
Study title: A single Integrated Study of the Impact of Pneumococcal Conjugate Vaccination 
(PCV-7 and PCV13) on childhood pneumococcal diseases in both the community and hospital 
setting in the UK  
Committee opinion: Approved  
______________________________________________________________  
The following feedback has been supplied by the SRC.  
The chair has approved this study with the following advice:  
“A caution in terms of ensuring that they are clear about their exposures and outcomes and 
appropriate analyses to address their question -they need to seek further understanding of this. 
In particular their answer to Q4. Is “Following our discussion with our statistical advisor, we 
agreed to use Linear Regression for the analysis.” – as their outcome is incidence it is not clear 
how this is appropriate – more careful consideration is needed in how they plan to do this 
analysis. I trust that they will seek this out doing the course of the study, however.” 
______________________________________________________________  
We are pleased to inform that you can proceed with the study as this is now approved.  
Once the study has been completed and published, you must let CSD Medical Research know 
in order for your reference number to be closed.  
CSD Medical Research will let the relevant Ethics committee know this study has been approved 
by the SRC and will inform them of study completion (when known) on your behalf.  
I wish you and your team all the best with the study progression.  
Kind Regards,  
Mustafa Dungarwalla  
Research Associate 
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APPENDIX 9: QUALITY CHECK OF THE TWO STUDIES INCLUDED IN META-
ANALYSIS VIA CONSORT STATEMENT 2001 – CHECKLIST  
Article: Cheng Li, R et al, Safety and immunogenicity of a 7-valent pneumococcal 
conjugate vaccine (PCV7): primary dosing series in healthy Chinese infants, Vaccine 
26, 2260-2269 (2008)  
PAPER SECTION 
And topic 
Item Descriptor Report
ed on 
Page # 
TITLE & ABSTRACT 1 How participants were allocated to interventions (e.g., "random 
allocation", "randomized", or "randomly assigned"). 
2260 
INTRODUCTION 
Background 
2 Scientific background and explanation of rationale. 2260,2
261 
METHODS 
Participants 
3 Eligibility criteria for participants and the settings and locations 
where the data were collected. 
2261 
Interventions 4 Precise details of the interventions intended for each group 
and how and when they were actually administered. 
2261 
Objectives 5 Specific objectives and hypotheses. 2261 
Outcomes 6 Clearly defined primary and secondary outcome measures 
and, when applicable, any methods used to enhance the 
quality of measurements (e.g., multiple observations, training 
of assessors). 
2261 
Sample size 7 How sample size was determined and, when applicable, 
explanation of any interim analyses and stopping rules. 
2262 
Randomization -- 
Sequence generation 
8 Method used to generate the random allocation sequence, 
including details of any restrictions (e.g., blocking, 
stratification) 
N/A 
Randomization -- 
Allocation concealment 
9 Method used to implement the random allocation sequence 
(e.g., numbered containers or central telephone), clarifying 
whether the sequence was concealed until interventions were 
N/A 
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assigned. 
Randomization -- 
Implementation 
10 Who generated the allocation sequence, who enrolled 
participants, and who assigned participants to their groups. 
N/A 
Blinding (masking) 11 Whether or not participants, those administering the 
interventions, and those assessing the outcomes were blinded 
to group assignment. If done, how the success of blinding was 
evaluated. 
N/A 
Statistical methods 12 Statistical methods used to compare groups for primary 
outcome(s); Methods for additional analyses, such as 
subgroup analyses and adjusted analyses. 
2263 
    RESULTS 
Participant flow 
 
13 Flow of participants through each stage (a diagram is strongly 
recommended). Specifically, for each group report the 
numbers of participants randomly assigned, receiving intended 
treatment, completing the study protocol, and analyzed for the 
primary outcome. Describe protocol deviations from study as 
planned, together with reasons. 
2262 
Recruitment 14 Dates defining the periods of recruitment and follow-up. 2261 
Baseline data 15 Baseline demographic and clinical characteristics of each 
group. 
2263 
Numbers analyzed 16 Number of participants (denominator) in each group included 
in each analysis and whether the analysis was by "intention-to-
treat". State the results in absolute numbers when feasible 
(e.g., 10/20, not 50%). 
2263 
Outcomes and estimation 17 For each primary and secondary outcome, a summary of 
results for each group, and the estimated effect size and its 
precision (e.g., 95% confidence interval). 
2263,2
264, 
2265 
Ancillary analyses 18 Address multiplicity by reporting any other analyses performed, 
including subgroup analyses and adjusted analyses, indicating 
N/A 
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those pre-specified and those exploratory. 
Adverse events 19 All important adverse events or side effects in each 
intervention group. 
2267,2
268,22
69 
DISCUSSION 
Interpretation 
20 Interpretation of the results, taking into account study 
hypotheses, sources of potential bias or imprecision and the 
dangers associated with multiplicity of analyses and outcomes. 
2268 
Generalizability 21 Generalizability (external validity) of the trial findings. N/A 
Overall evidence 22 General interpretation of the results in the context of current 
evidence. 
N/A 
 
www.consort-statement.org 
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Article: Black,S et al, Efficacy, safety and immunogenicity of heptavalent pneumococcal 
conjugate vaccine in children, The Pediatric Infectious Diseases Journal, 187-195 
(2000) 
PAPER SECTION 
And topic 
Item Descriptor Reported 
on Page # 
TITLE & ABSTRACT 1 How participants were allocated to interventions (e.g., "random 
allocation", "randomized", or "randomly assigned"). 
187 
INTRODUCTION 
Background 
2 Scientific background and explanation of rationale. 187 
METHODS 
Participants 
3 Eligibility criteria for participants and the settings and locations 
where the data were collected. 
188 
Interventions 4 Precise details of the interventions intended for each group 
and how and when they were actually administered. 
188 
Objectives 5 Specific objectives and hypotheses. 187 
Outcomes 6 Clearly defined primary and secondary outcome measures 
and, when applicable, any methods used to enhance the 
quality of measurements (e.g., multiple observations, training 
of assessors). 
N/A 
Sample size 7 How sample size was determined and, when applicable, 
explanation of any interim analyses and stopping rules. 
N/A 
Randomization -- 
Sequence generation 
8 Method used to generate the random allocation sequence, 
including details of any restrictions (e.g., blocking, 
stratification) 
188 
Randomization -- 
Allocation concealment 
9 Method used to implement the random allocation sequence 
(e.g., numbered containers or central telephone), clarifying 
whether the sequence was concealed until interventions were 
assigned. 
N/A 
Randomization -- 10 Who generated the allocation sequence, who enrolled N/A 
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Implementation participants, and who assigned participants to their groups. 
Blinding (masking) 11 Whether or not participants, those administering the 
interventions, and those assessing the outcomes were blinded 
to group assignment. If done, how the success of blinding was 
evaluated. 
189 
Statistical methods 12 Statistical methods used to compare groups for primary 
outcome(s); Methods for additional analyses, such as 
subgroup analyses and adjusted analyses. 
190 
RESULTS 
Participant flow 
 
13 Flow of participants through each stage (a diagram is strongly 
recommended). Specifically, for each group report the 
numbers of participants randomly assigned, receiving intended 
treatment, completing the study protocol, and analyzed for the 
primary outcome. Describe protocol deviations from study as 
planned, together with reasons. 
189,190 
Recruitment 14 Dates defining the periods of recruitment and follow-up.  
Baseline data 15 Baseline demographic and clinical characteristics of each 
group. 
 
Numbers analyzed 16 Number of participants (denominator) in each group included 
in each analysis and whether the analysis was by "intention-to-
treat". State the results in absolute numbers when feasible 
(e.g., 10/20, not 50%). 
189,190 
Outcomes and estimation 17 For each primary and secondary outcome, a summary of 
results for each group, and the estimated effect size and its 
precision (e.g., 95% confidence interval). 
193 
Ancillary analyses 18 Address multiplicity by reporting any other analyses performed, 
including subgroup analyses and adjusted analyses, indicating 
those pre-specified and those exploratory. 
N/A 
Adverse events 19 All important adverse events or side effects in each 192 
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intervention group. 
DISCUSSION 
Interpretation 
20 Interpretation of the results, taking into account study 
hypotheses, sources of potential bias or imprecision and the 
dangers associated with multiplicity of analyses and outcomes. 
194,195 
Generalizability 21 Generalizability (external validity) of the trial findings. N/A 
Overall evidence 22 General interpretation of the results in the context of current 
evidence. 
194,195 
www.consort-statement.org 
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APPENDIX 10: POSTER PRESENTATION (DRUG UTILISATION RESEARCH 
GROUP) 
Impact of 7-valent Pneumococcal Conjugate Vaccine (PCV-7) on Otitis Media and Antibiotic 
Prescribing for Otitis Media on children and adolescent aged 0-18 years in United Kingdom 
 
A.A. Elturki
1
, Y.F. Hsia
1
, P.F.Long
2
, M. Sharland
3
and I.C.K.Wong
1
.  
1
Centre for Paediatric Pharmacy Research, The School of Pharmacy, University of London 
2
Department of Pharmaceutics and Centre for Paediatric Pharmacy Research, The School of 
Pharmacy 
3
Paediatric Infectious Disease Unit, St. George’s Hospital 
 
ABSTRACT 
Background:  In 2006, the 7-valent pneumococcal conjugate vaccine (PCV-7) was introduced to 
the childhood immunization schedule in the UK. Studies from the USA and continental Europe 
have shown that PCV-7 reduced the incidence of Otitis Media (OM) and antibiotic prescribing in 
children. Our previous study reported a similar decline in OM diagnosis and antibiotic prescribing 
for OM treatment that may be related to the introduction of UK guidance in 1997 to restrict the 
use of antibiotic for OM treatment. However, it still remains unclear if there has been any change 
in OM management since the introduction of PCV-7 into UK General Practice.  
 
 
Objectives: To investigate the incidence rate of OM and antibiotic prescribing for OM treatment 
before and after the introduction of PCV-7 in children and adolescents. 
 
 
Methods: A retrospective cohort study was conducted using the UK Integrated Medical Systems 
Disease Analyzer (IMS DA) database. The cohort comprised all children and adolescents aged 
0-18 years between 1 January 2001 and 31 December 2008.  
 
 
 
Results: The IMS DA study population was composed of 270,092 children and adolescents. Of 
these, 35,184 had a diagnosis of OM, of which 30,703 (87%) received a prescription.  
The incidence rate of OM significantly declined from 76 per 1000 person-years (95% CI: 75-78) 
in 2001 to 47 per 1000 person-years (95% CI: 46-48) in 2008. During the same time period, 
antibiotic prescribing for OM treatment also declined from 54 per 1000 person-year (95% CI: 53-
55) in 2001 to 31 per 1000 person-year (95% CI: 30-31) in 2008.  
 
 
Conclusion: The incidence of OM and antibiotic prescribing has significantly declined in the 
past 8 years. This decline, however, predated the introduction of PCV-7.  The data will now be 
analyzed using an interrupted time series (ITS).  
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APPENDIX 11: ORAL PRESENTATION (ROYAL COLLEGE OF PAEDIATRICS AND 
CHILD HEALTH)  
Impact of 7-valent Pneumococcal Conjugate Vaccine (PVC-7) on the incidence and treatment of 
Pneumonia diagnosed in primary care in children and adolescents in United Kingdom                        
A.A. Elturki
1
, Y.F. Hsia
1
, S Saxena 
2
, P.F.Long
3
, I.C.K.Wong
1
and M. Sharland
4  
 
1Centre for Paediatric Pharmacy Research, The School of Pharmacy, University of 
London 
2 Departments of Primary Care and Public Health, Imperial College London 
3Pharmaceutical Science Institute, King’s College London 
4Paediatric Infectious Disease Unit, St. George’s Hospital 
 
ABSTRACT 
Background: It has been estimated that over 2 million children under 5 years of age die from 
pneumonia each year worldwide. Streptococcus pneumonia is the main cause of pneumonia in 
children. In September 2006, 7-valent Pneumococcal Conjugate Vaccine (PCV7) vaccine was 
introduced into the childhood immunisation schedule. A study from USA has noted that PCV7 
vaccine reduced the incidence of pneumococcal pneumonia diagnoses in children under- 5 
years of age by 18%.  However, the impact of PCV7 on the diagnosis and antibiotic treatment of 
all cause pneumonia in primary care in the UK is unclear.  
 
Objective: To investigate the incidence rate of pneumonia and antibiotic prescription for 
pneumonia treatment in children aged 0-18 years in the UK primary care between 2002 and 
2009.  
 
Methods: A retrospective cohort study was conducted using the UK IMS Disease Analyzer (IMS 
DA) database. The cohort comprised all children and adolescents aged 0-18 years between 1 
January 2002 and 31 December 2009 (study period). Broad Read Codes of all cause 
pneumonia were used and the impact of PCV7 was determined by comparing different age 
groups over time. 
 
Results: 302,781 children and adolescents aged 0 to 18 years within the IMS DA study 
population between 2002 and 2009 were identified. There were 813 patients (0.3%) with a 
diagnosis of pneumonia, and 51% of these (417/813) received an antibiotic prescription.  
Overall pneumonia diagnoses were stable, but there was a significant decline in pneumonia 
diagnoses in the under 2 year age group from 2.8/1000 person-years (95% CI: 2.6-3.1) in 2006 
to 1.8/1000 person-years (95%CI: 1.6-2.0) in 2009, a 35.7 % reduction. 
 Antibiotic prescribing for pneumonia in children aged under 2 years had also declined from 2007 
from 8.7/1000 person-years (95% CI: 7.2-10.2) to 0.9/1000 person-years (95% CI: 0.4-1.5) in 
2009, with no similar change noted in other age groups.  
 
Conclusion: Following the introduction of PCV7 into UK childhood immunization programme, 
there was a reduction in the diagnosis of all cause primary care diagnoses and antibiotic 
treatment of pneumonia in children under 2 in the UK that was not seen in older. 
. 
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